<td class='article_title' rowspan='2'>
Inspiratory	JJ	inspiratory
Muscle	NP	<unknown>
Training	NP	Training
in	IN	in
Late-Onset	NP	<unknown>
Pompe	NP	<unknown>
Disease	NP	Disease
:	:	:
The	DT	the
Effects	NN	effects
on	IN	on
Pulmonary	NP	<unknown>
Function	NP	<unknown>
Tests	NP	<unknown>
,	,	,
Quality	NP	Quality
of	IN	of
Life	NP	Life
,	,	,
and	CC	and
Sleep	NP	Sleep
Quality	NP	Quality
.	SENT	.
</td>
Late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
LOPD	NP	<unknown>
)	)	)
is	VBZ	be
characterized	VBN	characterize
by	IN	by
progressive	JJ	progressive
skeletal	JJ	skeletal
and	CC	and
<span class='symptom'>
respiratory	JJ	respiratory
muscle	NN	muscle
weakness	NN	weakness
</span>
.	SENT	.
Little	RB	little
is	VBZ	be
known	VBN	know
about	IN	about
the	DT	the
effect	NN	effect
of	IN	of
inspiratory	JJ	inspiratory
muscle	NN	muscle
training	NN	training
(	(	(
IMT	NP	IMT
)	)	)
on	IN	on
pulmonary	JJ	pulmonary
function	NN	function
in	IN	in
subjects	NNS	subject
with	IN	with
LOPD	NP	<unknown>
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
the	DT	the
present	JJ	present
study	NN	study
was	VBD	be
to	TO	to
investigate	VB	investigate
the	DT	the
effect	NN	effect
of	IN	of
an	DT	an
8-week	JJ	<unknown>
IMT	NP	IMT
program	NN	program
on	IN	on
pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
,	,	,
quality	NN	quality
of	IN	of
life	NN	life
,	,	,
and	CC	and
sleep	VB	sleep
quality	NN	quality
in	IN	in
eight	CD	eight
patients	NNS	patient
with	IN	with
LOPD	NN	<unknown>
who	WP	who
were	VBD	be
receiving	VBG	receive
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(ERT).Before	NN	<unknown>
and	CC	and
after	IN	after
the	DT	the
IMT	NP	IMT
program	NN	program
,	,	,
spirometric	JJ	spirometric
measurements	NNS	measurement
in	IN	in
sitting	VBG	sit
and	CC	and
supine	JJ	supine
positions	NNS	position
,	,	,
and	CC	and
measurements	NNS	measurement
of	IN	of
maximum	JJ	maximum
inspiratory	JJ	inspiratory
and	CC	and
expiratory	JJ	expiratory
pressures	NNS	pressure
,	,	,
peak	JJ	peak
cough	NN	cough
flow	NN	flow
,	,	,
quality	NN	quality
of	IN	of
life	NN	life
(	(	(
assessed	VBD	assess
using	VBG	use
the	DT	the
Nottingham	NP	Nottingham
Health	NP	Health
Profile	NP	<unknown>
)	)	)
,	,	,
and	CC	and
sleep	NN	sleep
quality	NN	quality
(	(	(
assessed	VBD	assess
using	VBG	use
the	DT	the
Pittsburgh	NP	Pittsburgh
sleep	NN	sleep
quality	NN	quality
index	NN	index
)	)	)
were	VBD	be
performed.A	NN	<unknown>
significant	JJ	significant
increase	NN	increase
in	IN	in
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
(	(	(
cmH2O	NN	<unknown>
and	CC	and
%	NN	%
predicted	VBD	predict
)	)	)
(	(	(
median	NN	median
[	SYM	[
interquartile	JJ	<unknown>
range	NN	range
]	SYM	]
:	:	:
30.0	CD	@card@
cmH2O	NN	<unknown>
[	SYM	[
21.5-48	CD	@card@
]	SYM	]
versus	FW	versus
39	CD	@card@
cmH2O	NN	<unknown>
[	SYM	[
31.2-56.5	CD	@card@
]	SYM	]
and	CC	and
38.3	CD	@card@
%	NN	%
[	SYM	[
28.1-48.4	CD	@card@
]	SYM	]
versus	FW	versus
50.5	CD	@card@
%	NN	%
[	SYM	[
37.7-54.9	CD	@card@
]	SYM	]
)	)	)
was	VBD	be
observed	VBN	observe
after	IN	after
training	NN	training
(	(	(
p	NN	p
=	SYM	=
0.01)	JJ	<unknown>
.	SENT	.
There	EX	there
were	VBD	be
no	DT	no
significant	JJ	significant
changes	NNS	change
in	IN	in
the	DT	the
other	JJ	other
pulmonary	JJ	pulmonary
function	NN	function
measurements	NNS	measurement
.	SENT	.
With	IN	with
the	DT	the
exception	NN	exception
of	IN	of
the	DT	the
social	JJ	social
isolation	NN	isolation
subscore	NNS	<unknown>
(	(	(
p	NN	p
=	SYM	=
0.02	CD	@card@
)	)	)
,	,	,
quality	NN	quality
of	IN	of
life	NN	life
subscores	NNS	<unknown>
did	VBD	do
not	RB	not
change	VB	change
after	IN	after
IMT	NP	IMT
(	(	(
p	NN	p
>	SYM	>
0.05)	JJ	<unknown>
.	SENT	.
Sleep	NN	sleep
quality	NN	quality
subscores	NNS	<unknown>
and	CC	and
total	JJ	total
scores	NNS	score
were	VBD	be
similar	JJ	similar
before	IN	before
and	CC	and
after	IN	after
IMT.These	NP	<unknown>
results	NNS	result
suggest	VBP	suggest
that	IN	that
IMT	NP	IMT
has	VBZ	have
a	DT	a
positive	JJ	positive
effect	NN	effect
on	IN	on
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
in	IN	in
subjects	NNS	subject
with	IN	with
LOPD	NNS	<unknown>
who	WP	who
are	VBP	be
under	IN	under
ERT	NN	ERT
.	SENT	.
<td class='article_title' rowspan='2'>
Late-onset	NN	late-onset
Pompe	NN	<unknown>
disease	NN	disease
with	IN	with
complicated	JJ	complicated
intracranial	JJ	intracranial
aneurysm	NN	aneurysm
:	:	:
a	DT	a
Chinese	JJ	Chinese
case	NN	case
report	NN	report
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
rare	JJ	rare
autosomal	JJ	autosomal
recessive	JJ	recessive
hereditary	JJ	hereditary
disease	NN	disease
caused	VBN	cause
by	IN	by
genetic	JJ	genetic
defects	NNS	defect
of	IN	of
acid	JJ	acid
maltase	NN	maltase
.	SENT	.
This	DT	this
disease	NN	disease
could	MD	could
be	VB	be
divided	VBN	divide
into	IN	into
two	CD	two
forms	NNS	form
:	:	:
infantile	JJ	infantile
and	CC	and
late-onset	NN	late-onset
,	,	,
which	WDT	which
mainly	RB	mainly
affect	VBP	affect
cardiac	JJ	cardiac
,	,	,
respiratory	JJ	respiratory
,	,	,
and	CC	and
skeletal	JJ	skeletal
muscle	NN	muscle
systems	NNS	system
.	SENT	.
Late-onset	NN	late-onset
patients	NNS	patient
mainly	RB	mainly
show	VBP	show
symptoms	NNS	symptom
of	IN	of
skeletal	JJ	skeletal
muscle	NN	muscle
involvement	NN	involvement
,	,	,
but	CC	but
recent	JJ	recent
reports	NNS	report
have	VBP	have
found	VBN	find
that	IN	that
the	DT	the
central	JJ	central
nervous	JJ	nervous
system	NN	system
was	VBD	be
also	RB	also
affected	VBN	affect
in	IN	in
some	DT	some
patients	NNS	patient
.	SENT	.
Herein	RB	herein
,	,	,
we	PP	we
report	VBP	report
a	DT	a
case	NN	case
of	IN	of
a	DT	a
female	NN	female
,	,	,
adolescent-onset	NN	<unknown>
Pompe	NN	<unknown>
patient	NN	patient
,	,	,
who	WP	who
was	VBD	be
diagnosed	VBN	diagnose
with	IN	with
complicated	JJ	complicated
<span class='symptom'>
intracranial	JJ	intracranial
aneurysm	NN	aneurysm
</span>
in	IN	in
adulthood	NN	adulthood
.	SENT	.
<td class='article_title' rowspan='2'>
Pompe	NP	<unknown>
Disease	NP	Disease
:	:	:
Diagnosis	NN	diagnosis
and	CC	and
Management	NP	Management
.	SENT	.
Evidence-Based	JJ	<unknown>
Guidelines	NNS	guideline
from	IN	from
a	DT	a
Canadian	JJ	Canadian
Expert	NP	<unknown>
Panel	NP	Panel
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
lysosomal	JJ	lysosomal
storage	NN	storage
disorder	NN	disorder
caused	VBN	cause
by	IN	by
a	DT	a
deficiency	NN	deficiency
of	IN	of
the	DT	the
enzyme	NN	enzyme
acid	NN	acid
alpha-glucosidase	NN	<unknown>
.	SENT	.
Patients	NNS	patient
have	VBP	have
skeletal	JJ	skeletal
muscle	NN	muscle
and	CC	and
respiratory	JJ	respiratory
<span class='symptom'>
weakness	NN	weakness
</span>
with	IN	with
or	CC	or
without	IN	without
<span class='symptom'>
cardiomyopathy	NN	<unknown>
</span>
.	SENT	.
The	DT	the
objective	NN	objective
of	IN	of
our	PP$	our
review	NN	review
was	VBD	be
to	TO	to
systematically	RB	systematically
evaluate	VB	evaluate
the	DT	the
quality	NN	quality
of	IN	of
evidence	NN	evidence
from	IN	from
the	DT	the
literature	NN	literature
to	TO	to
formulate	VB	formulate
evidence-based	JJ	<unknown>
guidelines	NNS	guideline
for	IN	for
the	DT	the
diagnosis	NN	diagnosis
and	CC	and
management	NN	management
of	IN	of
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
The	DT	the
literature	NN	literature
review	NN	review
was	VBD	be
conducted	VBN	conduct
using	VBG	use
published	VBN	publish
literature	NN	literature
,	,	,
clinical	JJ	clinical
trials	NNS	trial
,	,	,
cohort	NN	cohort
studies	NNS	study
and	CC	and
systematic	JJ	systematic
reviews	NNS	review
.	SENT	.
Cardinal	NP	Cardinal
treatment	NN	treatment
decisions	NNS	decision
produced	VBD	produce
seven	CD	seven
management	NN	management
guidelines	NNS	guideline
and	CC	and
were	VBD	be
assigned	VBN	assign
a	DT	a
GRADE	NP	Grade
classification	NN	classification
based	VBN	base
on	IN	on
the	DT	the
quality	NN	quality
of	IN	of
evidence	NN	evidence
in	IN	in
the	DT	the
published	VBN	publish
literature	NN	literature
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
six	CD	six
recommendations	NNS	recommendation
were	VBD	be
made	VBN	make
based	VBN	base
on	IN	on
best	JJS	good
clinical	JJ	clinical
practices	NNS	practice
but	CC	but
with	IN	with
insufficient	JJ	insufficient
data	NNS	datum
to	TO	to
form	VB	form
a	DT	a
guideline	NN	guideline
.	SENT	.
Studying	VBG	study
outcomes	NNS	outcome
in	IN	in
rare	JJ	rare
diseases	NNS	disease
is	VBZ	be
challenging	VBG	challenge
due	JJ	due
to	TO	to
the	DT	the
small	JJ	small
number	NN	number
of	IN	of
patients	NNS	patient
,	,	,
but	CC	but
this	DT	this
is	VBZ	be
in	RB	in
particular	JJ	particular
the	DT	the
reason	NN	reason
why	WRB	why
we	PP	we
believe	VBP	believe
that	IN	that
informed	JJ	informed
treatment	NN	treatment
decisions	NNS	decision
need	VBP	need
to	TO	to
consider	VB	consider
the	DT	the
quality	NN	quality
of	IN	of
the	DT	the
evidence	NN	evidence
.	SENT	.
<td class='article_title' rowspan='2'>
Production	NN	production
and	CC	and
characterization	NN	characterization
of	IN	of
recombinant	JJ	recombinant
human	JJ	human
acid	NN	acid
α-glucosidase	NN	<unknown>
in	IN	in
transgenic	JJ	transgenic
rice	NN	rice
cell	NN	cell
suspension	NN	suspension
culture	NN	culture
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
fatal	JJ	fatal
genetic	JJ	genetic
muscle	NN	muscle
disorder	NN	disorder
caused	VBN	cause
by	IN	by
a	DT	a
deficiency	NN	deficiency
of	IN	of
acid	JJ	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
,	,	,
a	DT	a
glycogen-degrading	JJ	<unknown>
lysosomal	JJ	lysosomal
enzyme	NN	enzyme
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
the	DT	the
human	JJ	human
<span class='gene'>
GAA	NP	<unknown>
</span>
cDNA	NN	<unknown>
gene	NN	gene
was	VBD	be
synthesized	VBN	synthesize
from	IN	from
human	JJ	human
placenta	NN	placenta
cells	NNS	cell
and	CC	and
cloned	VBN	clon
into	IN	into
a	DT	a
plant	NN	plant
expression	NN	expression
vector	NN	vector
under	IN	under
the	DT	the
control	NN	control
of	IN	of
the	DT	the
rice	NN	rice
α-amylase	NN	<unknown>
3D	JJ	3D
(	(	(
RAmy3D	NP	<unknown>
)	)	)
promoter	NN	promoter
.	SENT	.
The	DT	the
plant	NN	plant
expression	NN	expression
vector	NN	vector
was	VBD	be
introduced	VBN	introduce
into	IN	into
rice	NN	rice
calli	NNS	<unknown>
(	(	(
Oryza	NP	<unknown>
sativa	NP	<unknown>
L.	NP	L.
cv	NP	Cv
.	SENT	.
Dongjin	NP	<unknown>
)	)	)
mediated	VBD	mediate
by	IN	by
Agrobacterium	NN	<unknown>
tumefaciens	NNS	<unknown>
.	SENT	.
Genomic	NP	<unknown>
DNA	NP	DNA
PCR	NP	PCR
and	CC	and
Northern	NP	Northern
blot	NN	blot
analysis	NN	analysis
were	VBD	be
used	VBN	use
to	TO	to
determine	VB	determine
the	DT	the
integration	NN	integration
and	CC	and
mRNA	NN	<unknown>
expression	NN	expression
of	IN	of
the	DT	the
hGAA	NN	<unknown>
gene	NN	gene
in	IN	in
the	DT	the
putative	JJ	putative
transgenic	JJ	transgenic
rice	NN	rice
cells	NNS	cell
.	SENT	.
SDS-PAGE	NP	<unknown>
and	CC	and
Western	NP	Western
blot	NN	blot
analysis	NN	analysis
showed	VBD	show
that	IN	that
the	DT	the
glycosylated	JJ	<unknown>
precursor	NN	precursor
recombinant	JJ	recombinant
hGAA	NN	<unknown>
had	VBD	have
a	DT	a
molecular	JJ	molecular
mass	NN	mass
of	IN	of
110kDa	NP	<unknown>
due	JJ	due
to	TO	to
the	DT	the
presence	NN	presence
of	IN	of
seven	CD	seven
N-glycosylation	NN	<unknown>
sites	NNS	site
.	SENT	.
The	DT	the
accumulation	NN	accumulation
of	IN	of
hGAA	NN	<unknown>
protein	NN	protein
in	IN	in
the	DT	the
culture	NN	culture
medium	NN	medium
was	VBD	be
approximately	RB	approximately
37mg/L	JJ	<unknown>
after	IN	after
11	CD	@card@
days	NNS	day
of	IN	of
culturing	VBG	culture
in	IN	in
a	DT	a
sugar	NN	sugar
depletion	NN	depletion
medium	NN	medium
.	SENT	.
The	DT	the
His	PP$	his
tagged-hGAA	NN	<unknown>
protein	NN	protein
was	VBD	be
purified	VBN	purify
using	VBG	use
an	DT	an
Ni-NTA	NP	<unknown>
column	NN	column
and	CC	and
confirmed	VBD	confirm
as	IN	as
the	DT	the
precursor	NN	precursor
form	NN	form
of	IN	of
hGAA	NN	<unknown>
without	IN	without
the	DT	the
signal	NN	signal
peptide	NN	peptide
encoded	VBN	encode
by	IN	by
the	DT	the
cDNA	NN	<unknown>
on	IN	on
the	DT	the
N-terminal	JJ	<unknown>
amino	NN	amino
acid	NN	acid
sequence	NN	sequence
.	SENT	.
The	DT	the
acid	JJ	acid
alpha-glucosidase	NN	<unknown>
activity	NN	activity
of	IN	of
hGAA	NN	<unknown>
produced	VBN	produce
in	IN	in
transgenic	JJ	transgenic
rice	NN	rice
cells	NNS	cell
gave	VBD	give
results	NNS	result
similar	JJ	similar
to	TO	to
those	DT	those
of	IN	of
the	DT	the
enzyme	NN	enzyme
produced	VBN	produce
by	IN	by
CHO	NP	Cho
cells	NNS	cell
.	SENT	.
<td class='article_title' rowspan='2'>
Reevaluating	VBG	reevaluate
Muscle	NP	<unknown>
Biopsies	NP	<unknown>
in	IN	in
the	DT	the
Diagnosis	NN	diagnosis
of	IN	of
Pompe	NP	<unknown>
Disease	NP	Disease
:	:	:
A	DT	a
Corroborative	NP	<unknown>
Report	NP	Report
.	SENT	.
</td>
Previous	JJ	previous
reports	NNS	report
suggest	VBP	suggest
that	IN	that
although	IN	although
a	DT	a
diagnostic	JJ	diagnostic
muscle	NN	muscle
biopsy	NN	biopsy
can	MD	can
confirm	VB	confirm
the	DT	the
presence	NN	presence
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
the	DT	the
absence	NN	absence
of	IN	of
a	DT	a
definitive	JJ	definitive
biopsy	NN	biopsy
result	NN	result
does	VBZ	do
not	RB	not
rule	VB	rule
out	RP	out
the	DT	the
diagnosis.In	NN	<unknown>
this	DT	this
study	NN	study
,	,	,
we	PP	we
reviewed	VBD	review
patients	NNS	patient
with	IN	with
a	DT	a
limb-girdle	NN	<unknown>
syndrome	NN	syndrome
who	WP	who
demonstrated	VBD	demonstrate
nonspecific	JJ	<unknown>
abnormalities	NNS	abnormality
of	IN	of
muscle	NN	muscle
,	,	,
without	IN	without
evidence	NN	evidence
of	IN	of
the	DT	the
classical	JJ	classical
changes	NNS	change
of	IN	of
acid	JJ	acid
maltase	NN	maltase
deficiency	NN	deficiency
.	SENT	.
These	DT	these
patients	NNS	patient
were	VBD	be
rescreened	VBN	<unknown>
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
using	VBG	use
dried	VBN	dry
blood	NN	blood
spot	NN	spot
(	(	(
DBS	NP	DBS
)	)	)
testing.Twenty-seven	JJ	<unknown>
patients	NNS	patient
provided	VBD	provide
blood	NN	blood
samples	NNS	sample
for	IN	for
the	DT	the
DBS	NP	DBS
test	NN	test
.	SENT	.
Four	CD	Four
patients	NNS	patient
underwent	VBD	undergo
subsequent	JJ	subsequent
genetic	JJ	genetic
testing	NN	testing
.	SENT	.
Genetic	JJ	genetic
analysis	NN	analysis
demonstrated	VBD	demonstrate
that	IN	that
one	CD	one
patient	NN	patient
tested	VBD	test
positive	JJ	positive
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
and	CC	and
one	CD	one
patient	NN	patient
had	VBD	have
one	CD	one
copy	NN	copy
of	IN	of
a	DT	a
pathogenic	JJ	pathogenic
variant.In	NN	<unknown>
conclusion	NN	conclusion
,	,	,
the	DT	the
ability	NN	ability
of	IN	of
a	DT	a
diagnostic	JJ	diagnostic
muscle	NN	muscle
biopsy	NN	biopsy
to	TO	to
definitively	RB	definitively
rule	VB	rule
out	RP	out
the	DT	the
presence	NN	presence
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
is	VBZ	be
limited	VBN	limit
.	SENT	.
There	EX	there
is	VBZ	be
a	DT	a
role	NN	role
for	IN	for
a	DT	a
screening	VBG	screen
DBS	NP	DBS
in	IN	in
all	DT	all
patients	NNS	patient
presenting	VBG	present
with	IN	with
a	DT	a
limb-girdle	NN	<unknown>
syndrome	NN	syndrome
without	IN	without
a	DT	a
clear	JJ	clear
diagnosis	NN	diagnosis
.	SENT	.
<td class='article_title' rowspan='2'>
Human-induced	JJ	<unknown>
pluripotent	JJ	<unknown>
stem	NN	stem
cell	NN	cell
approaches	VBZ	approach
to	TO	to
model	VB	model
inborn	JJ	inborn
and	CC	and
acquired	JJ	acquired
metabolic	JJ	metabolic
heart	NN	heart
diseases	NNS	disease
.	SENT	.
</td>
The	DT	the
article	NN	article
provides	VBZ	provide
an	DT	an
overview	NN	overview
of	IN	of
advances	NNS	advance
in	IN	in
the	DT	the
induced	VBN	induce
pluripotent	JJ	<unknown>
stem	NN	stem
cell	NN	cell
field	NN	field
to	TO	to
model	NN	model
cardiomyopathies	NNS	<unknown>
of	IN	of
inherited	VBN	inherit
inborn	JJ	inborn
errors	NNS	error
of	IN	of
metabolism	NN	metabolism
and	CC	and
acquired	VBD	acquire
metabolic	JJ	metabolic
syndromes	NNS	syndrome
in	IN	in
vitro.Several	JJ	<unknown>
inborn	JJ	inborn
errors	NNS	error
of	IN	of
metabolism	NN	metabolism
have	VBP	have
been	VBN	be
studied	VBN	study
using	VBG	use
'	''	'
disease	NN	disease
in	IN	in
a	DT	a
dish	NN	dish
'	POS	'
models	NNS	model
,	,	,
including	VBG	include
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
<span class='disease'>
Danon	NP	<unknown>
disease	NN	disease
</span>
,	,	,
<span class='disease'>
Fabry	NP	Fabry
disease	NN	disease
</span>
,	,	,
and	CC	and
<span class='disease'>
Barth	NP	Barth
syndrome	NN	syndrome
</span>
.	SENT	.
Disease	NN	disease
phenotypes	NNS	phenotype
of	IN	of
complex	JJ	complex
metabolic	JJ	metabolic
syndromes	NNS	syndrome
,	,	,
such	JJ	such
as	IN	as
<span class='symptom'>
diabetes	NN	diabetes
mellitus	NN	<unknown>
</span>
and	CC	and
aldehyde	NN	aldehyde
dehydrogenase	NN	dehydrogenase
2	CD	2
deficiency	NN	deficiency
,	,	,
have	VBP	have
also	RB	also
been	VBN	be
observed.Differentiation	NN	<unknown>
of	IN	of
patient	NN	patient
and	CC	and
disease-specific	JJ	<unknown>
induced	VBN	induce
pluripotent	NN	<unknown>
stem	VBP	stem
cell-derived	JJ	<unknown>
cardiomyocytes	NNS	<unknown>
has	VBZ	have
provided	VBN	provide
the	DT	the
capacity	NN	capacity
to	TO	to
model	VB	model
deleterious	JJ	deleterious
cardiometabolic	JJ	<unknown>
diseases	NNS	disease
to	TO	to
understand	VB	understand
molecular	JJ	molecular
mechanisms	NNS	mechanism
,	,	,
perform	VB	perform
drug	NN	drug
screens	NNS	screen
,	,	,
and	CC	and
identify	VB	identify
novel	JJ	novel
drug	NN	drug
targets	NNS	target
.	SENT	.
<td class='article_title' rowspan='2'>
Salmeterol	NP	<unknown>
enhances	VBZ	enhance
the	DT	the
cardiac	JJ	cardiac
response	NN	response
to	TO	to
gene	NN	gene
therapy	NN	therapy
in	IN	in
Pompe	NP	<unknown>
disease	NN	disease
.	SENT	.
</td>
Enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
recombinant	JJ	recombinant
human	JJ	human
(	(	(
rh	NN	<unknown>
)	)	)
acid	NN	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
has	VBZ	have
prolonged	VBN	prolong
the	DT	the
survival	NN	survival
of	IN	of
patients	NNS	patient
.	SENT	.
However	RB	however
,	,	,
the	DT	the
paucity	NN	paucity
of	IN	of
cation-independent	JJ	<unknown>
mannose-6-phosphate	NN	<unknown>
receptor	NN	receptor
(	(	(
CI-MPR	NP	<unknown>
)	)	)
in	IN	in
skeletal	JJ	skeletal
muscle	NN	muscle
,	,	,
where	WRB	where
it	PP	it
is	VBZ	be
needed	VBN	need
to	TO	to
take	VB	take
up	RP	up
rhGAA	NN	<unknown>
,	,	,
correlated	VBN	correlate
with	IN	with
a	DT	a
poor	JJ	poor
response	NN	response
to	TO	to
ERT	NN	ERT
by	IN	by
muscle	NN	muscle
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
Clenbuterol	NP	<unknown>
,	,	,
a	DT	a
selective	JJ	selective
β2	JJ	<unknown>
receptor	NN	receptor
agonist	NN	agonist
,	,	,
enhanced	VBD	enhance
the	DT	the
CI-MPR	NP	<unknown>
expression	NN	expression
in	IN	in
striated	VBN	striate
muscle	NN	muscle
through	IN	through
Igf-1	NP	<unknown>
mediated	VBD	mediate
<span class='symptom'>
muscle	NN	muscle
hypertrophy	NN	hypertrophy
</span>
,	,	,
which	WDT	which
correlated	VBD	correlate
with	IN	with
increased	VBN	increase
CI-MPR	NP	<unknown>
(	(	(
also	RB	also
the	DT	the
Igf-2	NP	<unknown>
receptor	NN	receptor
)	)	)
expression	NN	expression
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
we	PP	we
have	VBP	have
evaluated	VBN	evaluate
4	CD	4
new	JJ	new
drugs	NNS	drug
in	IN	in
<span class='gene'>
GAA	NP	<unknown>
</span>
knockout	NN	knockout
(	(	(
KO	NP	KO
)	)	)
mice	NNS	mouse
in	IN	in
combination	NN	combination
with	IN	with
an	DT	an
adeno-associated	JJ	<unknown>
virus	NN	virus
(	(	(
AAV	NP	<unknown>
)	)	)
vector	NN	vector
encoding	VBG	encode
human	JJ	human
<span class='gene'>
GAA	NP	<unknown>
</span>
,	,	,
3	CD	3
alternative	JJ	alternative
β2	JJ	<unknown>
agonists	NNS	agonist
and	CC	and
dehydroepiandrosterone	NN	<unknown>
(DHEA)	NN	<unknown>
.	SENT	.
Mice	NNS	mouse
were	VBD	be
injected	VBN	inject
with	IN	with
AAV2/9-CBhGAA	NP	<unknown>
(	(	(
1E+11	JJ	<unknown>
vector	NN	vector
particles	NNS	particle
)	)	)
at	IN	at
a	DT	a
dose	NN	dose
that	WDT	that
was	VBD	be
not	RB	not
effective	JJ	effective
at	IN	at
clearing	VBG	clear
glycogen	NN	glycogen
storage	NN	storage
from	IN	from
the	DT	the
heart	NN	heart
.	SENT	.
Heart	NP	Heart
<span class='gene'>
GAA	NP	<unknown>
</span>
activity	NN	activity
was	VBD	be
significantly	RB	significantly
increased	VBN	increase
by	IN	by
either	DT	either
salmeterol	NN	<unknown>
(	(	(
p<0.01	JJ	<unknown>
)	)	)
or	CC	or
DHEA	NP	<unknown>
(	(	(
p<0.05	NN	<unknown>
)	)	)
,	,	,
in	IN	in
comparison	NN	comparison
with	IN	with
untreated	JJ	untreated
mice	NNS	mouse
.	SENT	.
Furthermore	RB	furthermore
,	,	,
glycogen	NN	glycogen
content	NN	content
was	VBD	be
reduced	VBN	reduce
in	IN	in
the	DT	the
heart	NN	heart
by	IN	by
treatment	NN	treatment
with	IN	with
DHEA	NP	<unknown>
(	(	(
p<0.001	JJ	<unknown>
)	)	)
,	,	,
salmeterol	NN	<unknown>
(	(	(
p<0.05	NN	<unknown>
)	)	)
,	,	,
formoterol	NN	<unknown>
(	(	(
p<0.01	JJ	<unknown>
)	)	)
,	,	,
or	CC	or
clenbuterol	NN	<unknown>
(	(	(
p<0.01	JJ	<unknown>
)	)	)
in	IN	in
combination	NN	combination
with	IN	with
the	DT	the
AAV	NP	<unknown>
vector	NN	vector
,	,	,
in	IN	in
comparison	NN	comparison
with	IN	with
untreated	JJ	untreated
GAA-KO	NP	<unknown>
mice	NNS	mouse
.	SENT	.
Wirehang	NP	<unknown>
testing	NN	testing
revealed	VBD	reveal
that	IN	that
salmeterol	NN	<unknown>
and	CC	and
the	DT	the
AAV	NP	<unknown>
vector	NN	vector
significantly	RB	significantly
increased	VBN	increase
performance	NN	performance
,	,	,
in	IN	in
comparison	NN	comparison
with	IN	with
the	DT	the
AAV	NP	<unknown>
vector	NN	vector
alone	RB	alone
(p<0.001)	JJ	<unknown>
.	SENT	.
Similarly	RB	similarly
,	,	,
salmeterol	NN	<unknown>
with	IN	with
the	DT	the
vector	NN	vector
increased	VBD	increase
performance	NN	performance
significantly	RB	significantly
more	RBR	more
than	IN	than
any	DT	any
of	IN	of
the	DT	the
other	JJ	other
drugs	NNS	drug
.	SENT	.
The	DT	the
most	RBS	most
effective	JJ	effective
individual	JJ	individual
drugs	NNS	drug
had	VBD	have
no	DT	no
significant	JJ	significant
effect	NN	effect
in	IN	in
absence	NN	absence
of	IN	of
vector	NN	vector
,	,	,
in	IN	in
comparison	NN	comparison
with	IN	with
untreated	JJ	untreated
mice	NNS	mouse
.	SENT	.
Thus	RB	thus
,	,	,
salmeterol	NN	<unknown>
should	MD	should
be	VB	be
further	RBR	further
developed	VBN	develop
as	IN	as
adjunctive	JJ	adjunctive
therapy	NN	therapy
in	IN	in
combination	NN	combination
with	IN	with
either	DT	either
ERT	NN	ERT
or	CC	or
gene	NN	gene
therapy	NN	therapy
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<td class='article_title' rowspan='2'>
Blunted	VBN	blunt
Hypercapnic	NP	<unknown>
Respiratory	NP	<unknown>
Drive	NP	Drive
Response	NP	Response
in	IN	in
Subjects	NPS	<unknown>
With	IN	with
Late-Onset	NP	<unknown>
Pompe	NP	<unknown>
Disease	NP	Disease
.	SENT	.
</td>
Patients	NNS	patient
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
develop	VB	develop
progressive	JJ	progressive
hypercapnic	JJ	<unknown>
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
that	WDT	that
can	MD	can
be	VB	be
disproportionate	JJ	disproportionate
to	TO	to
the	DT	the
respiratory	JJ	respiratory
muscle	NN	muscle
compromise	NN	compromise
and/or	CC	and/or
thoracic	JJ	thoracic
restriction	NN	restriction
.	SENT	.
Although	IN	although
recent	JJ	recent
studies	NNS	study
have	VBP	have
reported	VBN	report
the	DT	the
presence	NN	presence
of	IN	of
a	DT	a
blunted	VBN	blunt
hypercapnic	JJ	<unknown>
respiratory	JJ	respiratory
response	NN	response
in	IN	in
some	DT	some
subjects	NNS	subject
with	IN	with
neuromuscular	JJ	neuromuscular
disorders	NNS	disorder
and	CC	and
chronic	JJ	chronic
<span class='symptom'>
hypercapnia	NN	<unknown>
</span>
,	,	,
no	DT	no
study	NN	study
has	VBZ	have
evaluated	VBN	evaluate
the	DT	the
integrity	NN	integrity
of	IN	of
the	DT	the
respiratory	JJ	respiratory
drive	NN	drive
in	IN	in
subjects	NNS	subject
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
.	SENT	.
Thus	RB	thus
,	,	,
we	PP	we
endeavor	VBP	endeavor
to	TO	to
determine	VB	determine
the	DT	the
CO2	NP	<unknown>
rebreathing	NN	<unknown>
response	NN	response
in	IN	in
subjects	NNS	subject
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
.Respiratory	JJ	<unknown>
muscle	NN	muscle
strength	NN	strength
was	VBD	be
assessed	VBN	assess
by	IN	by
measuring	VBG	measure
the	DT	the
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
,	,	,
and	CC	and
the	DT	the
maximum	JJ	maximum
expiratory	JJ	expiratory
pressure	NN	pressure
.	SENT	.
The	DT	the
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
reflects	VBZ	reflect
the	DT	the
strength	NN	strength
of	IN	of
the	DT	the
diaphragm	NN	diaphragm
and	CC	and
other	JJ	other
inspiratory	JJ	inspiratory
muscles	NNS	muscle
,	,	,
whereas	IN	whereas
the	DT	the
maximum	JJ	maximum
expiratory	JJ	expiratory
pressure	NN	pressure
reflects	VBZ	reflect
the	DT	the
strength	NN	strength
of	IN	of
the	DT	the
abdominal	JJ	abdominal
muscles	NNS	muscle
and	CC	and
other	JJ	other
expiratory	JJ	expiratory
muscles	NNS	muscle
.	SENT	.
We	PP	we
studied	VBD	study
the	DT	the
hypercapnic	JJ	<unknown>
drive	NN	drive
response	NN	response
(	(	(
measured	VBN	measure
as	IN	as
the	DT	the
ratio	NN	ratio
of	IN	of
the	DT	the
change	NN	change
in	IN	in
airway-occlusion	NN	<unknown>
pressure	NN	pressure
0.1	CD	@card@
s	NNS	<unknown>
after	IN	after
the	DT	the
start	NN	start
of	IN	of
inspiration	NN	inspiration
and	CC	and
end-tidal	JJ	<unknown>
PCO2	NN	<unknown>
in	IN	in
13	CD	@card@
subjects	NNS	subject
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
and	CC	and
51	CD	@card@
healthy	JJ	healthy
controls.Overall	NN	<unknown>
inspiratory	JJ	inspiratory
muscle	NN	muscle
strength	NN	strength
was	VBD	be
within	IN	within
normal	JJ	normal
limits	NNS	limit
or	CC	or
slightly	RB	slightly
diminished	VBN	diminish
in	IN	in
the	DT	the
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
group	NN	group
.	SENT	.
Five	CD	Five
subjects	NNS	subject
(	(	(
38.5	CD	@card@
%	NN	%
)	)	)
were	VBD	be
chronically	RB	chronically
hypercapnic	JJ	<unknown>
,	,	,
and	CC	and
9	CD	9
(	(	(
69.2	CD	@card@
%	NN	%
)	)	)
had	VBD	have
an	DT	an
increased	VBN	increase
breath-holding	NN	<unknown>
time	NN	time
.	SENT	.
Compared	VBN	compare
with	IN	with
controls	NNS	control
,	,	,
the	DT	the
change	NN	change
in	IN	in
airway-occlusion	NN	<unknown>
pressure	NN	pressure
0.1	CD	@card@
s/change	NN	<unknown>
in	IN	in
end-tidal	JJ	<unknown>
CO2	NP	<unknown>
pressure	NN	pressure
slope	NN	slope
(	(	(
hypercapnic	JJ	<unknown>
respiratory	JJ	respiratory
drive	NN	drive
)	)	)
was	VBD	be
lower	JJR	low
in	IN	in
the	DT	the
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
group	NN	group
(	(	(
median	NN	median
0.050	CD	@card@
[	SYM	[
interquartile	JJ	<unknown>
range	NN	range
0.027-0.118	CD	@card@
]	SYM	]
vs	NP	vs
0.183	CD	@card@
[	SYM	[
0.153-0.233	CD	@card@
]	SYM	]
,	,	,
P	NN	P
<	SYM	<
.001)	JJ	<unknown>
.	SENT	.
Nine	CD	Nine
subjects	NNS	subject
(	(	(
69.2	CD	@card@
%	NN	%
)	)	)
had	VBD	have
a	DT	a
blunted	VBN	blunt
change	NN	change
in	IN	in
airway-occlusion	NN	<unknown>
pressure	NN	pressure
0.1	CD	@card@
s/change	NN	<unknown>
in	IN	in
end-tidal	JJ	<unknown>
carbon	NN	carbon
dioxide	NN	dioxide
pressure	NN	pressure
slope.Subjects	NNS	<unknown>
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
had	VBD	have
an	DT	an
impaired	JJ	impaired
hypercapnic	JJ	<unknown>
respiratory	JJ	respiratory
drive	NN	drive
response	NN	response
.	SENT	.
The	DT	the
clinical	JJ	clinical
<span class='gene'>
impact	NN	impact
</span>
of	IN	of
this	DT	this
phenomenon	NN	phenomenon
in	IN	in
this	DT	this
subject	JJ	subject
subset	NN	subset
deserves	VBZ	deserve
further	JJR	further
investigation	NN	investigation
.	SENT	.
<td class='article_title' rowspan='2'>
Diagnostic	JJ	diagnostic
support	NN	support
for	IN	for
selected	JJ	selected
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
using	VBG	use
answer-pattern	JJ	<unknown>
recognition	NN	recognition
and	CC	and
data	NN	data
mining	NN	mining
techniques	NNS	technique
:	:	:
a	DT	a
proof	NN	proof
of	IN	of
concept	NN	concept
multicenter	NN	multicenter
prospective	JJ	prospective
trial	NN	trial
.	SENT	.
</td>
Diagnosis	NN	diagnosis
of	IN	of
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
in	IN	in
primary	JJ	primary
care	NN	care
is	VBZ	be
often	RB	often
challenging	VBG	challenge
.	SENT	.
Rare	JJ	rare
diseases	NNS	disease
such	JJ	such
as	IN	as
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
are	VBP	be
easily	RB	easily
overlooked	VBN	overlook
by	IN	by
the	DT	the
general	JJ	general
practitioner	NN	practitioner
.	SENT	.
We	PP	we
therefore	RB	therefore
aimed	VBD	aim
to	TO	to
develop	VB	develop
a	DT	a
diagnostic	JJ	diagnostic
support	NN	support
tool	NN	tool
using	VBG	use
patient-oriented	JJ	patient-oriented
questions	NNS	question
and	CC	and
combined	JJ	combined
data	NNS	datum
mining	VBG	mine
algorithms	NNS	algorithm
recognizing	VBG	recognize
answer	NN	answer
patterns	NNS	pattern
in	IN	in
individuals	NNS	individual
with	IN	with
selected	JJ	selected
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
.	SENT	.
A	DT	a
multicenter	NN	multicenter
prospective	JJ	prospective
study	NN	study
for	IN	for
the	DT	the
proof	NN	proof
of	IN	of
concept	NN	concept
was	VBD	be
conducted	VBN	conduct
thereafter.First	RB	<unknown>
,	,	,
16	CD	@card@
interviews	NNS	interview
with	IN	with
patients	NNS	patient
were	VBD	be
conducted	VBN	conduct
focusing	VBG	focus
on	IN	on
their	PP$	their
pre-diagnostic	JJ	<unknown>
observations	NNS	observation
and	CC	and
experiences	NNS	experience
.	SENT	.
From	IN	from
these	DT	these
interviews	NNS	interview
,	,	,
we	PP	we
developed	VBD	develop
a	DT	a
questionnaire	NN	questionnaire
with	IN	with
46	CD	@card@
items	NNS	item
.	SENT	.
Then	RB	then
,	,	,
patients	NNS	patient
with	IN	with
diagnosed	VBN	diagnose
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
as	RB	as
well	RB	well
as	IN	as
patients	NNS	patient
without	IN	without
such	PDT	such
a	DT	a
disease	NN	disease
answered	VBD	answer
the	DT	the
questionnaire	NN	questionnaire
to	TO	to
establish	VB	establish
a	DT	a
database	NN	database
for	IN	for
data	NN	data
mining	NN	mining
.	SENT	.
For	IN	for
proof	NN	proof
of	IN	of
concept	NN	concept
,	,	,
initially	RB	initially
only	RB	only
six	CD	six
diagnoses	NNS	diagnosis
were	VBD	be
chosen	VBN	choose
(	(	(
myotonic	JJ	myotonic
dystrophy	NN	dystrophy
and	CC	and
<span class='symptom'>
myotonia	NN	myotonia
</span>
(	(	(
MdMy	NP	<unknown>
)	)	)
,	,	,
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(	(	(
MP	NN	MP
)	)	)
,	,	,
<span class='disease'>
amyotrophic	JJ	<unknown>
lateral	JJ	lateral
sclerosis	NN	sclerosis
</span>
(	(	(
<span class='disease'>
ALS	NP	<unknown>
</span>
)	)	)
,	,	,
<span class='symptom'>
polyneuropathy	NN	<unknown>
</span>
(	(	(
<span class='gene'>
PNP	NP	<unknown>
</span>
)	)	)
,	,	,
<span class='symptom'>
spinal	JJ	spinal
muscular	JJ	muscular
atrophy	NN	atrophy
</span>
(	(	(
<span class='disease'>
SMA	NP	<unknown>
</span>
)	)	)
,	,	,
other	JJ	other
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
,	,	,
and	CC	and
no	DT	no
neuromuscular	JJ	neuromuscular
disease	NN	disease
(NND)	NN	<unknown>
.	SENT	.
A	DT	a
prospective	JJ	prospective
study	NN	study
was	VBD	be
performed	VBN	perform
to	TO	to
validate	VB	validate
the	DT	the
automated	JJ	automated
malleable	JJ	malleable
system	NN	system
,	,	,
which	WDT	which
included	VBD	include
six	CD	six
different	JJ	different
classification	NN	classification
methods	NNS	method
combined	VBN	combine
in	IN	in
a	DT	a
fusion	NN	fusion
algorithm	NN	algorithm
proposing	VBG	propose
a	DT	a
final	JJ	final
diagnosis	NN	diagnosis
.	SENT	.
Finally	RB	finally
,	,	,
new	JJ	new
diagnoses	NNS	diagnosis
were	VBD	be
incorporated	VBN	incorporate
into	IN	into
the	DT	the
system.In	NN	<unknown>
total	NN	total
,	,	,
questionnaires	NNS	questionnaire
from	IN	from
210	CD	@card@
individuals	NNS	individual
were	VBD	be
used	VBN	use
to	TO	to
train	VB	train
the	DT	the
system	NN	system
.	SENT	.
89.5	CD	@card@
%	NN	%
correct	JJ	correct
diagnoses	NNS	diagnosis
were	VBD	be
achieved	VBN	achieve
during	IN	during
cross-validation	JJ	cross-validation
.	SENT	.
The	DT	the
sensitivity	NN	sensitivity
of	IN	of
the	DT	the
system	NN	system
was	VBD	be
93-97	CD	@card@
%	NN	%
for	IN	for
individuals	NNS	individual
with	IN	with
MP	NN	MP
,	,	,
with	IN	with
MdMy	NP	<unknown>
and	CC	and
without	IN	without
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
,	,	,
but	CC	but
only	RB	only
69	CD	@card@
%	NN	%
in	IN	in
<span class='disease'>
SMA	NP	<unknown>
</span>
and	CC	and
81	CD	@card@
%	NN	%
in	IN	in
<span class='disease'>
ALS	JJ	<unknown>
</span>
patients	NNS	patient
.	SENT	.
In	IN	in
the	DT	the
prospective	JJ	prospective
trial	NN	trial
,	,	,
57/64	CD	@card@
(	(	(
89	CD	@card@
%	NN	%
)	)	)
diagnoses	NNS	diagnosis
were	VBD	be
predicted	VBN	predict
correctly	RB	correctly
by	IN	by
the	DT	the
computerized	JJ	computerized
system	NN	system
.	SENT	.
All	DT	all
questions	NNS	question
,	,	,
or	CC	or
rather	RB	rather
all	DT	all
answers	NNS	answer
,	,	,
increased	VBD	increase
the	DT	the
diagnostic	JJ	diagnostic
accuracy	NN	accuracy
of	IN	of
the	DT	the
system	NN	system
,	,	,
with	IN	with
the	DT	the
best	JJS	good
results	NNS	result
reached	VBN	reach
by	IN	by
the	DT	the
fusion	NN	fusion
of	IN	of
different	JJ	different
classifier	NN	classifier
methods	NNS	method
.	SENT	.
Receiver	NN	receiver
operating	VBG	operate
curve	NN	curve
(	(	(
ROC	NP	<unknown>
)	)	)
and	CC	and
p-value	NN	<unknown>
analyses	NNS	analysis
confirmed	VBD	confirm
the	DT	the
results.A	NN	<unknown>
questionnaire-based	JJ	<unknown>
diagnostic	JJ	diagnostic
support	NN	support
tool	NN	tool
using	VBG	use
data	NN	data
mining	NN	mining
methods	NNS	method
exhibited	VBD	exhibit
good	JJ	good
results	NNS	result
in	IN	in
predicting	VBG	predict
selected	JJ	selected
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
.	SENT	.
Due	JJ	due
to	TO	to
the	DT	the
variety	NN	variety
of	IN	of
neuromuscular	JJ	neuromuscular
diseases	NNS	disease
,	,	,
additional	JJ	additional
studies	NNS	study
are	VBP	be
required	VBN	require
to	TO	to
measure	VB	measure
beneficial	JJ	beneficial
effects	NNS	effect
in	IN	in
the	DT	the
clinical	JJ	clinical
setting	NN	setting
.	SENT	.
<td class='article_title' rowspan='2'>
Combination	NN	combination
of	IN	of
two	CD	two
different	JJ	different
homozygote	NN	homozygote
mutations	NNS	mutation
in	IN	in
Pompe	NP	<unknown>
disease	NN	disease
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
OMIM	NP	<unknown>
no	RB	no
232300	CD	@card@
)	)	)
is	VBZ	be
an	DT	an
autosomal	JJ	autosomal
recessive	NN	recessive
inherited	VBD	inherit
metabolic	JJ	metabolic
disorder	NN	disorder
,	,	,
caused	VBN	cause
by	IN	by
glycogen	NN	glycogen
accumulation	NN	accumulation
in	IN	in
the	DT	the
lysosome	NN	lysosome
due	JJ	due
to	TO	to
deficiency	NN	deficiency
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
acid	JJ	acid
03B1-glucosidase	NN	<unknown>
enzyme	NN	enzyme
.	SENT	.
Here	RB	here
we	PP	we
report	VBP	report
the	DT	the
case	NN	case
of	IN	of
an	DT	an
8-month-old	JJ	<unknown>
girl	NN	girl
of	IN	of
consanguineous	JJ	consanguineous
Turkish	JJ	Turkish
parents	NNS	parent
,	,	,
who	WP	who
was	VBD	be
diagnosed	VBN	diagnose
with	IN	with
the	DT	the
infantile	JJ	infantile
form	NN	form
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
Two	CD	Two
different	JJ	different
uncommon	JJ	uncommon
homozygote	NN	homozygote
mutations	NNS	mutation
(	(	(
c.32-13	JJ	<unknown>
T	NN	T
>	SYM	>
G	NP	G
homozygote	NN	homozygote
and	CC	and
c.1856G	NNS	<unknown>
>	SYM	>
A	DT	a
homozygote	NN	homozygote
)	)	)
were	VBD	be
detected	VBN	detect
.	SENT	.
The	DT	the
patient	NN	patient
had	VBD	have
a	DT	a
more	RBR	more
progressive	JJ	progressive
clinical	JJ	clinical
course	NN	course
than	IN	than
expected	VBN	expect
.	SENT	.
We	PP	we
emphasize	VBP	emphasize
the	DT	the
rare	JJ	rare
combination	NN	combination
of	IN	of
genetic	JJ	genetic
mutations	NNS	mutation
in	IN	in
this	DT	this
Turkish	JJ	Turkish
family	NN	family
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<td class='article_title' rowspan='2'>
Cognitive	JJ	cognitive
decline	NN	decline
in	IN	in
classic	JJ	classic
infantile	JJ	infantile
Pompe	NP	<unknown>
disease	NN	disease
:	:	:
An	DT	an
underacknowledged	JJ	<unknown>
challenge	NN	challenge
.	SENT	.
</td>
<td class='article_title' rowspan='2'>
Muscle	NN	muscle
imaging	NN	imaging
data	NNS	datum
in	IN	in
late-onset	NN	late-onset
Pompe	NP	<unknown>
disease	NN	disease
reveal	VBP	reveal
a	DT	a
correlation	NN	correlation
between	IN	between
the	DT	the
pre-existing	VBG	pre-exist
degree	NN	degree
of	IN	of
lipomatous	JJ	lipomatous
muscle	NN	muscle
alterations	NNS	alteration
and	CC	and
the	DT	the
efficacy	NN	efficacy
of	IN	of
long-term	JJ	long-term
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
.	SENT	.
</td>
Late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
LOPD	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
metabolic	JJ	metabolic
<span class='symptom'>
myopathy	NN	<unknown>
</span>
caused	VBN	cause
by	IN	by
mutations	NNS	mutation
in	IN	in
<span class='gene'>
GAA	NP	<unknown>
</span>
and	CC	and
characterized	VBN	characterize
by	IN	by
<span class='symptom'>
proximal	JJ	proximal
muscle	NN	muscle
weakness	NN	weakness
</span>
and	CC	and
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
.	SENT	.
There	EX	there
is	VBZ	be
evidence	NN	evidence
from	IN	from
clinical	JJ	clinical
studies	NNS	study
that	IN	that
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
human	JJ	human
recombinant	JJ	recombinant
alpha-glucosidase	NN	<unknown>
improves	VBZ	improve
motor	NN	motor
performance	NN	performance
and	CC	and
respiratory	JJ	respiratory
function	NN	function
in	IN	in
LOPD.We	NP	<unknown>
analyzed	VBD	analyze
quantitative	JJ	quantitative
muscle	NN	muscle
MRI	NP	MRI
data	NNS	datum
of	IN	of
lower	JJR	low
limbs	NNS	limb
to	TO	to
evaluate	VB	evaluate
the	DT	the
effects	NNS	effect
of	IN	of
long-term	JJ	long-term
ERT	NN	ERT
on	IN	on
muscle	NN	muscle
parameters.Three	NN	<unknown>
symptomatic	JJ	symptomatic
LOPD	NP	<unknown>
patients	NNS	patient
who	WP	who
received	VBD	receive
ERT	NN	ERT
for	IN	for
five	CD	five
years	NNS	year
and	CC	and
four	CD	four
untreated	JJ	untreated
presymptomatic	JJ	<unknown>
LOPD	NN	<unknown>
patients	NNS	patient
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
T1-weighted	NP	<unknown>
MRI	NP	MRI
images	NNS	image
were	VBD	be
used	VBN	use
to	TO	to
determine	VB	determine
volumes	NNS	volume
of	IN	of
thigh	NN	thigh
and	CC	and
lower	JJR	low
leg	NN	leg
muscles	NNS	muscle
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
mean	VBP	mean
gray	JJ	gray
values	NNS	value
of	IN	of
eight	CD	eight
individual	JJ	individual
thigh	NN	thigh
muscles	NNS	muscle
were	VBD	be
calculated	VBN	calculate
to	TO	to
assess	VB	assess
the	DT	the
degree	NN	degree
of	IN	of
lipomatous	JJ	lipomatous
muscle	NN	muscle
alterations.We	NP	<unknown>
detected	VBD	detect
a	DT	a
decrease	NN	decrease
in	IN	in
thigh	NN	thigh
muscle	NN	muscle
volume	NN	volume
of	IN	of
6.7	CD	@card@
%	NN	%
(	(	(
p	NN	p
<	SYM	<
0.001	CD	@card@
)	)	)
and	CC	and
an	DT	an
increase	NN	increase
in	IN	in
lower	JJR	low
leg	NN	leg
muscle	NN	muscle
volume	NN	volume
of	IN	of
8.2	CD	@card@
%	NN	%
(	(	(
p	NN	p
=	SYM	=
0.049	CD	@card@
)	)	)
after	IN	after
five	CD	five
years	NNS	year
of	IN	of
ERT	NN	ERT
.	SENT	.
Analysis	NN	analysis
of	IN	of
individual	JJ	individual
thigh	NN	thigh
muscles	NNS	muscle
revealed	VBD	reveal
a	DT	a
positive	JJ	positive
correlation	NN	correlation
between	IN	between
the	DT	the
degree	NN	degree
of	IN	of
lipomatous	JJ	lipomatous
muscle	NN	muscle
alterations	NNS	alteration
at	IN	at
baseline	NN	baseline
and	CC	and
the	DT	the
increase	NN	increase
of	IN	of
gray	JJ	gray
values	NNS	value
after	IN	after
five	CD	five
years	NNS	year
of	IN	of
ERT	NN	ERT
(	(	(
R(2)	NP	<unknown>
=	SYM	=
0.68	CD	@card@
,	,	,
p	NN	p
<	SYM	<
0.001)	JJ	<unknown>
.	SENT	.
Muscle	NN	muscle
imaging	NN	imaging
in	IN	in
presymptomatic	JJ	<unknown>
patients	NNS	patient
showed	VBD	show
in	IN	in
one	CD	one
case	NN	case
pronounced	VBD	pronounce
lipomatous	JJ	lipomatous
alteration	NN	alteration
of	IN	of
the	DT	the
adductor	NN	adductor
magnus	NN	<unknown>
muscle	NN	muscle
and	CC	and
mild	JJ	mild
to	TO	to
moderate	JJ	moderate
changes	NNS	change
in	IN	in
further	JJR	further
thigh	NN	thigh
muscles.The	NN	<unknown>
results	NNS	result
demonstrate	VBP	demonstrate
that	IN	that
fatty	JJ	fatty
muscle	NN	muscle
degeneration	NN	degeneration
can	MD	can
occur	VB	occur
before	IN	before
clinical	JJ	clinical
manifestation	NN	manifestation
of	IN	of
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
and	CC	and
suggest	VBP	suggest
that	IN	that
mildly	RB	mildly
affected	VBN	affect
muscles	NNS	muscle
may	MD	may
respond	VB	respond
better	RBR	well
to	TO	to
ERT	NN	ERT
treatment	NN	treatment
than	IN	than
severely	RB	severely
involved	VBN	involve
muscles	NNS	muscle
.	SENT	.
If	IN	if
these	DT	these
findings	NNS	finding
can	MD	can
be	VB	be
validated	VBN	validate
by	IN	by
further	JJR	further
studies	NNS	study
,	,	,
it	PP	it
should	MD	should
be	VB	be
discussed	VBN	discuss
if	IN	if
muscle	NN	muscle
alterations	NNS	alteration
detected	VBN	detect
by	IN	by
muscle	NN	muscle
MRI	NP	MRI
may	MD	may
be	VB	be
an	DT	an
objective	JJ	objective
sign	NN	sign
of	IN	of
disease	NN	disease
manifestation	NN	manifestation
justifying	VBG	justify
an	DT	an
early	JJ	early
start	NN	start
of	IN	of
ERT	NN	ERT
in	IN	in
clinically	RB	clinically
asymptomatic	JJ	asymptomatic
patients	NNS	patient
in	IN	in
order	NN	order
to	TO	to
improve	VB	improve
the	DT	the
long-term	JJ	long-term
outcome	NN	outcome
.	SENT	.
<td class='article_title' rowspan='2'>
Neuropathology	NN	neuropathology
in	IN	in
respiratory-related	JJ	<unknown>
motoneurons	NNS	motoneuron
in	IN	in
young	JJ	young
Pompe	NP	<unknown>
(Gaa(-/-))	NN	<unknown>
mice	NNS	mouse
.	SENT	.
</td>
Respiratory	JJ	respiratory
and/or	CC	and/or
lingual	JJ	lingual
dysfunction	NN	dysfunction
are	VBP	be
among	IN	among
the	DT	the
first	JJ	first
motor	NN	motor
symptoms	NNS	symptom
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
a	DT	a
disorder	NN	disorder
resulting	VBG	result
from	IN	from
absence	NN	absence
or	CC	or
dysfunction	NN	dysfunction
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
enzyme	NN	enzyme
acid	NN	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
histologically	RB	histologically
evaluated	VBD	evaluate
the	DT	the
medulla	NN	medulla
,	,	,
cervical	JJ	cervical
and	CC	and
thoracic	JJ	thoracic
spinal	JJ	spinal
cords	NNS	cord
in	IN	in
6	CD	6
weeks	NNS	week
old	JJ	old
asymptomatic	JJ	asymptomatic
Pompe	NP	<unknown>
(Gaa(-/-))	NN	<unknown>
mice	NNS	mouse
to	TO	to
determine	VB	determine
if	IN	if
neuropathology	NN	neuropathology
in	IN	in
respiratory	JJ	respiratory
motor	NN	motor
regions	NNS	region
has	VBZ	have
an	DT	an
early	JJ	early
onset	NN	onset
.	SENT	.
Periodic	JJ	periodic
acid-Schiff	NN	<unknown>
(	(	(
PAS	NP	Pas
)	)	)
staining	VBG	stain
indicated	JJ	indicated
glycogen	NN	glycogen
accumulation	NN	accumulation
was	VBD	be
exclusively	RB	exclusively
occurring	VBG	occur
in	IN	in
Gaa(-/-)	NP	<unknown>
hypoglossal	NN	hypoglossal
,	,	,
mid-cervical	JJ	<unknown>
and	CC	and
upper	JJ	upper
thoracic	JJ	thoracic
motoneurons	NNS	motoneuron
.	SENT	.
Markers	NNS	marker
of	IN	of
DNA	NN	DNA
damage	NN	damage
(	(	(
Tunel	NP	<unknown>
)	)	)
and	CC	and
ongoing	JJ	ongoing
apoptosis	NN	<unknown>
(	(	(
Cleaved	NP	<unknown>
Caspase	NP	<unknown>
3	CD	3
)	)	)
did	VBD	do
not	RB	not
co-localize	VB	<unknown>
with	IN	with
PAS	NP	Pas
staining	VBG	stain
,	,	,
but	CC	but
were	VBD	be
prominent	JJ	prominent
in	IN	in
a	DT	a
medullary	JJ	medullary
region	NN	region
which	WDT	which
included	VBD	include
the	DT	the
nucleus	NN	nucleus
tractus	NN	<unknown>
solitarius	NN	<unknown>
,	,	,
and	CC	and
also	RB	also
in	IN	in
the	DT	the
thoracic	JJ	thoracic
spinal	JJ	spinal
dorsal	JJ	dorsal
horn	NN	horn
.	SENT	.
We	PP	we
conclude	VBP	conclude
that	IN	that
respiratory-related	JJ	<unknown>
motoneurons	NNS	motoneuron
are	VBP	be
particularly	RB	particularly
susceptible	JJ	susceptible
to	TO	to
<span class='gene'>
GAA	NP	<unknown>
</span>
deficiency	NN	deficiency
and	CC	and
that	DT	that
neuronal	JJ	<unknown>
glycogen	NN	glycogen
accumulation	NN	accumulation
and	CC	and
<span class='symptom'>
neurodegeneration	NN	<unknown>
</span>
may	MD	may
occur	VB	occur
independently	RB	independently
in	IN	in
early	JJ	early
stage	NN	stage
disease	NN	disease
.	SENT	.
The	DT	the
data	NNS	datum
support	VBP	support
early	JJ	early
therapeutic	JJ	therapeutic
intervention	NN	intervention
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
PD	NP	PD
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
,	,	,
inherited	JJ	inherited
autosomal	JJ	autosomal
recessive	JJ	recessive
metabolic	JJ	metabolic
disorder	NN	disorder
caused	VBN	cause
by	IN	by
the	DT	the
deficiency	NN	deficiency
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
acid	NN	acid
alpha-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
enzyme	NN	enzyme
described	VBN	describe
in	IN	in
1932	CD	@card@
by	IN	by
the	DT	the
Dutch	JJ	Dutch
pathologist	NN	pathologist
Joannes	NP	Joannes
Cassianus	NP	<unknown>
Pompe	NP	<unknown>
.	SENT	.
The	DT	the
prevalence	NN	prevalence
of	IN	of
PD	JJ	PD
ranges	NNS	range
from	IN	from
1:40,000	CD	@card@
to	TO	to
1:300,000	CD	@card@
births	NNS	birth
and	CC	and
depends	VBZ	depend
on	IN	on
geographic	JJ	geographic
and	CC	and
ethnic	JJ	ethnic
factors	NNS	factor
.	SENT	.
Clinical	JJ	clinical
manifestations	NNS	manifestation
may	MD	may
vary	VB	vary
from	IN	from
a	DT	a
rapidly	RB	rapidly
progressive	JJ	progressive
disabling	VBG	disable
disease	NN	disease
with	IN	with
<span class='symptom'>
cardiomegaly	NN	cardiomegaly
</span>
,	,	,
<span class='symptom'>
hepatomegaly	RB	<unknown>
</span>
,	,	,
<span class='symptom'>
weakness	NN	weakness
</span>
,	,	,
<span class='symptom'>
generalized	VBN	generalize
hypotonia	NN	<unknown>
</span>
,	,	,
and	CC	and
death	NN	death
within	IN	within
the	DT	the
first	JJ	first
year	NN	year
of	IN	of
life	NN	life
,	,	,
to	TO	to
a	DT	a
mild	JJ	mild
presentation	NN	presentation
characterized	VBN	characterize
by	IN	by
slowly	RB	slowly
progressive	JJ	progressive
<span class='symptom'>
myopathy	NN	<unknown>
</span>
predominantly	RB	predominantly
involving	VBG	involve
the	DT	the
skeletal	JJ	skeletal
muscles	NNS	muscle
.	SENT	.
The	DT	the
laboratory	NN	laboratory
diagnostic	JJ	diagnostic
gold	NN	gold
standard	NN	standard
is	VBZ	be
represented	VBN	represent
by	IN	by
the	DT	the
determination	NN	determination
of	IN	of
the	DT	the
alpha-glucosidase	NN	<unknown>
activity	NN	activity
.	SENT	.
However	RB	however
,	,	,
the	DT	the
muscle	NN	muscle
histology	NN	histology
may	MD	may
also	RB	also
yield	VB	yield
the	DT	the
diagnosis	NN	diagnosis
by	IN	by
evaluating	VBG	evaluate
the	DT	the
tissular	JJ	<unknown>
glycogen	NN	glycogen
accumulation	NN	accumulation
.	SENT	.
Until	IN	until
recently	RB	recently
,	,	,
supportive	JJ	supportive
measures	NNS	measure
constituted	VBD	constitute
the	DT	the
unique	JJ	unique
available	JJ	available
therapy	NN	therapy
.	SENT	.
Currently	RB	currently
,	,	,
the	DT	the
administration	NN	administration
of	IN	of
the	DT	the
recombinant	JJ	recombinant
<span class='gene'>
GAA	NP	<unknown>
</span>
is	VBZ	be
being	VBG	be
used	VBN	use
with	IN	with
promising	JJ	promising
results	NNS	result
.	SENT	.
The	DT	the
authors	NNS	author
present	VBP	present
the	DT	the
case	NN	case
of	IN	of
a	DT	a
5-month-old	JJ	<unknown>
boy	NN	boy
,	,	,
previously	RB	previously
diagnosed	VBN	diagnose
with	IN	with
<span class='symptom'>
hypertrophic	JJ	hypertrophic
cardiomyopathy	NN	<unknown>
</span>
since	IN	since
the	DT	the
age	NN	age
of	IN	of
2	CD	2
months	NNS	month
,	,	,
who	WP	who
presented	VBD	present
acute	JJ	acute
<span class='symptom'>
heart	NN	heart
failure	NN	failure
</span>
accompanied	VBN	accompany
by	IN	by
biventricular	JJ	<unknown>
dilation	NN	dilation
followed	VBN	follow
by	IN	by
refractory	JJ	refractory
shock	NN	shock
and	CC	and
death	NN	death
.	SENT	.
The	DT	the
autopsy	NN	autopsy
findings	NNS	finding
confirmed	VBD	confirm
the	DT	the
glycogen-accumulation	NN	<unknown>
disease	NN	disease
.	SENT	.
<td class='article_title' rowspan='2'>
Diaphragm	NN	diaphragm
Pacing	NN	<unknown>
as	IN	as
a	DT	a
Rehabilitative	NP	<unknown>
Tool	NP	Tool
for	IN	for
Patients	NPS	Patients
With	IN	with
Pompe	NP	<unknown>
Disease	NP	Disease
Who	WP	who
Are	VBP	be
Ventilator-Dependent	JJ	<unknown>
:	:	:
Case	NN	case
Series	NN	series
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
an	DT	an
inherited	JJ	inherited
disorder	NN	disorder
notable	JJ	notable
for	IN	for
severe	JJ	severe
,	,	,
progressive	JJ	progressive
ventilatory	JJ	ventilatory
compromise	NN	compromise
.	SENT	.
Although	IN	although
ventilatory	JJ	ventilatory
failure	NN	failure
has	VBZ	have
been	VBN	be
attributed	VBN	attribute
to	TO	to
myofiber	NN	<unknown>
dysfunction	NN	dysfunction
secondary	JJ	secondary
to	TO	to
diaphragmatic	JJ	diaphragmatic
glycogen	NN	glycogen
accumulation	NN	accumulation
,	,	,
neural	JJ	neural
involvement	NN	involvement
of	IN	of
the	DT	the
phrenic	JJ	phrenic
motor	NN	motor
system	NN	system
is	VBZ	be
also	RB	also
a	DT	a
prominent	JJ	prominent
feature	NN	feature
.	SENT	.
Direct	JJ	direct
diaphragm	NN	diaphragm
pacing	VBG	pace
supplements	NNS	supplement
respiratory	JJ	respiratory
function	NN	function
in	IN	in
other	JJ	other
disorders	NNS	disorder
of	IN	of
the	DT	the
phrenic	JJ	phrenic
motor	NN	motor
system	NN	system
.	SENT	.
Accordingly	RB	accordingly
,	,	,
it	PP	it
is	VBZ	be
hypothesized	VBN	hypothesize
that	IN	that
augmented	JJ	augmented
neuromuscular	JJ	neuromuscular
activity	NN	activity
via	IN	via
diaphragm	NN	diaphragm
pacing	VBG	pace
would	MD	would
promote	VB	promote
weaning	VBG	wean
from	IN	from
mechanical	JJ	mechanical
ventilation	NN	ventilation
in	IN	in
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
who	WP	who
are	VBP	be
unresponsive	JJ	unresponsive
to	TO	to
conventional	JJ	conventional
,	,	,
muscle-directed	JJ	<unknown>
treatments.Three	NN	<unknown>
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
developed	VBD	develop
diaphragm	NN	diaphragm
paresis	NN	paresis
that	WDT	that
resulted	VBD	result
in	IN	in
chronic	JJ	chronic
mechanical	JJ	mechanical
ventilation	NN	ventilation
dependence	NN	dependence
.	SENT	.
After	IN	after
preoperative	JJ	<unknown>
inspiratory	JJ	inspiratory
muscle	NN	muscle
strengthening	NN	strengthening
exercises	NNS	exercise
failed	VBD	fail
to	TO	to
improve	VB	improve
function	NN	function
,	,	,
fine-wire	NN	<unknown>
pacing	VBG	pace
electrodes	NNS	electrode
were	VBD	be
laparoscopically	RB	<unknown>
implanted	VBN	implant
into	IN	into
the	DT	the
diaphragm	NN	diaphragm
.	SENT	.
Diaphragm	NN	diaphragm
conditioning	NN	conditioning
was	VBD	be
initiated	VBN	initiate
the	DT	the
first	JJ	first
postoperative	JJ	postoperative
week	NN	week
and	CC	and
consisted	VBN	consist
of	IN	of
gradual	JJ	gradual
increases	NNS	increase
in	IN	in
stimulation	NN	stimulation
parameters	NNS	parameter
,	,	,
lengthening	VBG	lengthen
of	IN	of
stimulation	NN	stimulation
sessions	NNS	session
,	,	,
and	CC	and
ventilator	NN	ventilator
weaning	VBG	wean
.	SENT	.
Ventilation	NN	ventilation
and	CC	and
intramuscular	JJ	intramuscular
electromyographic	JJ	<unknown>
activity	NN	activity
were	VBD	be
recorded	VBN	record
periodically	RB	periodically
during	IN	during
conditioning	NN	conditioning
to	TO	to
quantify	VB	quantify
diaphragm	NN	diaphragm
neuromuscular	JJ	neuromuscular
function.During	NN	<unknown>
paced	VBD	pace
breathing	VBG	breathe
without	IN	without
mechanical	JJ	mechanical
ventilation	NN	ventilation
,	,	,
tidal	JJ	tidal
volumes	NNS	volume
increased	VBD	increase
,	,	,
and	CC	and
2	CD	2
patients	NNS	patient
were	VBD	be
weaned	VBN	wean
from	IN	from
daytime	JJ	daytime
ventilator	NN	ventilator
dependence	NN	dependence
within	IN	within
the	DT	the
first	JJ	first
3	CD	3
months	NNS	month
of	IN	of
pacing	VBG	pace
,	,	,
which	WDT	which
has	VBZ	have
been	VBN	be
sustained	VBN	sustain
over	IN	over
the	DT	the
long-term	JJ	long-term
.	SENT	.
A	DT	a
third	JJ	third
patient	NN	patient
reduced	VBD	reduce
reliance	NN	reliance
on	IN	on
daytime	JJ	daytime
ventilation	NN	ventilation
,	,	,
but	CC	but
weaning	VBG	wean
was	VBD	be
delayed	VBN	delay
by	IN	by
malacia	NNS	<unknown>
of	IN	of
the	DT	the
large	JJ	large
airways	NNS	airway
.	SENT	.
In	IN	in
all	DT	all
patients	NNS	patient
,	,	,
pacing	VBG	pace
appeared	VBD	appear
to	TO	to
facilitate	VB	facilitate
spontaneous	JJ	spontaneous
phrenic	JJ	phrenic
motor	NN	motor
unit	NN	unit
activity	NN	activity
during	IN	during
independent	JJ	independent
breathing	NN	breathing
without	IN	without
ventilator	NN	ventilator
or	CC	or
pacer	NN	pacer
support.The	NN	<unknown>
findings	NNS	finding
are	VBP	be
consistent	JJ	consistent
with	IN	with
the	DT	the
view	NN	view
that	IN	that
diaphragm	NN	diaphragm
pacing	VBG	pace
has	VBZ	have
potential	JJ	potential
rehabilitative	JJ	rehabilitative
value	NN	value
to	TO	to
reduce	VB	reduce
reliance	NN	reliance
on	IN	on
mechanical	JJ	mechanical
ventilation	NN	ventilation
in	IN	in
people	NNS	people
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
but	CC	but
further	JJR	further
study	NN	study
is	VBZ	be
needed	VBN	need
.	SENT	.
Diaphragm	NN	diaphragm
pacing	VBG	pace
represents	VBZ	represent
a	DT	a
paradigm	NN	paradigm
shift	NN	shift
in	IN	in
the	DT	the
management	NN	management
of	IN	of
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
that	WDT	that
warrants	VBZ	warrant
further	RBR	further
controlled	JJ	controlled
examination	NN	examination
.	SENT	.
<td class='article_title' rowspan='2'>
Infantile	JJ	infantile
Pompe	NP	<unknown>
disease	NN	disease
:	:	:
A	DT	a
case	NN	case
report	NN	report
and	CC	and
review	NN	review
of	IN	of
the	DT	the
Chinese	JJ	Chinese
literature	NN	literature
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
,	,	,
also	RB	also
known	VBN	know
as	IN	as
glycogen	NN	glycogen
storage	NN	storage
disease	NN	disease
type	NN	type
II	NP	II
,	,	,
is	VBZ	be
caused	VBN	cause
by	IN	by
acid	JJ	acid
maltase	NN	maltase
deficiency	NN	deficiency
,	,	,
and	CC	and
can	MD	can
lead	VB	lead
to	TO	to
lysosomal	JJ	lysosomal
glycogen	NN	glycogen
storage	NN	storage
.	SENT	.
The	DT	the
primal	JJ	primal
manifestations	NNS	manifestation
may	MD	may
be	VB	be
observed	VBN	observe
in	IN	in
children	NNS	child
and	CC	and
adults	NNS	adult
,	,	,
and	CC	and
also	RB	also
in	IN	in
infants	NNS	infant
.	SENT	.
In	IN	in
general	NN	general
,	,	,
the	DT	the
clinical	JJ	clinical
spectrum	NN	spectrum
in	IN	in
infants	NNS	infant
is	VBZ	be
more	RBR	more
progressive	JJ	progressive
and	CC	and
lethal	JJ	lethal
than	IN	than
that	IN	that
in	IN	in
older	JJR	old
patients	NNS	patient
.	SENT	.
This	DT	this
case	NN	case
report	NN	report
describes	VBZ	describe
the	DT	the
case	NN	case
of	IN	of
a	DT	a
newborn	NN	newborn
who	WP	who
was	VBD	be
found	VBN	find
to	TO	to
have	VB	have
cardiac	JJ	cardiac
hypertrophy	NN	hypertrophy
,	,	,
<span class='symptom'>
hepatomegaly	JJ	<unknown>
</span>
and	CC	and
elevated	JJ	elevated
serum	NN	serum
enzyme	NN	enzyme
levels	NNS	level
,	,	,
which	WDT	which
was	VBD	be
characterized	VBN	characterize
by	IN	by
an	DT	an
aspartate	JJ	<unknown>
aminotransferase	NN	<unknown>
level	NN	level
of	IN	of
95	CD	@card@
U/l	NN	<unknown>
,	,	,
lactate	NN	lactate
dehydrogenase	NN	dehydrogenase
level	NN	level
of	IN	of
778	CD	@card@
U/l	NN	<unknown>
and	CC	and
creatine	NN	creatine
kinase	NN	kinase
level	NN	level
of	IN	of
1,299	CD	@card@
U/l	NN	<unknown>
.	SENT	.
On	IN	on
the	DT	the
basis	NN	basis
of	IN	of
the	DT	the
clinical	JJ	clinical
signs	NNS	sign
and	CC	and
laboratory	NN	laboratory
results	NNS	result
,	,	,
dried	VBD	dry
blood	NN	blood
spots	NNS	spot
from	IN	from
the	DT	the
baby	NN	baby
were	VBD	be
tested	VBN	test
to	TO	to
determine	VB	determine
the	DT	the
acid	JJ	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
activity	NN	activity
,	,	,
and	CC	and
the	DT	the
result	NN	result
confirmed	VBD	confirm
that	IN	that
the	DT	the
<span class='gene'>
GAA	NP	<unknown>
</span>
activity	NN	activity
was	VBD	be
only	RB	only
0.10	CD	@card@
pmol/punch/h	NN	<unknown>
(	(	(
normal	JJ	normal
reference	NN	reference
range	NN	range
,	,	,
2.88-89.02	CD	@card@
pmol/punch/h	NN	<unknown>
)	)	)
at	IN	at
pH	NN	pH
3.8	CD	@card@
,	,	,
which	WDT	which
was	VBD	be
clearly	RB	clearly
lower	JJR	low
than	IN	than
the	DT	the
normal	JJ	normal
range	NN	range
,	,	,
leading	VBG	lead
to	TO	to
a	DT	a
diagnosis	NN	diagnosis
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
incurable	JJ	incurable
,	,	,
and	CC	and
before	IN	before
the	DT	the
introduction	NN	introduction
of	IN	of
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
,	,	,
pain	NN	pain
relief	NN	relief
was	VBD	be
the	DT	the
main	JJ	main
treatment	NN	treatment
.	SENT	.
Recognizing	VBG	recognize
this	DT	this
disease	NN	disease
earlier	RBR	earlier
and	CC	and
starting	VBG	start
ERT	NN	ERT
in	IN	in
infants	NNS	infant
prior	RB	prior
to	TO	to
the	DT	the
development	NN	development
of	IN	of
clinical	JJ	clinical
symptoms	NNS	symptom
is	VBZ	be
likely	JJ	likely
to	TO	to
improve	VB	improve
the	DT	the
quality	NN	quality
of	IN	of
life	NN	life
of	IN	of
patients	NNS	patient
.	SENT	.
<td class='article_title' rowspan='2'>
Observational	JJ	observational
clinical	JJ	clinical
study	NN	study
of	IN	of
22	CD	@card@
adult-onset	NN	<unknown>
Pompe	NP	<unknown>
disease	NN	disease
patients	NNS	patient
undergoing	VBG	undergo
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
over	IN	over
5years	NNS	<unknown>
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
an	DT	an
autosomal	JJ	autosomal
recessive	JJ	recessive
disease	NN	disease
resulting	VBG	result
from	IN	from
deficiency	NN	deficiency
of	IN	of
the	DT	the
acid	JJ	acid
alpha-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
.	SENT	.
The	DT	the
late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
Disease	NP	Disease
</span>
(	(	(
LOPD	NP	<unknown>
)	)	)
patients	NNS	patient
develop	VBP	develop
muscular	JJ	muscular
and	CC	and
respiratory	JJ	respiratory
complications	NNS	complication
later	RBR	later
in	IN	in
life	NN	life
.	SENT	.
We	PP	we
describe	VBP	describe
a	DT	a
retrospective	JJ	retrospective
observational	JJ	observational
cohort	NN	cohort
study	NN	study
including	VBG	include
22	CD	@card@
patients	NNS	patient
with	IN	with
LOPD	NP	<unknown>
.	SENT	.
The	DT	the
cohort	NN	cohort
was	VBD	be
assessed	VBN	assess
at	IN	at
baseline	NN	baseline
before	IN	before
Enzyme	NP	<unknown>
Replacement	NP	<unknown>
Therapy	NP	<unknown>
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
alglucosidase	NN	<unknown>
alpha	NN	alpha
(	(	(
20mg/kg	JJ	<unknown>
biweekly	NN	biweekly
)	)	)
was	VBD	be
commenced	VBN	commence
and	CC	and
subsequently	RB	subsequently
relevant	JJ	relevant
information	NN	information
was	VBD	be
collected	VBN	collect
at	IN	at
2	CD	2
,	,	,
4	CD	4
and	CC	and
5years	NNS	<unknown>
later	RBR	later
.	SENT	.
The	DT	the
median	JJ	median
age	NN	age
of	IN	of
the	DT	the
patients	NNS	patient
at	IN	at
study	NN	study
entry	NN	entry
was	VBD	be
44years	JJ	<unknown>
(	(	(
16-64years	NNS	<unknown>
)	)	)
,	,	,
with	IN	with
median	JJ	median
disease	NN	disease
duration	NN	duration
of	IN	of
11.5years	JJ	<unknown>
(4-31years)	NN	<unknown>
.	SENT	.
At	IN	at
baseline	NN	baseline
,	,	,
10	CD	@card@
patients	NNS	patient
(	(	(
45	CD	@card@
%	NN	%
)	)	)
could	MD	could
walk	VB	walk
without	IN	without
support	NN	support
,	,	,
12	CD	@card@
(	(	(
55	CD	@card@
%	NN	%
)	)	)
could	MD	could
walk	VB	walk
with	IN	with
unilateral	JJ	unilateral
or	CC	or
bilateral	JJ	bilateral
support	NN	support
including	VBG	include
3/12	CD	@card@
were	VBD	be
wheelchair	NN	wheelchair
bound	VBN	bind
.	SENT	.
Mean	NN	mean
predicted	VBD	predict
FVC	NP	<unknown>
%	NN	%
was	VBD	be
55.7	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
45-66	CD	@card@
)	)	)
of	IN	of
predicted	VBN	predict
normal	JJ	normal
at	IN	at
baseline	NN	baseline
and	CC	and
showed	VBD	show
no	DT	no
significant	JJ	significant
change	NN	change
after	IN	after
5years	NNS	<unknown>
(	(	(
54.6	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
43-66	CD	@card@
)	)	)
)	)	)
,	,	,
(	(	(
all	DT	all
p=0.9815)	NN	<unknown>
.	SENT	.
Mean	JJ	mean
FVC	NP	<unknown>
%	NN	%
supine	NN	supine
was	VBD	be
41.8	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
33.8-49	CD	@card@
)	)	)
of	IN	of
predicted	VBN	predict
normal	JJ	normal
at	IN	at
baseline	NN	baseline
and	CC	and
remained	VBD	remain
significantly	RB	significantly
unchanged	JJ	unchanged
at	IN	at
5years	NNS	<unknown>
(	(	(
48.4	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
37-59.6	CD	@card@
)	)	)
)	)	)
,	,	,
(	(	(
all	DT	all
p=0.8680)	NN	<unknown>
.	SENT	.
The	DT	the
overnight	JJ	overnight
non-invasive	JJ	non-invasive
ventilator	NN	ventilator
dependence	NN	dependence
increased	VBN	increase
by	IN	by
18.2	CD	@card@
%	NN	%
as	IN	as
compared	VBN	compare
with	IN	with
baseline	NN	baseline
and	CC	and
requirement	NN	requirement
of	IN	of
mobility	NN	mobility
aids	NNS	aid
increased	VBN	increase
during	IN	during
this	DT	this
period	NN	period
by	IN	by
5.2	CD	@card@
%	NN	%
as	IN	as
compared	VBN	compare
with	IN	with
the	DT	the
baseline	NN	baseline
.	SENT	.
Mean	VB	mean
walking	VBG	walk
distance	NN	distance
at	IN	at
6min	JJ	<unknown>
walk	NN	walk
test	NN	test
was	VBD	be
411.5	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
338-485	CD	@card@
)	)	)
at	IN	at
baseline	NN	baseline
,	,	,
266.5	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
187-346	CD	@card@
)	)	)
m	NN	m
at	IN	at
2years	NNS	<unknown>
,	,	,
238.6	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
162-315	CD	@card@
)	)	)
m	NN	m
at	IN	at
4years	NNS	<unknown>
and	CC	and
286.8	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	<unknown>
203-370	CD	@card@
)	)	)
m	NN	m
at	IN	at
5years	NNS	<unknown>
(	(	(
p=0.1981	NP	<unknown>
;	:	;
ANOVA	NP	<unknown>
was	VBD	be
completed	VBN	complete
only	RB	only
for	IN	for
14	CD	@card@
patients)	NN	<unknown>
.	SENT	.
A	DT	a
gradual	JJ	gradual
decline	NN	decline
in	IN	in
FVC	NP	<unknown>
%	NN	%
predicted	VBD	predict
was	VBD	be
noted	VBN	note
only	RB	only
in	IN	in
four	CD	four
cases	NNS	case
and	CC	and
a	DT	a
decline	NN	decline
in	IN	in
FVC	NP	<unknown>
%	NN	%
supine	NN	supine
in	IN	in
two	CD	two
other	JJ	other
.	SENT	.
Only	RB	only
one	CD	one
patient	NN	patient
showed	VBD	show
a	DT	a
decline	NN	decline
in	IN	in
both	DT	both
pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
.	SENT	.
In	IN	in
all	DT	all
remaining	VBG	remain
cases	NNS	case
(	(	(
17/22	CD	@card@
)	)	)
respiratory	JJ	respiratory
function	NN	function
remains	VBZ	remain
stable	JJ	stable
.	SENT	.
In	IN	in
conclusion	NN	conclusion
overall	JJ	overall
pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
and	CC	and
mobility	NN	mobility
remained	VBD	remain
stable	JJ	stable
for	IN	for
5years	NNS	<unknown>
in	IN	in
majority	NN	majority
of	IN	of
patients	NNS	patient
on	IN	on
ERT	NN	ERT
.	SENT	.
However	RB	however
,	,	,
in	IN	in
some	DT	some
patients	NNS	patient
they	PP	they
continued	VBD	continue
to	TO	to
decline	VB	decline
in	IN	in
spite	NN	spite
of	IN	of
ERT	NN	ERT
resulting	VBG	result
in	IN	in
increased	VBN	increase
number	NN	number
of	IN	of
patients	NNS	patient
requiring	VBG	require
ventilation	NN	ventilation
and	CC	and
increase	NN	increase
wheel	NN	wheel
chair	NN	chair
dependence	NN	dependence
at	IN	at
the	DT	the
end	NN	end
of	IN	of
5years	NNS	<unknown>
.	SENT	.
<td class='article_title' rowspan='2'>
ANESTHESIA	NN	anesthesia
MANAGEMENT	NN	management
IN	IN	in
AN	DT	an
INFANT	NP	<unknown>
WITH	NP	<unknown>
GLYCOGEN	NP	<unknown>
STORAGE	NP	Storage
DISEASE	NP	Disease
TYPE	NP	<unknown>
II	NP	II
(	(	(
POMPE	NP	<unknown>
DISEASE)	NP	<unknown>
.	SENT	.
</td>
Pompe	NP	<unknown>
or	CC	or
Glycogen	NP	<unknown>
Storage	NP	Storage
Disease	NP	Disease
type	NN	type
II	NP	II
(	(	(
GSD-II	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
genetic	JJ	genetic
disorder	NN	disorder
affecting	VBG	affect
both	DT	both
cardiac	JJ	cardiac
and	CC	and
skeletal	JJ	skeletal
muscle	NN	muscle
.	SENT	.
Historically	RB	historically
,	,	,
patients	NNS	patient
with	IN	with
the	DT	the
infantile	JJ	infantile
form	NN	form
usually	RB	usually
die	VB	die
within	IN	within
the	DT	the
first	JJ	first
year	NN	year
of	IN	of
life	NN	life
due	JJ	due
to	TO	to
cardiac	JJ	cardiac
and	CC	and
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
.	SENT	.
Recently	RB	recently
a	DT	a
promising	JJ	promising
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
has	VBZ	have
resulted	VBN	result
in	IN	in
improved	VBN	improve
clinical	JJ	clinical
outcomes	NNS	outcome
and	CC	and
a	DT	a
resurgence	NN	resurgence
of	IN	of
elective	JJ	elective
anesthesia	NN	anesthesia
for	IN	for
these	DT	these
patients	NNS	patient
.	SENT	.
Understanding	VBG	understand
the	DT	the
unique	JJ	unique
cardiac	JJ	cardiac
physiology	NN	physiology
in	IN	in
patients	NNS	patient
with	IN	with
GSD-II	NP	<unknown>
is	VBZ	be
essential	JJ	essential
to	TO	to
providing	VBG	provide
safe	JJ	safe
general	JJ	general
anesthesia	NN	anesthesia
.	SENT	.
Additional	JJ	additional
care	NN	care
in	IN	in
maximizing	VBG	maximize
coronary	JJ	coronary
perfusion	NN	perfusion
pressure	NN	pressure
and	CC	and
minimizing	VBG	minimize
<span class='symptom'>
arrhythmia	NN	arrhythmia
</span>
risk	NN	risk
must	MD	must
be	VB	be
given	VBN	give
.	SENT	.
For	IN	for
these	DT	these
reasons	NNS	reason
,	,	,
it	PP	it
is	VBZ	be
recommended	VBN	recommend
that	IN	that
anesthesia	NN	anesthesia
for	IN	for
infantile	JJ	infantile
Pompe	NP	<unknown>
patients	NNS	patient
should	MD	should
specifically	RB	specifically
avoid	VB	avoid
propofol	NN	<unknown>
or	CC	or
high	JJ	high
concentrations	NNS	concentration
of	IN	of
sevoflurane	NN	<unknown>
and	CC	and
,	,	,
instead	RB	instead
,	,	,
use	VBP	use
an	DT	an
agent	NN	agent
such	JJ	such
as	IN	as
ketamine	NN	<unknown>
as	IN	as
the	DT	the
cornerstone	NN	cornerstone
for	IN	for
induction	NN	induction
in	IN	in
order	NN	order
to	TO	to
better	RBR	well
support	VB	support
coronary	JJ	coronary
perfusion	NN	perfusion
pressure	NN	pressure
and	CC	and
to	TO	to
avoid	VB	avoid
decreasing	VBG	decrease
diastolic	JJ	diastolic
blood	NN	blood
pressure	NN	pressure
(	(	(
<span class='gene'>
DBP	NP	<unknown>
</span>
)	)	)
with	IN	with
vasodilatory	JJ	<unknown>
agents	NNS	agent
.	SENT	.
We	PP	we
present	VBP	present
the	DT	the
anesthetic	JJ	anesthetic
technique	NN	technique
in	IN	in
a	DT	a
case	NN	case
of	IN	of
infantile	JJ	infantile
type	NN	type
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
.	SENT	.
<td class='article_title' rowspan='2'>
Targeted	JJ	targeted
approaches	NNS	approach
to	TO	to
induce	VB	induce
immune	JJ	immune
tolerance	NN	tolerance
for	IN	for
Pompe	NP	<unknown>
disease	NN	disease
therapy	NN	therapy
.	SENT	.
</td>
Enzyme	NN	enzyme
and	CC	and
gene	NN	gene
replacement	NN	replacement
strategies	NNS	strategy
have	VBP	have
developed	VBN	develop
into	IN	into
viable	JJ	viable
therapeutic	JJ	therapeutic
approaches	NNS	approach
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(	(	(
acid	JJ	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
deficiency)	NN	<unknown>
.	SENT	.
Unfortunately	RB	unfortunately
,	,	,
the	DT	the
introduction	NN	introduction
of	IN	of
<span class='gene'>
GAA	NP	<unknown>
</span>
and	CC	and
viral	JJ	viral
vectors	NNS	vector
encoding	VBG	encode
the	DT	the
enzyme	NN	enzyme
can	MD	can
lead	VB	lead
to	TO	to
detrimental	JJ	detrimental
immune	JJ	immune
responses	NNS	response
that	WDT	that
attenuate	VBP	attenuate
treatment	NN	treatment
benefits	NNS	benefit
and	CC	and
can	MD	can
<span class='gene'>
impact	VB	impact
</span>
patient	JJ	patient
safety	NN	safety
.	SENT	.
Preclinical	JJ	preclinical
and	CC	and
clinical	JJ	clinical
experience	NN	experience
in	IN	in
addressing	VBG	address
humoral	JJ	humoral
responses	NNS	response
toward	IN	toward
enzyme	NN	enzyme
and	CC	and
gene	NN	gene
therapy	NN	therapy
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
have	VBP	have
provided	VBN	provide
greater	JJR	great
understanding	NN	understanding
of	IN	of
the	DT	the
immunological	JJ	immunological
consequences	NNS	consequence
of	IN	of
the	DT	the
provided	VBN	provide
therapy	NN	therapy
.	SENT	.
B-	NP	B-
and	CC	and
T-cell	NN	T-cell
modulation	NN	modulation
has	VBZ	have
been	VBN	be
shown	VBN	show
to	TO	to
be	VB	be
effective	JJ	effective
in	IN	in
preventing	VBG	prevent
infusion-associated	JJ	<unknown>
reactions	NNS	reaction
during	IN	during
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
in	IN	in
patients	NNS	patient
and	CC	and
has	VBZ	have
shown	VBN	show
similar	JJ	similar
success	NN	success
in	IN	in
the	DT	the
context	NN	context
of	IN	of
gene	NN	gene
therapy	NN	therapy
.	SENT	.
Additional	JJ	additional
techniques	NNS	technique
to	TO	to
induce	VB	induce
humoral	JJ	humoral
tolerance	NN	tolerance
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
have	VBP	have
been	VBN	be
the	DT	the
targeted	JJ	targeted
expression	NN	expression
or	CC	or
delivery	NN	delivery
of	IN	of
<span class='gene'>
GAA	NP	<unknown>
</span>
to	TO	to
discrete	JJ	discrete
cell	NN	cell
types	NNS	type
or	CC	or
tissues	NNS	tissue
such	JJ	such
as	IN	as
the	DT	the
gut-associated	JJ	<unknown>
lymphoid	JJ	lymphoid
tissues	NNS	tissue
,	,	,
red	JJ	red
blood	NN	blood
cells	NNS	cell
,	,	,
hematopoietic	JJ	hematopoietic
stem	NN	stem
cells	NNS	cell
,	,	,
and	CC	and
the	DT	the
liver	NN	liver
.	SENT	.
Research	NN	research
into	IN	into
overcoming	VBG	overcome
preexisting	VBG	preexist
immunity	NN	immunity
through	IN	through
immunomodulation	NN	<unknown>
and	CC	and
gene	NN	gene
transfer	NN	transfer
are	VBP	be
becoming	VBG	become
increasingly	RB	increasingly
important	JJ	important
to	TO	to
achieve	VB	achieve
long-term	JJ	long-term
efficacy	NN	efficacy
.	SENT	.
This	DT	this
review	NN	review
highlights	VBZ	highlight
the	DT	the
advances	NNS	advance
in	IN	in
therapies	NNS	therapy
as	RB	as
well	RB	well
as	IN	as
the	DT	the
improved	VBN	improve
understanding	NN	understanding
of	IN	of
the	DT	the
molecular	JJ	molecular
mechanisms	NNS	mechanism
involved	VBN	involve
in	IN	in
the	DT	the
humoral	JJ	humoral
immune	JJ	immune
response	NN	response
with	IN	with
emphasis	NN	emphasis
on	IN	on
methods	NNS	method
employed	VBN	employ
to	TO	to
overcome	VB	overcome
responses	NNS	response
associated	VBN	associate
with	IN	with
enzyme	NN	enzyme
and	CC	and
gene	NN	gene
therapies	NNS	therapy
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<td class='article_title' rowspan='2'>
The	DT	the
Outcome	NN	outcome
of	IN	of
Infantile	NP	<unknown>
Onset	NP	<unknown>
Pompe	NP	<unknown>
Disease	NP	Disease
in	IN	in
South	NP	South
of	IN	of
Iran	NP	Iran
.	SENT	.
</td>
Infantile	JJ	infantile
Onset	NN	onset
<span class='disease'>
Pompe	NP	<unknown>
Disease	NP	Disease
</span>
(	(	(
IOPD	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
autosomal	JJ	autosomal
recessive	JJ	recessive
neuromuscular	JJ	neuromuscular
disorder	NN	disorder
.	SENT	.
It	PP	it
is	VBZ	be
associated	VBN	associate
with	IN	with
<span class='symptom'>
cardiomegaly	NN	cardiomegaly
</span>
,	,	,
hypotonia	NN	<unknown>
,	,	,
paresis	NN	paresis
,	,	,
and	CC	and
death	NN	death
in	IN	in
the	DT	the
first	JJ	first
year	NN	year
of	IN	of
life	NN	life
.	SENT	.
Since	IN	since
2006	CD	@card@
,	,	,
following	VBG	follow
the	DT	the
use	NN	use
of	IN	of
Alglucosidase	NN	<unknown>
alfa	NN	<unknown>
as	IN	as
Enzyme	NP	<unknown>
Replacement	NP	<unknown>
Therapy	NP	<unknown>
(	(	(
ERT	NN	ERT
)	)	)
,	,	,
the	DT	the
patients	NNS	patient
'	POS	'
survival	NN	survival
is	VBZ	be
improved	VBN	improve
to	TO	to
a	DT	a
noticeable	JJ	noticeable
extent.The	NN	<unknown>
purpose	NN	purpose
of	IN	of
this	DT	this
study	NN	study
is	VBZ	be
to	TO	to
examine	VB	examine
the	DT	the
outcome	NN	outcome
of	IN	of
IOPD	JJ	<unknown>
patients	NNS	patient
in	IN	in
South	NP	South
of	IN	of
Iran	NP	Iran
and	CC	and
the	DT	the
degree	NN	degree
of	IN	of
responsiveness	NN	responsiveness
to	TO	to
ERT.All	NP	<unknown>
patients	NNS	patient
who	WP	who
were	VBD	be
diagnosed	VBN	diagnose
with	IN	with
IOPD	NN	<unknown>
on	IN	on
the	DT	the
bases	NNS	base
of	IN	of
clinical	JJ	clinical
symptoms	NNS	symptom
,	,	,
and	CC	and
enzyme	NN	enzyme
assay	NN	assay
on	IN	on
dried	VBN	dry
blood	NN	blood
spot	NN	spot
,	,	,
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
study	NN	study
;	:	;
and	CC	and
were	VBD	be
followed	VBN	follow
up	RP	up
regarding	VBG	regard
cardiac	JJ	cardiac
function	NN	function
,	,	,
locomotor	JJ	locomotor
activity	NN	activity
,	,	,
and	CC	and
cognition.Six	NN	<unknown>
patients	NNS	patient
with	IN	with
IOPD	NN	<unknown>
were	VBD	be
identified	VBN	identify
.	SENT	.
All	PDT	All
these	DT	these
six	CD	six
patients	NNS	patient
suffered	VBN	suffer
from	IN	from
<span class='symptom'>
Hypertrophic	NP	<unknown>
Cardiomyopathy	NP	<unknown>
</span>
(HCM)	NN	<unknown>
.	SENT	.
Four	NP	Four
(	(	(
67	CD	@card@
%	NN	%
)	)	)
of	IN	of
them	PP	them
also	RB	also
had	VBD	have
<span class='symptom'>
generalized	VBN	generalize
hypotonia	NN	<unknown>
</span>
.	SENT	.
Three	CD	Three
patients	NNS	patient
expired	VBN	expire
during	IN	during
the	DT	the
first	JJ	first
weeks	NNS	week
due	JJ	due
to	TO	to
severe	JJ	severe
<span class='symptom'>
respiratory	JJ	respiratory
infection	NN	infection
</span>
.	SENT	.
One	CD	One
of	IN	of
them	PP	them
also	RB	also
got	VBD	get
involved	VBN	involve
with	IN	with
Acute	JJ	acute
Cardiopulmonary	JJ	cardiopulmonary
Failure	NN	failure
while	IN	while
receiving	VBG	receive
the	DT	the
fifth	JJ	fifth
dose	NN	dose
of	IN	of
ERT	NN	ERT
;	:	;
and	CC	and
expired	VBD	expire
.	SENT	.
However	RB	however
,	,	,
the	DT	the
remaining	VBG	remain
two	CD	two
patients	NNS	patient
had	VBD	have
a	DT	a
significant	JJ	significant
improvement	NN	improvement
after	IN	after
the	DT	the
maximum	NN	maximum
of	IN	of
117	CD	@card@
weeks	NNS	week
of	IN	of
following	VBG	follow
up	RP	up
both	DT	both
cardiac	JJ	cardiac
and	CC	and
locomotor	JJ	locomotor
findings	NNS	finding
.	SENT	.
These	DT	these
two	CD	two
patients	NNS	patient
were	VBD	be
the	DT	the
same	JJ	same
patients	NNS	patient
who	WP	who
showed	VBD	show
cardiac	JJ	cardiac
symptoms	NNS	symptom
from	IN	from
the	DT	the
beginning	NN	beginning
but	CC	but
did	VBD	do
not	RB	not
have	VB	have
<span class='symptom'>
generalized	VBN	generalize
hypotonia	NN	<unknown>
</span>
.Although	NN	<unknown>
ERT	NN	ERT
has	VBZ	have
a	DT	a
significant	JJ	significant
effect	NN	effect
on	IN	on
enhancing	VBG	enhance
the	DT	the
survival	NN	survival
of	IN	of
IOPD	JJ	<unknown>
patients	NNS	patient
,	,	,
it	PP	it
should	MD	should
be	VB	be
associated	VBN	associate
with	IN	with
meticulous	JJ	meticulous
heart-respiratory	NN	<unknown>
cares	VBZ	care
during	IN	during
the	DT	the
first	JJ	first
months	NNS	month
of	IN	of
treatment	NN	treatment
and	CC	and
preventing	VBG	prevent
infection	NN	infection
especially	RB	especially
nosocomial	JJ	<unknown>
infections	NNS	infection
.	SENT	.
<td class='article_title' rowspan='2'>
Intracranial	JJ	intracranial
arterial	JJ	arterial
abnormalities	NNS	abnormality
in	IN	in
patients	NNS	patient
with	IN	with
late	JJ	late
onset	NN	onset
Pompe	NP	<unknown>
disease	NN	disease
(LOPD)	NN	<unknown>
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
rare	JJ	rare
metabolic	JJ	metabolic
disorder	NN	disorder
due	JJ	due
to	TO	to
lysosomal	JJ	lysosomal
alpha-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
deficiency	NN	deficiency
.	SENT	.
It	PP	it
is	VBZ	be
considered	VBN	consider
as	IN	as
a	DT	a
multi-systemic	JJ	<unknown>
disease	NN	disease
since	IN	since
,	,	,
although	IN	although
glycogen	NN	glycogen
accumulation	NN	accumulation
is	VBZ	be
largely	RB	largely
prominent	JJ	prominent
in	IN	in
heart	NN	heart
,	,	,
skeletal	JJ	skeletal
and	CC	and
respiratory	JJ	respiratory
muscles	NNS	muscle
,	,	,
other	JJ	other
organs	NNS	organ
can	MD	can
also	RB	also
be	VB	be
affected	VBN	affect
.	SENT	.
As	RB	as
regards	VBZ	regard
the	DT	the
vascular	JJ	vascular
system	NN	system
,	,	,
few	JJ	few
reports	NNS	report
have	VBP	have
documented	VBN	document
cerebrovascular	JJ	cerebrovascular
malformations	NNS	malformation
in	IN	in
Pompe	NP	<unknown>
patients	NNS	patient
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
define	VB	define
the	DT	the
presence	NN	presence
and	CC	and
type	NN	type
of	IN	of
intracranial	JJ	intracranial
<span class='symptom'>
arterial	JJ	arterial
abnormalities	NNS	abnormality
</span>
in	IN	in
a	DT	a
cohort	NN	cohort
of	IN	of
late	JJ	late
onset	NN	onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
LOPD	JJ	<unknown>
)	)	)
patients.We	NNS	<unknown>
have	VBP	have
studied	VBN	study
21	CD	@card@
LOPD	JJ	<unknown>
patients	NNS	patient
with	IN	with
cerebral	JJ	cerebral
CT	NP	CT
angiography	NN	angiography
(	(	(
CTA	NP	CTA
)	)	)
,	,	,
using	VBG	use
maximum	JJ	maximum
intensity	NN	intensity
projection	NN	projection
and	CC	and
volume	NN	volume
rendering	NN	rendering
technique	NN	technique
for	IN	for
3D-image	JJ	<unknown>
reconstruction.We	NNS	<unknown>
found	VBD	find
intracranial	JJ	intracranial
<span class='symptom'>
arterial	JJ	arterial
abnormalities	NNS	abnormality
</span>
in	IN	in
13/21	CD	@card@
patients	NNS	patient
(	(	(
62	CD	@card@
%	NN	%
)	)	)
,	,	,
of	IN	of
whom	WP	whom
:	:	:
2/21	CD	@card@
patients	NNS	patient
(	(	(
9.5	CD	@card@
%	NN	%
)	)	)
showed	VBD	show
an	DT	an
unruptured	JJ	<unknown>
<span class='symptom'>
intracranial	JJ	intracranial
aneurysm	NN	aneurysm
</span>
(	(	(
respectively	RB	respectively
2	CD	2
and	CC	and
4	CD	4
mm	NN	mm.
)	)	)
,	,	,
10/21	CD	@card@
(	(	(
47	CD	@card@
%	NN	%
)	)	)
had	VBD	have
a	DT	a
vertebrobasilar	JJ	<unknown>
dolichoectasia	NN	<unknown>
(	(	(
VBD	NP	<unknown>
)	)	)
and	CC	and
1/21	CD	@card@
a	DT	a
basilar	JJ	basilar
artery	NN	artery
fenestration	NN	fenestration
.	SENT	.
Signs	NNS	sign
of	IN	of
lacunar	JJ	lacunar
<span class='symptom'>
encephalopathy	NN	<unknown>
</span>
(	(	(
insular	JJ	insular
,	,	,
capsular	NN	capsular
and	CC	and
frontal	JJ	frontal
subcortical	JJ	subcortical
lesions	NNS	lesion
)	)	)
were	VBD	be
detected	VBN	detect
in	IN	in
13/21	CD	@card@
patients	NNS	patient
(	(	(
62	CD	@card@
%	NN	%
)	)	)
and	CC	and
this	DT	this
correlated	VBN	correlate
with	IN	with
the	DT	the
presence	NN	presence
of	IN	of
<span class='symptom'>
respiratory	JJ	respiratory
impairment	NN	impairment
</span>
(	(	(
p	NN	p
=	SYM	=
0.017).These	JJ	<unknown>
findings	NNS	finding
differ	VBP	differ
from	IN	from
what	WP	what
has	VBZ	have
been	VBN	be
previously	RB	previously
observed	VBN	observe
in	IN	in
healthy	JJ	healthy
,	,	,
aged-matched	JJ	<unknown>
populations	NNS	population
and	CC	and
confirm	VBP	confirm
that	IN	that
cerebral	JJ	cerebral
arteries	NNS	artery
abnormalities	NNS	abnormality
,	,	,
mainly	RB	mainly
involving	VBG	involve
the	DT	the
posterior	JJ	posterior
circle	NN	circle
,	,	,
are	VBP	be
not	RB	not
so	RB	so
rare	JJ	rare
in	IN	in
LOPD	JJ	<unknown>
patients	NNS	patient
and	CC	and
are	VBP	be
often	RB	often
accompanied	VBN	accompany
by	IN	by
a	DT	a
lacunar	JJ	lacunar
<span class='symptom'>
encephalopathy	NN	<unknown>
</span>
that	WDT	that
might	MD	might
represent	VB	represent
a	DT	a
hypoxic-ischemic	JJ	<unknown>
origin	NN	origin
.	SENT	.
A	DT	a
CTA	NP	CTA
or	CC	or
an	DT	an
MRA	NP	<unknown>
is	VBZ	be
recommended	VBN	recommend
,	,	,
in	IN	in
LOPD	JJ	<unknown>
patients	NNS	patient
,	,	,
for	IN	for
early	JJ	early
detection	NN	detection
of	IN	of
cerebrovascular	JJ	cerebrovascular
malformations	NNS	malformation
as	IN	as
they	PP	they
could	MD	could
lead	VB	lead
to	TO	to
life-threatening	JJ	life-threatening
events	NNS	event
such	JJ	such
as	IN	as
sub-arachnoid	JJ	<unknown>
haemorrhage	NN	haemorrhage
or	CC	or
brainstem	NN	<unknown>
compression	NN	compression
.	SENT	.
<td class='article_title' rowspan='2'>
Bright	JJ	bright
tongue	NN	tongue
sign	NN	sign
in	IN	in
Pompe	NP	<unknown>
disease	NN	disease
.	SENT	.
</td>
<td class='article_title' rowspan='2'>
Timing	NN	timing
of	IN	of
treatment	NN	treatment
for	IN	for
Pompe	NP	<unknown>
disease	NN	disease
.	SENT	.
</td>
<td class='article_title' rowspan='2'>
Diagnosis	NN	diagnosis
of	IN	of
late-onset	NN	late-onset
Pompe	NP	<unknown>
disease	NN	disease
and	CC	and
other	JJ	other
muscle	NN	muscle
disorders	NNS	disorder
by	IN	by
next-generation	NN	next-generation
sequencing	VBG	sequence
.	SENT	.
</td>
Late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
LOPD	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
treatable	JJ	treatable
lysosomal	JJ	lysosomal
storage	NN	storage
disorder	NN	disorder
characterized	VBN	characterize
by	IN	by
progressive	JJ	progressive
lysosomal	JJ	lysosomal
glycogen	NN	glycogen
accumulation	NN	accumulation
and	CC	and
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
,	,	,
with	IN	with
often	RB	often
a	DT	a
limb-girdle	NN	<unknown>
pattern	NN	pattern
.	SENT	.
Despite	IN	despite
published	VBN	publish
guidelines	NNS	guideline
,	,	,
testing	VBG	test
for	IN	for
LOPD	NN	<unknown>
is	VBZ	be
often	RB	often
overlooked	VBN	overlook
or	CC	or
delayed	VBN	delay
in	IN	in
adults	NNS	adult
,	,	,
owing	VBG	owe
to	TO	to
its	PP$	its
low	JJ	low
frequency	NN	frequency
compared	VBN	compare
to	TO	to
other	JJ	other
muscle	NN	muscle
disorders	NNS	disorder
with	IN	with
similar	JJ	similar
muscle	NN	muscle
patterns	NNS	pattern
.	SENT	.
Next-generation	NN	next-generation
sequencing	NP	sequencing
has	VBZ	have
the	DT	the
capability	NN	capability
to	TO	to
test	VB	test
concurrently	RB	concurrently
for	IN	for
several	JJ	several
muscle	NN	muscle
disorders	NNS	disorder
.	SENT	.
This	DT	this
could	MD	could
potentially	RB	potentially
lead	VB	lead
to	TO	to
increased	VBN	increase
diagnosis	NN	diagnosis
of	IN	of
LOPD	NP	<unknown>
,	,	,
disorders	NNS	disorder
with	IN	with
non-specific	JJ	<unknown>
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
or	CC	or
atypical	JJ	atypical
patients.We	NNS	<unknown>
developed	VBD	develop
a	DT	a
gene	NN	gene
panel	NN	panel
to	TO	to
further	RBR	further
study	VB	study
its	PP$	its
clinical	JJ	clinical
utility	NN	utility
in	IN	in
a	DT	a
cohort	NN	cohort
of	IN	of
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
.	SENT	.
We	PP	we
designed	VBD	design
a	DT	a
gene	NN	gene
panel	NN	panel
to	TO	to
analyze	VB	analyze
the	DT	the
coding	VBG	code
sequences	NNS	sequence
and	CC	and
splice	NN	splice
site	NN	site
junctions	NNS	junction
of	IN	of
<span class='gene'>
GAA	NP	<unknown>
</span>
causing	VBG	cause
LOPD	NN	<unknown>
,	,	,
along	RB	along
with	IN	with
77	CD	@card@
other	JJ	other
genes	NNS	gene
causing	VBG	cause
muscle	NN	muscle
disorders	NNS	disorder
with	IN	with
overlapping	JJ	overlapping
phenotypes.At	NN	<unknown>
a	DT	a
median	JJ	median
coverage	NN	coverage
of	IN	of
~200X	NN	<unknown>
(	(	(
sequences	NNS	sequence
per	IN	per
base	NN	base
)	)	)
,	,	,
all	DT	all
<span class='gene'>
GAA	NP	<unknown>
</span>
exons	NNS	exon
were	VBD	be
successfully	RB	successfully
covered	VBN	cover
with	IN	with
>20X	NN	<unknown>
and	CC	and
only	RB	only
0.3	CD	@card@
%	NN	%
of	IN	of
exons	NNS	exon
across	IN	across
all	DT	all
genes	NNS	gene
were	VBD	be
<20X	NN	<unknown>
.	SENT	.
The	DT	the
panel	NN	panel
showed	VBD	show
an	DT	an
excellent	JJ	excellent
sensitivity	NN	sensitivity
(	(	(
100	CD	@card@
%	NN	%
)	)	)
and	CC	and
specificity	NN	specificity
(	(	(
98	CD	@card@
%	NN	%
)	)	)
across	IN	across
all	DT	all
selected	JJ	selected
genes	NNS	gene
,	,	,
using	VBG	use
known	VBN	know
variations	NNS	variation
in	IN	in
Pompe	NP	<unknown>
patients	NNS	patient
and	CC	and
controls	NNS	control
.	SENT	.
We	PP	we
determined	VBD	determine
its	PP$	its
clinical	JJ	clinical
utility	NN	utility
by	IN	by
analyzing	VBG	analyze
34	CD	@card@
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
of	IN	of
undetermined	JJ	undetermined
etiology	NN	etiology
and	CC	and
various	JJ	various
muscle	NN	muscle
patterns	NNS	pattern
,	,	,
who	WP	who
were	VBD	be
referred	VBN	refer
or	CC	or
followed	VBN	follow
in	IN	in
neuromuscular	JJ	neuromuscular
and	CC	and
genetics	NN	genetics
clinics	NNS	clinic
.	SENT	.
A	DT	a
putative	JJ	putative
diagnosis	NN	diagnosis
was	VBD	be
found	VBN	find
in	IN	in
up	IN	up
to	TO	to
32	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
.	SENT	.
The	DT	the
gene	NN	gene
panel	NN	panel
was	VBD	be
instrumental	JJ	instrumental
in	IN	in
reaching	VBG	reach
a	DT	a
diagnosis	NN	diagnosis
in	IN	in
atypical	JJ	atypical
patients	NNS	patient
,	,	,
including	VBG	include
one	CD	one
LOPD	NN	<unknown>
case	NN	case
.	SENT	.
Acid	JJ	acid
alpha-glucosidase	NN	<unknown>
activity	NN	activity
was	VBD	be
used	VBN	use
to	TO	to
confirm	VB	confirm
the	DT	the
molecular	JJ	molecular
results	NNS	result
in	IN	in
all	DT	all
patients.This	NN	<unknown>
work	NN	work
highlights	VBZ	highlight
the	DT	the
high	JJ	high
clinical	JJ	clinical
utility	NN	utility
of	IN	of
gene	NN	gene
panels	NNS	panel
in	IN	in
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
and	CC	and
its	PP$	its
potential	NN	potential
to	TO	to
facilitate	VB	facilitate
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
patients	NNS	patient
showing	VBG	show
non-specific	JJ	<unknown>
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
or	CC	or
atypical	JJ	atypical
phenotypes	NNS	phenotype
.	SENT	.
We	PP	we
propose	VBP	propose
that	IN	that
gene	NN	gene
panels	NNS	panel
should	MD	should
be	VB	be
used	VBN	use
as	IN	as
a	DT	a
first-tier	NN	first-tier
test	NN	test
in	IN	in
patients	NNS	patient
with	IN	with
suspected	JJ	suspected
muscle	NN	muscle
disorders	NNS	disorder
of	IN	of
undetermined	JJ	undetermined
etiology	NN	etiology
,	,	,
which	WDT	which
could	MD	could
further	RBR	further
increase	VB	increase
overall	JJ	overall
diagnosis	NN	diagnosis
of	IN	of
muscle	NN	muscle
conditions	NNS	condition
,	,	,
and	CC	and
potentially	RB	potentially
reduce	VB	reduce
diagnostic	JJ	diagnostic
delay	NN	delay
.	SENT	.
Further	JJR	further
studies	NNS	study
are	VBP	be
necessary	JJ	necessary
to	TO	to
determine	VB	determine
the	DT	the
<span class='gene'>
impact	NN	impact
</span>
of	IN	of
first-tier	NN	first-tier
gene	NN	gene
panels	NNS	panel
on	IN	on
diagnostic	JJ	diagnostic
delay	NN	delay
and	CC	and
on	IN	on
treatment	NN	treatment
outcome	NN	outcome
for	IN	for
LOPD	NP	<unknown>
.	SENT	.
<td class='article_title' rowspan='2'>
Next	JJ	next
generation	NN	generation
sequencing	VBG	sequence
detection	NN	detection
of	IN	of
late	JJ	late
onset	NN	onset
Pompe	NN	<unknown>
disease	NN	disease
.	SENT	.
</td>
We	PP	we
report	VBP	report
a	DT	a
patient	NN	patient
in	IN	in
whom	WP	whom
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
a	DT	a
treatable	JJ	treatable
disease	NN	disease
was	VBD	be
delayed	VBN	delay
for	IN	for
30	CD	@card@
years.Recent	JJ	<unknown>
discoveries	NNS	discovery
of	IN	of
next	JJ	next
generation	NN	generation
sequencing	NP	sequencing
(	(	(
NGS	NP	<unknown>
)	)	)
have	VBP	have
allowed	VBN	allow
us	PP	us
to	TO	to
reconsider	VB	reconsider
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
limb	NN	limb
girdle	NN	girdle
<span class='symptom'>
muscular	JJ	muscular
dystrophy	NN	dystrophy
</span>
(	(	(
LGMD	JJ	<unknown>
)	)	)
cases	NNS	case
of	IN	of
unknown	JJ	unknown
etiology.A	NN	<unknown>
36-year	JJ	<unknown>
old	JJ	old
man	NN	man
appeared	VBD	appear
to	TO	to
have	VB	have
LGMD	NN	<unknown>
with	IN	with
onset	NN	onset
in	IN	in
shoulder	NN	shoulder
girdle	NN	girdle
muscles	NNS	muscle
,	,	,
but	CC	but
all	DT	all
sarcolemmal	JJ	<unknown>
and	CC	and
cytoskeletal	JJ	<unknown>
proteins	NNS	protein
tested	VBN	test
by	IN	by
immunoblotting	NN	<unknown>
and	CC	and
immunohistochemistry	NN	<unknown>
gave	VBD	give
normal	JJ	normal
results	NNS	result
.	SENT	.
He	PP	he
developed	VBD	develop
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
and	CC	and
became	VBD	become
dependent	JJ	dependent
on	IN	on
overnight	JJ	overnight
ventilation	NN	ventilation
at	IN	at
age	NN	age
44.	CD	@ord@
By	IN	by
NGS	NP	<unknown>
technology	NN	technology
,	,	,
2	CD	2
mutations	NNS	mutation
in	IN	in
the	DT	the
<span class='gene'>
GAA	NP	<unknown>
</span>
gene	NN	gene
(	(	(
IVS1	NP	<unknown>
and	CC	and
a	DT	a
missense	NN	<unknown>
mutation	NN	mutation
in	IN	in
exon	NN	exon
11	CD	@card@
)	)	)
allowed	VBD	allow
us	PP	us
to	TO	to
make	VB	make
a	DT	a
definite	JJ	definite
diagnosis	NN	diagnosis
of	IN	of
glycogenosis	NN	<unknown>
type	NN	type
II	NP	II
(	(	(
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
)	)	)
and	CC	and
start	VB	start
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
at	IN	at
age	NN	age
71.Mild	JJ	<unknown>
non-dystrophic	JJ	<unknown>
features	NNS	feature
on	IN	on
muscle	NN	muscle
biopsy	NN	biopsy
and	CC	and
respiratory	JJ	respiratory
muscle	NN	muscle
involvement	NN	involvement
should	MD	should
suggest	VB	suggest
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
in	IN	in
patients	NNS	patient
with	IN	with
an	DT	an
unclassified	JJ	unclassified
LGMD	NN	<unknown>
phenotype	NN	phenotype
.	SENT	.
NGS	NNS	<unknown>
may	MD	may
help	VB	help
make	VB	make
the	DT	the
diagnosis	NN	diagnosis
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
protected	VBN	protect
by	IN	by
copyright	NN	copyright
.	SENT	.
All	DT	all
rights	NNS	right
reserved	VBD	reserve
.	SENT	.
<td class='article_title' rowspan='2'>
Pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
(	(	(
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
,	,	,
maximum	JJ	maximum
expiratory	JJ	expiratory
pressure	NN	pressure
,	,	,
vital	JJ	vital
capacity	NN	capacity
,	,	,
forced	VBN	force
vital	JJ	vital
capacity	NN	capacity
)	)	)
predict	VBP	predict
ventilator	NN	ventilator
use	NN	use
in	IN	in
late-onset	NN	late-onset
Pompe	NN	<unknown>
disease	NN	disease
.	SENT	.
</td>
In	IN	in
patients	NNS	patient
with	IN	with
Late-Onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
Disease	NP	Disease
</span>
(	(	(
LOPD	NP	<unknown>
)	)	)
,	,	,
progressive	JJ	progressive
respiratory	JJ	respiratory
muscle	NN	muscle
involvement	NN	involvement
leads	VBZ	lead
to	TO	to
reduced	VBN	reduce
pulmonary	JJ	pulmonary
function	NN	function
,	,	,
with	IN	with
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
the	DT	the
most	RBS	most
common	JJ	common
cause	NN	cause
of	IN	of
mortality	NN	mortality
.	SENT	.
Early	JJ	early
disease	NN	disease
manifestations	NNS	manifestation
include	VBP	include
sleep-disordered	JJ	<unknown>
breathing	NN	breathing
,	,	,
which	WDT	which
can	MD	can
be	VB	be
treated	VBN	treat
with	IN	with
non-invasive	JJ	non-invasive
ventilation	NN	ventilation
;	:	;
however	RB	however
,	,	,
progressive	JJ	progressive
diurnal	JJ	diurnal
deficits	NNS	deficit
can	MD	can
require	VB	require
invasive	JJ	invasive
ventilation	NN	ventilation
.	SENT	.
To	TO	To
determine	VB	determine
if	IN	if
pulmonary	JJ	pulmonary
function	NN	function
tests	NNS	test
(	(	(
PFTs	NP	<unknown>
)	)	)
predict	VBP	predict
the	DT	the
thresholds	NNS	threshold
for	IN	for
ventilation	NN	ventilation
and	CC	and
wheelchair	NN	wheelchair
use	NN	use
,	,	,
a	DT	a
systematic	JJ	systematic
literature	NN	literature
review	NN	review
identified	VBD	identify
cross-sectional	JJ	cross-sectional
clinical	JJ	clinical
patient	JJ	patient
data	NNS	datum
(	(	(
N	NP	N
=	SYM	=
174	CD	@card@
)	)	)
that	WDT	that
was	VBD	be
classified	VBN	classify
into	IN	into
ventilation	NN	ventilation
and	CC	and
wheelchair	NN	wheelchair
cohorts	NNS	cohort
.	SENT	.
PFTs	NNS	<unknown>
included	VBD	include
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
(	(	(
<span class='gene'>
MIP	NP	<unknown>
</span>
)	)	)
,	,	,
maximum	JJ	maximum
expiratory	JJ	expiratory
pressure	NN	pressure
(	(	(
MEP	NP	<unknown>
)	)	)
,	,	,
forced	VBN	force
vital	JJ	vital
capacity	NN	capacity
(	(	(
FVC	NP	<unknown>
)	)	)
,	,	,
and	CC	and
vital	JJ	vital
capacity	NN	capacity
(	(	(
VC	NP	VC
)	)	)
,	,	,
with	IN	with
vital	JJ	vital
capacities	NNS	capacity
measured	VBN	measure
in	IN	in
the	DT	the
upright	JJ	upright
(	(	(
-U	NN	<unknown>
)	)	)
and	CC	and
supine	JJ	supine
(	(	(
-S	NN	<unknown>
)	)	)
positions	NNS	position
.	SENT	.
Receiver	NN	receiver
operating	VBG	operate
characteristic	JJ	characteristic
(	(	(
ROC	NP	<unknown>
)	)	)
curves	NNS	curve
were	VBD	be
used	VBN	use
to	TO	to
calculate	VB	calculate
cut-points	NNS	<unknown>
(	(	(
<span class='gene'>
CP	NP	CP
</span>
)	)	)
and	CC	and
area	NN	area
under	IN	under
the	DT	the
curve	NN	curve
(AUC)	NN	<unknown>
.	SENT	.
For	IN	for
all	DT	all
ventilation	NN	ventilation
and	CC	and
mobility	NN	mobility
thresholds	NNS	threshold
tested	VBD	test
,	,	,
ROC	NP	<unknown>
analyses	NNS	analysis
demonstrated	VBD	demonstrate
AUC	NP	<unknown>
values	NNS	value
from	IN	from
86-89	CD	@card@
%	NN	%
for	IN	for
<span class='gene'>
MIP	NP	<unknown>
</span>
,	,	,
72-96	CD	@card@
%	NN	%
for	IN	for
MEP	NN	<unknown>
,	,	,
and	CC	and
74-96	CD	@card@
%	NN	%
for	IN	for
all	DT	all
vital	JJ	vital
capacity	NN	capacity
metrics	NNS	metric
.	SENT	.
Thus	RB	thus
,	,	,
PFTs	NNS	<unknown>
are	VBP	be
useful	JJ	useful
in	IN	in
predicting	VBG	predict
the	DT	the
thresholds	NNS	threshold
for	IN	for
nighttime	NN	nighttime
ventilation	NN	ventilation
,	,	,
daytime	JJ	daytime
ventilation	NN	ventilation
,	,	,
and	CC	and
wheelchair	NN	wheelchair
use	NN	use
,	,	,
with	IN	with
<span class='gene'>
MIP	NP	<unknown>
</span>
and	CC	and
VC-U	NP	<unknown>
having	VBG	have
both	DT	both
high	JJ	high
AUC	NP	<unknown>
values	NNS	value
and	CC	and
consistency	NN	consistency
.	SENT	.
The	DT	the
PFT	NP	<unknown>
mobility	NN	mobility
CPs	NNS	<unknown>
were	VBD	be
low	JJ	low
(	(	(
<span class='gene'>
MIP	NP	<unknown>
</span>
CP	NP	CP
=	SYM	=
0.9	CD	@card@
kPa	NN	<unknown>
,	,	,
MEP	NP	<unknown>
,	,	,
CP	NP	CP
=	SYM	=
2.6	CD	@card@
kPa	NN	<unknown>
,	,	,
VC-U	NP	<unknown>
CP	NP	CP
=	SYM	=
19	CD	@card@
%	NN	%
predicted	VBN	predict
)	)	)
,	,	,
suggesting	VBG	suggest
an	DT	an
endurance	NN	endurance
component	NN	component
associated	VBN	associate
with	IN	with
wheelchair	NN	wheelchair
use	NN	use
.	SENT	.
<td class='article_title' rowspan='2'>
Elevated	JJ	elevated
Plasma	NP	<unknown>
Cardiac	NP	<unknown>
Troponin	NP	<unknown>
T	NN	T
Levels	NP	Levels
Caused	NP	<unknown>
by	IN	by
Skeletal	NP	<unknown>
Muscle	NP	<unknown>
Damage	NN	damage
in	IN	in
Pompe	NP	<unknown>
Disease	NP	Disease
.	SENT	.
</td>
Elevated	JJ	elevated
plasma	NN	plasma
cardiac	JJ	cardiac
troponin	NN	<unknown>
<span class='gene'>
T	NN	T
</span>
(	(	(
cTnT	NN	<unknown>
)	)	)
levels	NNS	level
in	IN	in
patients	NNS	patient
with	IN	with
neuromuscular	JJ	neuromuscular
disorders	NNS	disorder
may	MD	may
erroneously	RB	erroneously
lead	VB	lead
to	TO	to
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
acute	JJ	acute
<span class='symptom'>
myocardial	JJ	myocardial
infarction	NN	infarction
</span>
or	CC	or
myocardial	JJ	myocardial
injury.In	NN	<unknown>
122	CD	@card@
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
the	DT	the
relationship	NN	relationship
between	IN	between
cTnT	NN	<unknown>
,	,	,
cardiac	JJ	cardiac
troponin	NN	<unknown>
I	PP	I
,	,	,
creatine	NN	creatine
kinase	NN	kinase
(	(	(
CK	NP	CK
)	)	)
,	,	,
CK-myocardial	JJ	<unknown>
band	NN	band
levels	NNS	level
,	,	,
and	CC	and
skeletal	JJ	skeletal
muscle	NN	muscle
damage	NN	damage
was	VBD	be
assessed	VBN	assess
.	SENT	.
ECG	NN	<unknown>
and	CC	and
echocardiography	NN	<unknown>
were	VBD	be
used	VBN	use
to	TO	to
evaluate	VB	evaluate
possible	JJ	possible
cardiac	JJ	cardiac
disease	NN	disease
.	SENT	.
Patients	NNS	patient
were	VBD	be
divided	VBN	divide
into	IN	into
classic	JJ	classic
infantile	JJ	infantile
,	,	,
childhood-onset	NN	<unknown>
,	,	,
and	CC	and
adult-onset	NN	<unknown>
patients	NNS	patient
.	SENT	.
cTnT	NN	<unknown>
levels	NNS	level
were	VBD	be
elevated	VBN	elevate
in	IN	in
82	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
(	(	(
median	NN	median
27	CD	@card@
ng/L	NNS	<unknown>
,	,	,
normal	JJ	normal
values	NNS	value
<14	NN	<unknown>
ng/L)	NNS	<unknown>
.	SENT	.
Cardiac	JJ	cardiac
troponin	NN	<unknown>
I	NN	I
levels	NNS	level
were	VBD	be
normal	JJ	normal
in	IN	in
all	DT	all
patients	NNS	patient
,	,	,
whereas	IN	whereas
CK-myocardial	JJ	<unknown>
band	NN	band
levels	NNS	level
were	VBD	be
increased	VBN	increase
in	IN	in
59	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
.	SENT	.
cTnT	NN	<unknown>
levels	NNS	level
correlated	VBN	correlate
with	IN	with
CK	NP	CK
levels	NNS	level
in	IN	in
all	DT	all
3	CD	3
subgroups	NNS	subgroup
(P<0.001)	JJ	<unknown>
.	SENT	.
None	NN	none
of	IN	of
the	DT	the
abnormal	JJ	abnormal
ECGs	NNS	<unknown>
recorded	VBN	record
in	IN	in
21	CD	@card@
patients	NNS	patient
were	VBD	be
indicative	JJ	indicative
of	IN	of
acute	JJ	acute
<span class='symptom'>
myocardial	JJ	myocardial
infarction	NN	infarction
</span>
,	,	,
and	CC	and
there	EX	there
were	VBD	be
no	DT	no
differences	NNS	difference
in	IN	in
cTnT	NN	<unknown>
levels	NNS	level
between	IN	between
patients	NNS	patient
with	IN	with
and	CC	and
without	IN	without
(	(	(
n=90	NN	<unknown>
)	)	)
abnormalities	NNS	abnormality
on	IN	on
ECG	NP	<unknown>
(	(	(
median	NN	median
28	CD	@card@
ng/L	NNS	<unknown>
in	IN	in
both	DT	both
groups)	NN	<unknown>
.	SENT	.
The	DT	the
median	NN	median
left	VBD	leave
ventricular	JJ	ventricular
mass	NN	mass
index	NN	index
measured	VBN	measure
with	IN	with
echocardiography	NN	<unknown>
was	VBD	be
normal	JJ	normal
in	IN	in
all	PDT	all
the	DT	the
3	CD	3
subgroups	NNS	subgroup
.	SENT	.
cTnT	NN	<unknown>
mRNA	NN	<unknown>
expression	NN	expression
in	IN	in
skeletal	JJ	skeletal
muscle	NN	muscle
was	VBD	be
not	RB	not
detectable	JJ	detectable
in	IN	in
controls	NNS	control
but	CC	but
was	VBD	be
strongly	RB	strongly
induced	VBN	induce
in	IN	in
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
cTnT	NN	<unknown>
protein	NN	protein
was	VBD	be
identified	VBN	identify
by	IN	by
mass	JJ	mass
spectrometry	NN	spectrometry
in	IN	in
patient-derived	JJ	<unknown>
skeletal	JJ	skeletal
muscle	NN	muscle
tissue.Elevated	JJ	<unknown>
plasma	NN	plasma
cTnT	NN	<unknown>
levels	NNS	level
in	IN	in
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
are	VBP	be
associated	VBN	associate
with	IN	with
skeletal	JJ	skeletal
muscle	NN	muscle
damage	NN	damage
,	,	,
rather	RB	rather
than	IN	than
acute	JJ	acute
myocardial	JJ	myocardial
injury	NN	injury
.	SENT	.
Increased	VBN	increase
cTnT	NN	<unknown>
levels	NNS	level
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
and	CC	and
likely	JJ	likely
other	JJ	other
neuromuscular	JJ	neuromuscular
disorders	NNS	disorder
should	MD	should
be	VB	be
interpreted	VBN	interpret
with	IN	with
caution	NN	caution
to	TO	to
avoid	VB	avoid
unnecessary	JJ	unnecessary
cardiac	JJ	cardiac
interventions	NNS	intervention
.	SENT	.
<td class='article_title' rowspan='2'>
Effects	NNS	effect
of	IN	of
a	DT	a
higher	JJR	high
dose	NN	dose
of	IN	of
alglucosidase	NN	<unknown>
alfa	NN	<unknown>
on	IN	on
ventilator-free	JJ	<unknown>
survival	NN	survival
and	CC	and
motor	NN	motor
outcome	NN	outcome
in	IN	in
classic	JJ	classic
infantile	JJ	infantile
Pompe	NP	<unknown>
disease	NN	disease
:	:	:
an	DT	an
open-label	NN	<unknown>
single-center	NN	<unknown>
study	NN	study
.	SENT	.
</td>
Though	IN	though
enzyme-replacement	NN	<unknown>
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
alglucosidase	NN	<unknown>
alfa	NN	<unknown>
has	VBZ	have
significantly	RB	significantly
improved	VBN	improve
the	DT	the
prospects	NNS	prospect
for	IN	for
patients	NNS	patient
with	IN	with
classic	JJ	classic
infantile	JJ	infantile
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
some	DT	some
50	CD	@card@
%	NN	%
of	IN	of
treated	VBN	treat
infants	NNS	infant
do	VBP	do
not	RB	not
survive	VB	survive
ventilator-free	JJ	<unknown>
beyond	IN	beyond
the	DT	the
age	NN	age
of	IN	of
3	CD	3
years	NNS	year
.	SENT	.
We	PP	we
investigated	VBD	investigate
whether	IN	whether
higher	JJR	high
and	CC	and
more	JJR	more
frequent	JJ	frequent
dosing	VBG	dose
of	IN	of
alglucosidase	NN	<unknown>
alfa	NN	<unknown>
improves	VBZ	improve
outcome.Eight	JJ	<unknown>
cross-reactive	JJ	<unknown>
immunological	JJ	immunological
material	NN	material
(	(	(
CRIM	NP	Crim
)	)	)
positive	JJ	positive
patients	NNS	patient
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
All	DT	all
had	VBD	have
fully	RB	fully
deleterious	JJ	deleterious
mutations	NNS	mutation
in	IN	in
both	DT	both
<span class='gene'>
GAA	NP	<unknown>
</span>
alleles	NNS	allele
.	SENT	.
Four	NP	Four
received	VBD	receive
a	DT	a
dose	NN	dose
of	IN	of
20	CD	@card@
mg/kg	NN	<unknown>
every	DT	every
other	JJ	other
week	NN	week
(	(	(
eow	NN	<unknown>
)	)	)
and	CC	and
four	CD	four
received	VBD	receive
40	CD	@card@
mg/kg/week	NN	<unknown>
.	SENT	.
Survival	NN	survival
,	,	,
ventilator-free	JJ	<unknown>
survival	NN	survival
,	,	,
left-ventricular	JJ	<unknown>
mass	JJ	mass
index	NN	index
(	(	(
LVMI	NP	<unknown>
)	)	)
,	,	,
motor	NN	motor
outcome	NN	outcome
,	,	,
infusion-associated	JJ	<unknown>
reactions	NNS	reaction
(	(	(
IARs	NP	<unknown>
)	)	)
,	,	,
and	CC	and
antibody	NN	antibody
formation	NN	formation
were	VBD	be
evaluated.All	JJ	<unknown>
eight	CD	eight
patients	NNS	patient
were	VBD	be
alive	JJ	alive
at	IN	at
study	NN	study
end	NN	end
,	,	,
seven	CD	seven
of	IN	of
them	PP	them
remained	VBD	remain
ventilator-free	JJ	<unknown>
.	SENT	.
The	DT	the
patient	NN	patient
who	WP	who
became	VBD	become
ventilator	NN	ventilator
dependent	NN	dependent
was	VBD	be
treated	VBN	treat
with	IN	with
20	CD	@card@
mg/kg	NN	<unknown>
eow	NN	<unknown>
.	SENT	.
Three	CD	Three
of	IN	of
the	DT	the
four	CD	four
patients	NNS	patient
receiving	VBG	receive
20	CD	@card@
mg/kg	NN	<unknown>
eow	NN	<unknown>
learned	VBD	learn
to	TO	to
walk	VB	walk
;	:	;
two	CD	two
of	IN	of
them	PP	them
maintained	VBD	maintain
this	DT	this
ability	NN	ability
at	IN	at
study	NN	study
end	NN	end
.	SENT	.
All	DT	all
four	CD	four
patients	NNS	patient
receiving	VBG	receive
40	CD	@card@
mg/kg/week	NN	<unknown>
acquired	VBD	acquire
and	CC	and
maintained	VBD	maintain
the	DT	the
ability	NN	ability
to	TO	to
walk	VB	walk
at	IN	at
study	NN	study
end	NN	end
(	(	(
ages	NNS	age
of	IN	of
3.3-5.6	CD	@card@
years	NNS	year
)	)	)
,	,	,
even	RB	even
though	IN	though
their	PP$	their
baseline	JJ	baseline
motor	NN	motor
functioning	NN	functioning
was	VBD	be
poorer	JJR	poor
.	SENT	.
There	EX	there
were	VBD	be
no	DT	no
apparent	JJ	apparent
differences	NNS	difference
between	IN	between
the	DT	the
two	CD	two
dose	NN	dose
groups	NNS	group
with	IN	with
respect	NN	respect
to	TO	to
the	DT	the
effect	NN	effect
of	IN	of
ERT	NN	ERT
on	IN	on
LVMI	NP	<unknown>
,	,	,
the	DT	the
number	NN	number
of	IN	of
IARs	NNS	<unknown>
and	CC	and
antibody	NN	antibody
formation.Our	NN	<unknown>
data	NNS	datum
may	MD	may
suggest	VB	suggest
that	IN	that
a	DT	a
dose	NN	dose
of	IN	of
40	CD	@card@
mg/kg/week	NN	<unknown>
improves	VBZ	improve
outcome	NN	outcome
of	IN	of
CRIM	NP	Crim
positive	JJ	positive
patients	NNS	patient
over	IN	over
that	WDT	that
brought	VBD	bring
by	IN	by
the	DT	the
currently	RB	currently
recommended	VBN	recommend
dose	NN	dose
of	IN	of
20	CD	@card@
mg/kg	NN	<unknown>
eow	NN	<unknown>
.	SENT	.
Larger	JJR	large
studies	NNS	study
are	VBP	be
needed	VBN	need
to	TO	to
draw	VB	draw
definite	JJ	definite
conclusions	NNS	conclusion
.	SENT	.
<td class='article_title' rowspan='2'>
Quantitation	NN	<unknown>
of	IN	of
Alpha-Glucosidase	NN	<unknown>
Activity	NN	activity
Using	VBG	use
Fluorinated	NP	<unknown>
Carbohydrate	NP	<unknown>
Array	NP	<unknown>
and	CC	and
MALDI-TOF-MS	NP	<unknown>
.	SENT	.
</td>
Quantitation	NN	<unknown>
of	IN	of
alpha-glucosidase	NN	<unknown>
(	(	(
α-GD	NN	<unknown>
)	)	)
activity	NN	activity
is	VBZ	be
of	IN	of
significance	NN	significance
to	TO	to
diagnosis	NN	diagnosis
of	IN	of
many	JJ	many
diseases	NNS	disease
including	VBG	include
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
and	CC	and
type	NN	type
II	NP	II
diabetes	NN	diabetes
.	SENT	.
We	PP	we
report	VBP	report
here	RB	here
a	DT	a
new	JJ	new
method	NN	method
to	TO	to
determine	VB	determine
α-GD	JJ	<unknown>
activity	NN	activity
using	VBG	use
matrix-assisted	JJ	<unknown>
laser	NN	laser
desorption/ionization	NN	<unknown>
(MALDI)-time-of-flight	NN	<unknown>
(	(	(
TOF	NP	<unknown>
)	)	)
mass	NN	mass
spectrometry	NN	spectrometry
(	(	(
MS	NN	Ms
)	)	)
in	IN	in
combination	NN	combination
with	IN	with
carbohydrate	NN	carbohydrate
microarray	NN	<unknown>
and	CC	and
affinity	NN	affinity
surface	NN	surface
chemistry	NN	chemistry
.	SENT	.
Carbohydrate	NN	carbohydrate
probes	NNS	probe
are	VBP	be
synthesized	VBN	synthesize
for	IN	for
capture	NN	capture
of	IN	of
the	DT	the
enzymatic	JJ	enzymatic
reaction	NN	reaction
products	NNS	product
and	CC	and
the	DT	the
adducts	VBZ	adduct
are	VBP	be
loaded	VBN	load
onto	IN	onto
a	DT	a
fluorinated	VBN	fluorinate
gold	NN	gold
surface	NN	surface
to	TO	to
generate	VB	generate
an	DT	an
array	NN	array
,	,	,
which	WDT	which
is	VBZ	be
followed	VBN	follow
by	IN	by
characterization	NN	characterization
by	IN	by
MALDI-TOF-MS	NP	<unknown>
.	SENT	.
The	DT	the
ratio	NN	ratio
of	IN	of
intensities	NNS	intensity
is	VBZ	be
used	VBN	use
to	TO	to
determine	VB	determine
the	DT	the
level	NN	level
of	IN	of
activity	NN	activity
of	IN	of
several	JJ	several
enzymes	NNS	enzyme
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
half	DT	half
maximal	JJ	maximal
inhibitory	JJ	inhibitory
concentration	NN	concentration
(	(	(
IC50	NP	<unknown>
)	)	)
of	IN	of
acarbose	NN	<unknown>
and	CC	and
epigallocatechin	NP	<unknown>
gallate	NP	gallate
are	VBP	be
also	RB	also
determined	VBN	determine
using	VBG	use
this	DT	this
approach	NN	approach
,	,	,
and	CC	and
the	DT	the
results	NNS	result
agree	VBP	agree
well	RB	well
with	IN	with
the	DT	the
reported	VBN	report
values	NNS	value
.	SENT	.
This	DT	this
method	NN	method
is	VBZ	be
advantageous	JJ	advantageous
as	RB	as
compared	VBN	compare
to	TO	to
conventional	JJ	conventional
colorimetric	JJ	colorimetric
techniques	NNS	technique
that	WDT	that
typically	RB	typically
suffer	VBP	suffer
matrix	NN	matrix
interference	NN	interference
problems	NNS	problem
from	IN	from
samples	NNS	sample
.	SENT	.
The	DT	the
use	NN	use
of	IN	of
the	DT	the
polyfluorinated	JJ	<unknown>
surface	NN	surface
has	VBZ	have
effectively	RB	effectively
suppressed	VBN	suppress
the	DT	the
interference	NN	interference
.	SENT	.
<td class='article_title' rowspan='2'>
Effect	NN	effect
of	IN	of
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
added	VBD	add
to	TO	to
Home	NP	Home
Mechanical	NP	Mechanical
Ventilation	NP	<unknown>
(	(	(
HMV	NP	<unknown>
)	)	)
in	IN	in
Adult	NP	<unknown>
Pompe	NP	<unknown>
disease	NN	disease
.	SENT	.
</td>
Adult	JJ	adult
Pompe	NP	<unknown>
disease/acid	NN	<unknown>
maltase	NN	maltase
deficiency	NN	deficiency
is	VBZ	be
an	DT	an
autosomal	JJ	autosomal
recessive	JJ	recessive
disorder	NN	disorder
resulting	VBG	result
in	IN	in
accumulation	NN	accumulation
of	IN	of
glycogen	NN	glycogen
in	IN	in
skeletal	JJ	skeletal
muscles	NNS	muscle
,	,	,
leading	VBG	lead
to	TO	to
<span class='symptom'>
myopathy	NN	<unknown>
</span>
frequently	RB	frequently
involving	VBG	involve
respiratory	JJ	respiratory
muscles	NNS	muscle
.	SENT	.
This	DT	this
involvement	NN	involvement
can	MD	can
cause	VB	cause
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
that	WDT	that
may	MD	may
present	VB	present
as	IN	as
acute	JJ	acute
hypercapnic	JJ	<unknown>
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
.	SENT	.
Enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
alpha	NN	alpha
-	:	-
glucosidase	NN	<unknown>
alfa	NN	<unknown>
,	,	,
the	DT	the
only	JJ	only
disease-specific	JJ	<unknown>
treatment	NN	treatment
,	,	,
has	VBZ	have
been	VBN	be
available	JJ	available
as	IN	as
treatment	NN	treatment
option	NN	option
since	IN	since
2006.	CD	@ord@
ERT	NN	ERT
has	VBZ	have
shown	VBN	show
efficacy	NN	efficacy
concerning	VBG	concern
muscle	NN	muscle
strength	NN	strength
and	CC	and
pulmonary	JJ	pulmonary
function	NN	function
in	IN	in
adult	NN	adult
patients	NNS	patient
as	RB	as
well	RB	well
as	IN	as
positive	JJ	positive
association	NN	association
with	IN	with
survival	NN	survival
.	SENT	.
We	PP	we
present	VBP	present
two	CD	two
cases	NNS	case
where	WRB	where
addition	NN	addition
of	IN	of
ERT	NN	ERT
to	TO	to
Home	NP	Home
Mechanical	NP	Mechanical
Ventilation	NP	<unknown>
(	(	(
HMV	NP	<unknown>
)	)	)
showed	VBD	show
improvements	NNS	improvement
in	IN	in
lung	NN	lung
function	NN	function
and	CC	and
gas	NN	gas
exchange	NN	exchange
that	WDT	that
may	MD	may
not	RB	not
be	VB	be
entirely	RB	entirely
attributable	JJ	attributable
to	TO	to
nocturnal	JJ	nocturnal
HMV	NP	<unknown>
and	CC	and
therefore	RB	therefore
may	MD	may
further	RBR	further
indicate	VB	indicate
the	DT	the
beneficial	JJ	beneficial
role	NN	role
of	IN	of
ERT	NN	ERT
in	IN	in
conjunction	NN	conjunction
with	IN	with
HMV	NP	<unknown>
in	IN	in
Adult	NP	<unknown>
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<td class='article_title' rowspan='2'>
Demographic	JJ	demographic
characteristics	NNS	characteristic
and	CC	and
distribution	NN	distribution
of	IN	of
lysosomal	JJ	lysosomal
storage	NN	storage
disorder	NN	disorder
subtypes	NNS	subtype
in	IN	in
Eastern	NP	Eastern
China	NP	China
.	SENT	.
</td>
Lysosomal	JJ	lysosomal
storage	NN	storage
disorders	NNS	disorder
(	(	(
LSDs	NP	<unknown>
)	)	)
are	VBP	be
a	DT	a
group	NN	group
of	IN	of
>50	JJ	<unknown>
different	JJ	different
types	NNS	type
of	IN	of
inherited	VBN	inherit
metabolic	JJ	metabolic
disorders	NNS	disorder
that	WDT	that
result	VBP	result
from	IN	from
defects	NNS	defect
in	IN	in
the	DT	the
lysosome	NN	lysosome
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
investigate	VB	investigate
the	DT	the
distribution	NN	distribution
and	CC	and
demographic	JJ	demographic
characteristics	NNS	characteristic
of	IN	of
the	DT	the
different	JJ	different
subtypes	NNS	subtype
of	IN	of
LSDs	NP	<unknown>
in	IN	in
Eastern	NP	Eastern
China	NP	China
.	SENT	.
From	IN	from
2006	CD	@card@
to	TO	to
2012	CD	@card@
,	,	,
376	CD	@card@
out	IN	out
of	IN	of
1331	CD	@card@
clinically	RB	clinically
suspected	VBN	suspect
patients	NNS	patient
were	VBD	be
diagnosed	VBN	diagnose
with	IN	with
17	CD	@card@
different	JJ	different
subtypes	NNS	subtype
of	IN	of
LSDs	NP	<unknown>
at	IN	at
our	PP$	our
hospital	NN	hospital
.	SENT	.
Mucopolysaccharidoses	NP	<unknown>
(	(	(
MPS	NP	MPS
)	)	)
were	VBD	be
the	DT	the
most	RBS	most
common	JJ	common
group	NN	group
of	IN	of
LSDs	NP	<unknown>
(	(	(
50.5	CD	@card@
%	NN	%
)	)	)
,	,	,
followed	VBN	follow
by	IN	by
sphingolipidoses	NNS	<unknown>
(	(	(
25.4	CD	@card@
%	NN	%
)	)	)
and	CC	and
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(19.8%)	NN	<unknown>
.	SENT	.
Mucolipidosis	NN	<unknown>
type	NN	type
II/III	NP	<unknown>
accounted	VBD	account
for	IN	for
the	DT	the
remaining	VBG	remain
4	CD	4
%	NN	%
of	IN	of
diagnosed	VBN	diagnose
LSDs	NP	<unknown>
.	SENT	.
MPS	NP	MPS
II	NP	II
was	VBD	be
the	DT	the
most	RBS	most
common	JJ	common
form	NN	form
of	IN	of
MPS	NP	MPS
,	,	,
comprising	VBG	comprise
47.4	CD	@card@
%	NN	%
of	IN	of
all	DT	all
MPS	NP	MPS
cases	NNS	case
diagnosed	VBD	diagnose
,	,	,
followed	VBN	follow
by	IN	by
MPS	NP	MPS
IVA	NP	Iva
(	(	(
26.8	CD	@card@
%	NN	%
)	)	)
and	CC	and
MPS	NP	MPS
I	NP	I
(16.3%)	NN	<unknown>
.	SENT	.
<span class='disease'>
Gaucher	JJR	gauche
disease	NN	disease
</span>
and	CC	and
Niemann-Pick	NP	<unknown>
disease	NN	disease
type	NN	type
A/B	NP	<unknown>
were	VBD	be
the	DT	the
two	CD	two
most	RBS	most
common	JJ	common
forms	NNS	form
of	IN	of
sphingolipidoses	NNS	<unknown>
.	SENT	.
There	EX	there
was	VBD	be
a	DT	a
large	JJ	large
variation	NN	variation
in	IN	in
the	DT	the
time	NN	time
between	IN	between
disease	NN	disease
onset	NN	onset
and	CC	and
eventual	JJ	eventual
diagnosis	NN	diagnosis
,	,	,
from	IN	from
0.3	CD	@card@
years	NNS	year
in	IN	in
infantile-onset	NN	<unknown>
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
to	TO	to
30	CD	@card@
years	NNS	year
in	IN	in
<span class='disease'>
Fabry	NP	Fabry
disease	NN	disease
</span>
,	,	,
highlighting	VBG	highlight
timely	JJ	timely
and	CC	and
accurate	JJ	accurate
diagnosis	NN	diagnosis
of	IN	of
LSDs	NP	<unknown>
as	IN	as
the	DT	the
main	JJ	main
challenge	NN	challenge
in	IN	in
China	NP	China
.	SENT	.
<td class='article_title' rowspan='2'>
3D	JJ	3D
analysis	NN	analysis
of	IN	of
the	DT	the
chest	NN	chest
wall	NN	wall
motion	NN	motion
for	IN	for
monitoring	VBG	monitor
late-onset	NN	late-onset
Pompe	NN	<unknown>
disease	NN	disease
patients	NNS	patient
.	SENT	.
</td>
Late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
,	,	,
for	IN	for
which	WDT	which
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
is	VBZ	be
available	JJ	available
,	,	,
induces	VBZ	induce
progressive	JJ	progressive
<span class='symptom'>
diaphragmatic	JJ	diaphragmatic
weakness	NN	weakness
</span>
.	SENT	.
Monitoring	VBG	monitor
diaphragmatic	JJ	diaphragmatic
function	NN	function
is	VBZ	be
therefore	RB	therefore
crucial	JJ	crucial
but	CC	but
is	VBZ	be
hindered	VBN	hinder
by	IN	by
the	DT	the
need	NN	need
to	TO	to
insert	VB	insert
esophageal	JJ	esophageal
and	CC	and
gastric	JJ	gastric
probes	NNS	probe
.	SENT	.
Vital	JJ	vital
capacity	NN	capacity
(	(	(
VC	NP	VC
)	)	)
,	,	,
inspiratory	JJ	inspiratory
capacity	NN	capacity
,	,	,
maximal	JJ	maximal
inspiratory	JJ	inspiratory
pressure	NN	pressure
,	,	,
and	CC	and
sniff	VB	sniff
nasal	JJ	nasal
pressure	NN	pressure
are	VBP	be
noninvasive	JJ	noninvasive
measurements	NNS	measurement
but	CC	but
reflect	VBP	reflect
only	RB	only
global	JJ	global
inspiratory-muscle	NN	<unknown>
function	NN	function
.	SENT	.
Diaphragmatic	JJ	diaphragmatic
function	NN	function
may	MD	may
be	VB	be
assessable	JJ	assessable
noninvasively	RB	<unknown>
based	VBN	base
on	IN	on
abdominal	JJ	abdominal
contribution	NN	contribution
to	TO	to
breathing	NN	breathing
and	CC	and
abdominal	JJ	abdominal
volume	NN	volume
change	NN	change
during	IN	during
the	DT	the
VC	NP	VC
maneuver	NN	maneuver
(	(	(
AVC-VC	NP	<unknown>
)	)	)
,	,	,
obtained	VBN	obtain
by	IN	by
3-dimensional	JJ	<unknown>
chest-wall	NN	<unknown>
analysis	NN	analysis
.	SENT	.
In	IN	in
11	CD	@card@
patients	NNS	patient
,	,	,
we	PP	we
assessed	VBD	assess
the	DT	the
relationships	NNS	relationship
between	IN	between
the	DT	the
above-listed	JJ	<unknown>
noninvasive	JJ	noninvasive
variables	NNS	variable
and	CC	and
the	DT	the
invasively	RB	<unknown>
measured	VBN	measure
Gilbert	NP	Gilbert
index	NN	index
reflecting	VBG	reflect
the	DT	the
diaphragmatic	JJ	diaphragmatic
contribution	NN	contribution
to	TO	to
breathing	VBG	breathe
(	(	(
ratio	NN	ratio
of	IN	of
gastric	JJ	gastric
pressure	NN	pressure
over	IN	over
transdiaphragmatic	JJ	<unknown>
pressure	NN	pressure
swings	NNS	swing
during	IN	during
spontaneous	JJ	spontaneous
breathing)	NN	<unknown>
.	SENT	.
Only	RB	only
abdominal	JJ	abdominal
contribution	NN	contribution
to	TO	to
breathing	NN	breathing
and	CC	and
AVC-VC	NP	<unknown>
correlated	VBD	correlate
significantly	RB	significantly
with	IN	with
the	DT	the
Gilbert	NP	Gilbert
index	NN	index
(	(	(
R	NP	R
=	SYM	=
0.977	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.0001	CD	@card@
;	:	;
and	CC	and
R	NP	R
=	SYM	=
0.944	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.001	CD	@card@
respectively)	NN	<unknown>
.	SENT	.
AVC-VC	NP	<unknown>
correlated	VBD	correlate
significantly	RB	significantly
with	IN	with
transdiaphragmatic	JJ	<unknown>
pressure	NN	pressure
swing	NN	swing
during	IN	during
the	DT	the
sniff	VBP	sniff
maneuver	NN	maneuver
(	(	(
R	NP	R
=	SYM	=
0.743	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.0009	CD	@card@
)	)	)
and	CC	and
with	IN	with
phrenic	JJ	phrenic
magnetic	JJ	magnetic
stimulation	NN	stimulation
(	(	(
R	NP	R
=	SYM	=
0.610	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.046)	JJ	<unknown>
.	SENT	.
Repeat	VB	repeat
testing	VBG	test
1	CD	1
year	NN	year
later	RBR	later
in	IN	in
the	DT	the
first	JJ	first
6	CD	6
patients	NNS	patient
showed	VBD	show
concordant	JJ	concordant
changes	NNS	change
in	IN	in
abdominal	JJ	abdominal
contribution	NN	contribution
to	TO	to
breathing	NN	breathing
,	,	,
Gilbert	NP	Gilbert
index	NN	index
,	,	,
and	CC	and
VC	NP	VC
.	SENT	.
Abdominal	JJ	abdominal
contribution	NN	contribution
to	TO	to
breathing	NN	breathing
and	CC	and
AVC-VC	NP	<unknown>
are	VBP	be
reliable	JJ	reliable
and	CC	and
noninvasive	JJ	noninvasive
indices	NN	indices
of	IN	of
diaphragmatic	JJ	diaphragmatic
function	NN	function
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
and	CC	and
therefore	RB	therefore
hold	VB	hold
promise	NN	promise
as	IN	as
clinical	JJ	clinical
monitoring	NN	monitoring
tools	NNS	tool
.	SENT	.
<td class='article_title' rowspan='2'>
Clinical	JJ	clinical
Laboratory	NP	Laboratory
Experience	NN	experience
of	IN	of
Blood	NP	Blood
CRIM	NP	Crim
Testing	NP	Testing
in	IN	in
Infantile	NP	<unknown>
Pompe	NP	<unknown>
Disease	NP	Disease
.	SENT	.
</td>
Cross-reactive	JJ	<unknown>
immunological	JJ	immunological
material	NN	material
(	(	(
CRIM	NP	Crim
)	)	)
status	NN	status
is	VBZ	be
an	DT	an
important	JJ	important
prognostic	JJ	prognostic
factor	NN	factor
in	IN	in
patients	NNS	patient
with	IN	with
infantile	JJ	infantile
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(	(	(
<span class='disease'>
IPD	JJ	<unknown>
</span>
)	)	)
being	VBG	be
treated	VBN	treat
with	IN	with
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
.	SENT	.
Western	JJ	Western
blot	NN	blot
analysis	NN	analysis
of	IN	of
cultured	JJ	cultured
skin	NN	skin
fibroblast	NN	fibroblast
lysates	NNS	<unknown>
has	VBZ	have
been	VBN	be
the	DT	the
gold	JJ	gold
standard	NN	standard
for	IN	for
determining	VBG	determine
CRIM	NP	Crim
status	NN	status
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
evaluated	VBD	evaluate
CRIM	NP	Crim
status	NN	status
using	VBG	use
peripheral	JJ	peripheral
blood	NN	blood
mononuclear	JJ	mononuclear
cell	NN	cell
(	(	(
PBMC	NP	<unknown>
)	)	)
protein	NN	protein
.	SENT	.
For	IN	for
6	CD	6
of	IN	of
33	CD	@card@
patients	NNS	patient
(	(	(
18	CD	@card@
%	NN	%
)	)	)
CRIM	NP	Crim
status	NN	status
determination	NN	determination
using	VBG	use
PBMC	NP	<unknown>
was	VBD	be
either	RB	either
indeterminate	JJ	indeterminate
or	CC	or
discordant	JJ	discordant
with	IN	with
<span class='gene'>
GAA	NP	<unknown>
</span>
genotype	NN	genotype
or	CC	or
fibroblast	NN	fibroblast
CRIM	NP	Crim
analysis	NN	analysis
results	NNS	result
.	SENT	.
While	IN	while
the	DT	the
use	NN	use
of	IN	of
PBMCs	NP	<unknown>
for	IN	for
CRIM	NP	Crim
determination	NN	determination
has	VBZ	have
the	DT	the
advantage	NN	advantage
of	IN	of
a	DT	a
faster	JJR	fast
turnaround	NN	turnaround
time	NN	time
,	,	,
further	JJR	further
evaluation	NN	evaluation
is	VBZ	be
needed	VBN	need
to	TO	to
ensure	VB	ensure
the	DT	the
accuracy	NN	accuracy
of	IN	of
CRIM	NP	Crim
results	NNS	result
.	SENT	.
<td class='article_title' rowspan='2'>
Guidelines	NNS	guideline
for	IN	for
the	DT	the
diagnosis	NN	diagnosis
,	,	,
treatment	NN	treatment
and	CC	and
clinical	JJ	clinical
monitoring	NN	monitoring
of	IN	of
patients	NNS	patient
with	IN	with
juvenile	JJ	juvenile
and	CC	and
adult	JJ	adult
Pompe	NP	<unknown>
disease	NN	disease
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
PD	NP	PD
)	)	)
is	VBZ	be
a	DT	a
potentially	RB	potentially
lethal	JJ	lethal
illness	NN	illness
involving	VBG	involve
irreversible	JJ	irreversible
muscle	NN	muscle
damage	NN	damage
resulting	VBG	result
from	IN	from
glycogen	NN	glycogen
storage	NN	storage
in	IN	in
muscle	NN	muscle
fiber	NN	fiber
and	CC	and
activation	NN	activation
of	IN	of
autophagic	JJ	<unknown>
pathways	NNS	pathway
.	SENT	.
A	DT	a
promising	JJ	promising
therapeutic	JJ	therapeutic
perspective	NN	perspective
for	IN	for
PD	NP	PD
is	VBZ	be
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
the	DT	the
human	JJ	human
recombinant	JJ	recombinant
enzyme	NN	enzyme
acid	NN	acid
alpha-glucosidase	NN	<unknown>
(Myozyme®)	NN	<unknown>
.	SENT	.
The	DT	the
need	NN	need
to	TO	to
organize	VB	organize
a	DT	a
diagnostic	JJ	diagnostic
flowchart	NN	flowchart
,	,	,
systematize	VB	systematize
clinical	JJ	clinical
follow-up	NN	follow-up
,	,	,
and	CC	and
establish	VB	establish
new	JJ	new
therapeutic	JJ	therapeutic
recommendations	NNS	recommendation
has	VBZ	have
become	VBN	become
vital	JJ	vital
,	,	,
as	IN	as
ERT	NN	ERT
ensures	VBZ	ensure
greater	JJR	great
patient	NN	patient
longevity	NN	longevity
.	SENT	.
A	DT	a
task	NN	task
force	NN	force
of	IN	of
experienced	JJ	experienced
clinicians	NNS	clinician
outlined	VBD	outline
a	DT	a
protocol	NN	protocol
for	IN	for
diagnosis	NN	diagnosis
,	,	,
monitoring	NN	monitoring
,	,	,
treatment	NN	treatment
,	,	,
genetic	JJ	genetic
counseling	NN	counseling
,	,	,
and	CC	and
rehabilitation	NN	rehabilitation
for	IN	for
PD	JJ	PD
patients	NNS	patient
.	SENT	.
The	DT	the
study	NN	study
was	VBD	be
conducted	VBN	conduct
under	IN	under
the	DT	the
coordination	NN	coordination
of	IN	of
REBREPOM	NP	<unknown>
,	,	,
the	DT	the
Brazilian	JJ	Brazilian
Network	NP	Network
for	IN	for
Studies	NPS	Studies
of	IN	of
PD	NP	PD
.	SENT	.
The	DT	the
meeting	NN	meeting
of	IN	of
these	DT	these
experts	NNS	expert
took	VBD	take
place	NN	place
in	IN	in
October	NP	October
2013	CD	@card@
,	,	,
at	IN	at
L'Hotel	NP	<unknown>
Port	NP	Port
Bay	NP	Bay
in	IN	in
São	NP	São
Paulo	NP	Paulo
,	,	,
Brazil	NP	Brazil
.	SENT	.
In	IN	in
August	NP	August
2014	CD	@card@
,	,	,
the	DT	the
text	NN	text
was	VBD	be
reassessed	VBN	reassess
and	CC	and
updated	VBN	update
.	SENT	.
Given	VBN	give
the	DT	the
rarity	NN	rarity
of	IN	of
PD	JJ	PD
and	CC	and
limited	JJ	limited
high-impact	JJ	high-impact
publications	NNS	publication
,	,	,
experts	NNS	expert
submitted	VBD	submit
their	PP$	their
views	NNS	view
.	SENT	.
<td class='article_title' rowspan='2'>
Very	RB	very
Early	NP	Early
Treatment	NP	Treatment
for	IN	for
Infantile-Onset	NP	<unknown>
Pompe	NP	<unknown>
Disease	NP	Disease
Contributes	NP	<unknown>
to	TO	to
Better	NP	<unknown>
Outcomes	NP	<unknown>
.	SENT	.
</td>
To	TO	To
evaluate	VB	evaluate
whether	IN	whether
very	RB	very
early	JJ	early
treatment	NN	treatment
in	IN	in
our	PP$	our
patients	NNS	patient
would	MD	would
result	VB	result
in	IN	in
better	JJR	good
clinical	JJ	clinical
outcomes	NNS	outcome
and	CC	and
to	TO	to
compare	VB	compare
these	DT	these
data	NNS	datum
with	IN	with
other	JJ	other
infantile-onset	NN	<unknown>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
IOPD	JJ	<unknown>
)	)	)
cohort	NN	cohort
studies.In	NN	<unknown>
this	DT	this
nationwide	JJ	nationwide
program	NN	program
,	,	,
669	CD	@card@
797	CD	@card@
newborns	NNS	newborn
were	VBD	be
screened	VBN	screen
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
We	PP	we
diagnosed	VBD	diagnose
IOPD	NN	<unknown>
in	IN	in
14	CD	@card@
of	IN	of
these	DT	these
newborns	NNS	newborn
,	,	,
and	CC	and
all	DT	all
were	VBD	be
treated	VBN	treat
and	CC	and
followed	VBN	follow
in	IN	in
our	PP$	our
hospital.After	NN	<unknown>
2010	CD	@card@
,	,	,
the	DT	the
mean	JJ	mean
age	NN	age
at	IN	at
first	JJ	first
enzyme-replacement	NN	<unknown>
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
was	VBD	be
11.92	CD	@card@
days	NNS	day
.	SENT	.
Our	PP$	our
patients	NNS	patient
had	VBD	have
better	RBR	well
biological	JJ	biological
,	,	,
physical	JJ	physical
,	,	,
and	CC	and
developmental	JJ	developmental
outcomes	NNS	outcome
and	CC	and
lower	JJR	low
anti-rh	NP	<unknown>
acid	NN	acid
α-glucosidase	NN	<unknown>
antibodies	NNS	antibody
after	IN	after
2	CD	2
years	NNS	year
of	IN	of
treatment	NN	treatment
,	,	,
even	RB	even
compared	VBN	compare
with	IN	with
one	CD	one
group	NN	group
that	WDT	that
began	VBD	begin
ERT	NN	ERT
just	RB	just
10	CD	@card@
days	NNS	day
later	RBR	later
than	IN	than
our	PP$	our
cohort	NN	cohort
.	SENT	.
No	DT	no
patient	NN	patient
had	VBD	have
a	DT	a
hearing	NN	hearing
disorder	NN	disorder
or	CC	or
abnormal	JJ	abnormal
vision	NN	vision
.	SENT	.
The	DT	the
mean	JJ	mean
age	NN	age
for	IN	for
independent	JJ	independent
walking	NN	walking
was	VBD	be
11.6	CD	@card@
±	SYM	±
1.3	CD	@card@
months	NNS	month
,	,	,
the	DT	the
same	JJ	same
age	NN	age
as	IN	as
normal	JJ	normal
children.ERT	NN	<unknown>
for	IN	for
patients	NNS	patient
with	IN	with
IOPD	NN	<unknown>
should	MD	should
be	VB	be
initiated	VBN	initiate
as	RB	as
early	RB	early
as	RB	as
possible	JJ	possible
before	IN	before
irreversible	JJ	irreversible
damage	NN	damage
occurs	VBZ	occur
.	SENT	.
Our	PP$	our
results	NNS	result
indicate	VBP	indicate
that	IN	that
early	JJ	early
identification	NN	identification
of	IN	of
patients	NNS	patient
with	IN	with
IOPD	NN	<unknown>
allows	VBZ	allow
for	IN	for
the	DT	the
very	RB	very
early	JJ	early
initiation	NN	initiation
of	IN	of
ERT	NN	ERT
.	SENT	.
Starting	VBG	start
ERT	NN	ERT
even	RB	even
a	DT	a
few	JJ	few
days	NNS	day
earlier	RBR	earlier
may	MD	may
lead	VB	lead
to	TO	to
better	JJR	good
patient	NN	patient
outcomes	NNS	outcome
.	SENT	.
<td class='article_title' rowspan='2'>
Pompe	NP	<unknown>
Disease	NP	Disease
:	:	:
Cyanosed	JJ	<unknown>
Hypotonic	JJ	hypotonic
Infant	NN	infant
with	IN	with
Normal	JJ	normal
Respiratory	NP	<unknown>
Rate	NP	Rate
.	SENT	.
</td>
Infantile	JJ	infantile
hypotonia	NN	<unknown>
or	CC	or
floppy	JJ	floppy
infant	NN	infant
is	VBZ	be
a	DT	a
diagnostic	JJ	diagnostic
challenge	NN	challenge
when	WRB	when
it	PP	it
presents	VBZ	present
with	IN	with
other	JJ	other
presenting	VBG	present
complaints	NNS	complaint
such	JJ	such
as	IN	as
fever	NN	fever
,	,	,
cough	NN	cough
or	CC	or
<span class='symptom'>
diarrhea	NN	diarrhea
</span>
.	SENT	.
Many	JJ	many
times	NNS	time
the	DT	the
hypotonia	NN	<unknown>
goes	VBZ	go
unnoticed	JJ	unnoticed
when	WRB	when
other	JJ	other
symptom	NN	symptom
covers	VBZ	cover
the	DT	the
hypotonia	NN	<unknown>
and	CC	and
child	NN	child
continues	VBZ	continue
to	TO	to
receive	VB	receive
the	DT	the
treatment	NN	treatment
for	IN	for
other	JJ	other
symptoms	NNS	symptom
.	SENT	.
We	PP	we
report	VBP	report
a	DT	a
rare	JJ	rare
case	NN	case
from	IN	from
Nepal	NP	Nepal
of	IN	of
infantile	JJ	infantile
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
who	WP	who
presented	VBD	present
with	IN	with
the	DT	the
history	NN	history
of	IN	of
fever	NN	fever
and	CC	and
cough	NN	cough
in	IN	in
the	DT	the
recent	JJ	recent
earthquake	NN	earthquake
disaster	NN	disaster
camp	NN	camp
at	IN	at
remote	JJ	remote
part	NN	part
of	IN	of
Sindhupalchowk	NP	<unknown>
,	,	,
Nepal	NP	Nepal
.	SENT	.
He	PP	he
was	VBD	be
being	VBG	be
treated	VBN	treat
as	IN	as
a	DT	a
case	NN	case
of	IN	of
<span class='symptom'>
pneumonia	NN	pneumonia
</span>
.	SENT	.
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
can	MD	can
be	VB	be
diagnosed	VBN	diagnose
clinically	RB	clinically
by	IN	by
taking	VBG	take
detailed	JJ	detailed
history	NN	history
and	CC	and
correlating	VBG	correlate
the	DT	the
clinical	JJ	clinical
findings	NNS	finding
during	IN	during
the	DT	the
presentation	NN	presentation
with	IN	with
other	JJ	other
symptoms	NNS	symptom
.	SENT	.
In	IN	in
our	PP$	our
case	NN	case
the	DT	the
normal	JJ	normal
respiratory	JJ	respiratory
rate	NN	rate
,	,	,
reduced	VBD	reduce
Spo2	NP	<unknown>
and	CC	and
presence	NN	presence
of	IN	of
crackles	NNS	crackle
dominated	VBD	dominate
the	DT	the
hypotonia	NN	<unknown>
and	CC	and
was	VBD	be
mistreated	VBN	mistreat
as	IN	as
<span class='symptom'>
pneumonia	NN	pneumonia
</span>
.	SENT	.
High	JJ	high
index	NN	index
of	IN	of
suspicion	NN	suspicion
is	VBZ	be
necessary	JJ	necessary
in	IN	in
diagnosing	VBG	diagnose
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<td class='article_title' rowspan='2'>
Familial	JJ	familial
Pompe	NP	<unknown>
Disease	NP	Disease
.	SENT	.
</td>
Pompe	NN	<unknown>
disorder	NN	disorder
is	VBZ	be
a	DT	a
rare	JJ	rare
glycogen	NN	glycogen
storage	NN	storage
disorder	NN	disorder
that	WDT	that
is	VBZ	be
due	JJ	due
to	TO	to
a	DT	a
deficiency	NN	deficiency
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
alpha	NN	alpha
glycosidase	NN	<unknown>
enzyme	NN	enzyme
.	SENT	.
The	DT	the
heart	NN	heart
,	,	,
skeletal	JJ	skeletal
muscle	NN	muscle
,	,	,
liver	NN	liver
and	CC	and
nervous	JJ	nervous
system	NN	system
can	MD	can
be	VB	be
affected	VBN	affect
from	IN	from
the	DT	the
lysosomal	JJ	lysosomal
glycogen	NN	glycogen
accumulation	NN	accumulation
.	SENT	.
Symptoms	NNS	symptom
such	JJ	such
as	IN	as
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
,	,	,
hypotony	NN	<unknown>
,	,	,
<span class='symptom'>
myopathy	NN	<unknown>
</span>
and	CC	and
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
develop	VB	develop
.	SENT	.
The	DT	the
onset	NN	onset
may	MD	may
be	VB	be
at	IN	at
the	DT	the
infantile	JJ	infantile
,	,	,
adolescent	JJ	adolescent
or	CC	or
adult	JJ	adult
period	NN	period
depending	VBG	depend
on	IN	on
the	DT	the
enzyme	NN	enzyme
level	NN	level
.	SENT	.
The	DT	the
CK	NP	CK
level	NN	level
is	VBZ	be
high	JJ	high
in	IN	in
almost	RB	almost
all	DT	all
patients	NNS	patient
.	SENT	.
The	DT	the
diagnosis	NN	diagnosis
is	VBZ	be
made	VBN	make
with	IN	with
enzyme	NN	enzyme
level	NN	level
measurement	NN	measurement
and	CC	and
genetic	JJ	genetic
analysis.We	NNS	<unknown>
present	VBP	present
a	DT	a
family	NN	family
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
consisting	VBG	consist
of	IN	of
the	DT	the
asymptomatic	JJ	asymptomatic
mother	NN	mother
and	CC	and
two	CD	two
siblings	NNS	sibling
who	WP	who
presented	VBD	present
with	IN	with
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
and	CC	and
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
and	CC	and
who	WP	who
had	VBD	have
been	VBN	be
followed-up	JJ	<unknown>
with	IN	with
a	DT	a
diagnosis	NN	diagnosis
of	IN	of
<span class='symptom'>
muscular	JJ	muscular
dystrophy	NN	dystrophy
</span>
for	IN	for
a	DT	a
long	JJ	long
time	NN	time
.	SENT	.
<td class='article_title' rowspan='2'>
Pompe	NN	<unknown>
disease	NN	disease
:	:	:
Shared	JJ	shared
and	CC	and
unshared	JJ	<unknown>
features	NNS	feature
of	IN	of
lysosomal	JJ	lysosomal
storage	NN	storage
disorders	NNS	disorder
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
,	,	,
an	DT	an
inherited	JJ	inherited
deficiency	NN	deficiency
of	IN	of
lysosomal	JJ	lysosomal
acid	JJ	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
,	,	,
is	VBZ	be
a	DT	a
severe	JJ	severe
metabolic	JJ	metabolic
<span class='symptom'>
myopathy	NN	<unknown>
</span>
with	IN	with
a	DT	a
wide	JJ	wide
range	NN	range
of	IN	of
clinical	JJ	clinical
manifestations	NNS	manifestation
.	SENT	.
It	PP	it
is	VBZ	be
the	DT	the
first	RB	first
recognized	VBN	recognize
lysosomal	JJ	lysosomal
storage	NN	storage
disorder	NN	disorder
and	CC	and
the	DT	the
first	JJ	first
neuromuscular	JJ	neuromuscular
disorder	NN	disorder
for	IN	for
which	WDT	which
a	DT	a
therapy	NN	therapy
(	(	(
enzyme	NN	enzyme
replacement	NN	replacement
)	)	)
has	VBZ	have
been	VBN	be
approved	VBN	approve
.	SENT	.
As	IN	as
<span class='gene'>
GAA	NP	<unknown>
</span>
is	VBZ	be
the	DT	the
only	JJ	only
enzyme	NN	enzyme
that	WDT	that
hydrolyses	VBZ	hydrolyse
glycogen	NN	glycogen
to	TO	to
glucose	NN	glucose
in	IN	in
the	DT	the
acidic	JJ	acidic
environment	NN	environment
of	IN	of
the	DT	the
lysosome	NN	lysosome
,	,	,
its	PP$	its
deficiency	NN	deficiency
leads	VBZ	lead
to	TO	to
glycogen	NN	glycogen
accumulation	NN	accumulation
within	IN	within
and	CC	and
concomitant	JJ	concomitant
enlargement	NN	enlargement
of	IN	of
this	DT	this
organelle	NN	organelle
.	SENT	.
Since	IN	since
the	DT	the
introduction	NN	introduction
of	IN	of
the	DT	the
therapy	NN	therapy
,	,	,
the	DT	the
overall	JJ	overall
understanding	NN	understanding
of	IN	of
the	DT	the
disease	NN	disease
has	VBZ	have
progressed	VBN	progress
significantly	RB	significantly
,	,	,
but	CC	but
the	DT	the
pathophysiology	NN	<unknown>
of	IN	of
muscle	NN	muscle
damage	NN	damage
is	VBZ	be
still	RB	still
not	RB	not
fully	RB	fully
understood	VBN	understand
.	SENT	.
The	DT	the
emerging	VBG	emerge
complex	JJ	complex
picture	NN	picture
of	IN	of
the	DT	the
pathological	JJ	pathological
cascade	NN	cascade
involves	VBZ	involve
disturbance	NN	disturbance
of	IN	of
calcium	NN	calcium
homeostasis	NN	homeostasis
,	,	,
<span class='symptom'>
mitochondrial	JJ	mitochondrial
abnormalities	NNS	abnormality
</span>
,	,	,
dysfunctional	JJ	dysfunctional
autophagy	NN	<unknown>
,	,	,
accumulation	NN	accumulation
of	IN	of
toxic	JJ	toxic
undegradable	JJ	<unknown>
materials	NNS	material
,	,	,
and	CC	and
accelerated	VBD	accelerate
production	NN	production
of	IN	of
lipofuscin	NN	<unknown>
deposits	NNS	deposit
that	WDT	that
are	VBP	be
unrelated	JJ	unrelated
to	TO	to
aging	VBG	age
.	SENT	.
The	DT	the
relationship	NN	relationship
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
to	TO	to
other	JJ	other
lysosomal	JJ	lysosomal
storage	NN	storage
disorders	NNS	disorder
and	CC	and
potential	JJ	potential
therapeutic	JJ	therapeutic
interventions	NNS	intervention
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
are	VBP	be
discussed	VBN	discuss
.	SENT	.
<td class='article_title' rowspan='2'>
Altered	JJ	altered
activation	NN	activation
of	IN	of
the	DT	the
diaphragm	NN	diaphragm
in	IN	in
late-onset	NN	late-onset
Pompe	NN	<unknown>
disease	NN	disease
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
an	DT	an
inherited	JJ	inherited
neuromuscular	JJ	neuromuscular
disorder	NN	disorder
that	WDT	that
affects	VBZ	affect
respiratory	JJ	respiratory
function	NN	function
and	CC	and
leads	VBZ	lead
to	TO	to
dependence	NN	dependence
on	IN	on
external	JJ	external
ventilatory	JJ	ventilatory
support	NN	support
.	SENT	.
We	PP	we
studied	VBD	study
the	DT	the
activation	NN	activation
of	IN	of
the	DT	the
diaphragm	NN	diaphragm
using	VBG	use
bilateral	JJ	bilateral
phrenic	JJ	phrenic
magnetic	JJ	magnetic
stimulation	NN	stimulation
and	CC	and
hypothesized	VBD	hypothesize
that	IN	that
diaphragm	NN	diaphragm
compound	NN	compound
muscle	NN	muscle
action	NN	action
potential	NN	potential
(	(	(
CMAP	NP	<unknown>
)	)	)
amplitude	NN	amplitude
and	CC	and
evoked	VBD	evoke
transdiaphragmatic	JJ	<unknown>
pressure	NN	pressure
(	(	(
Twitch	NP	<unknown>
PDI	NP	PDI
)	)	)
would	MD	would
correlate	VB	correlate
to	TO	to
disease	NN	disease
severity	NN	severity
.	SENT	.
Eight	CD	Eight
patients	NNS	patient
with	IN	with
late	JJ	late
onset	NN	onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
LOPD	NP	<unknown>
,	,	,
aged	VBN	age
14-48	CD	@card@
years	NNS	year
)	)	)
and	CC	and
four	CD	four
healthy	JJ	healthy
control	NN	control
subjects	NNS	subject
completed	VBD	complete
the	DT	the
tests	NNS	test
.	SENT	.
Maximal	JJ	maximal
Twitch	NP	<unknown>
PDI	NP	PDI
responses	NNS	response
were	VBD	be
progressively	RB	progressively
reduced	VBN	reduce
in	IN	in
patients	NNS	patient
with	IN	with
LOPD	NN	<unknown>
compared	VBN	compare
to	TO	to
control	VB	control
subjects	NNS	subject
(	(	(
1.4-17.1cm	NP	<unknown>
H2O	NP	<unknown>
,	,	,
p<0.001	JJ	<unknown>
)	)	)
and	CC	and
correlated	VBN	correlate
to	TO	to
voluntary	JJ	voluntary
functional	JJ	functional
tests	NNS	test
(p<0.05)	NN	<unknown>
.	SENT	.
Additionally	RB	additionally
,	,	,
CMAP	NP	<unknown>
amplitude	NN	amplitude
(	(	(
mA	NNS	<unknown>
)	)	)
was	VBD	be
lower	JJR	low
in	IN	in
the	DT	the
patients	NNS	patient
who	WP	who
used	VBD	use
nighttime	NN	nighttime
or	CC	or
fulltime	JJ	fulltime
ventilatory	JJ	ventilatory
support	NN	support
,	,	,
when	WRB	when
compared	VBN	compare
to	TO	to
controls	NNS	control
and	CC	and
patients	NNS	patient
who	WP	who
used	VBD	use
no	DT	no
ventilatory	JJ	ventilatory
support	NN	support
(p<0.005)	NN	<unknown>
.	SENT	.
However	RB	however
,	,	,
the	DT	the
normalized	VBD	normalize
(	(	(
%peak	NN	<unknown>
)	)	)
Twitch	NP	<unknown>
PDI	NP	PDI
and	CC	and
CMAP	NP	<unknown>
responses	NNS	response
were	VBD	be
similar	JJ	similar
between	IN	between
patients	NNS	patient
and	CC	and
controls	NNS	control
.	SENT	.
This	DT	this
suggests	VBZ	suggest
a	DT	a
loss	NN	loss
of	IN	of
functional	JJ	functional
phrenic	JJ	phrenic
motor	NN	motor
units	NNS	unit
in	IN	in
patients	NNS	patient
,	,	,
with	IN	with
normal	JJ	normal
recruitment	NN	recruitment
of	IN	of
remaining	VBG	remain
motor	NN	motor
units	NNS	unit
.	SENT	.
<td class='article_title' rowspan='2'>
Copackaged	NP	<unknown>
AAV9	NP	<unknown>
Vectors	NP	<unknown>
Promote	NP	<unknown>
Simultaneous	NP	<unknown>
Immune	NP	Immune
Tolerance	NP	<unknown>
and	CC	and
Phenotypic	NP	<unknown>
Correction	NP	<unknown>
of	IN	of
Pompe	NP	<unknown>
Disease	NP	Disease
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
progressive	JJ	progressive
neuromuscular	JJ	neuromuscular
disorder	NN	disorder
caused	VBN	cause
by	IN	by
lysosomal	JJ	lysosomal
accumulation	NN	accumulation
of	IN	of
glycogen	NN	glycogen
from	IN	from
a	DT	a
deficiency	NN	deficiency
in	IN	in
acid	JJ	acid
alpha-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
.	SENT	.
Replacement	NN	replacement
of	IN	of
the	DT	the
missing	JJ	missing
enzyme	NN	enzyme
is	VBZ	be
available	JJ	available
by	IN	by
repeated	JJ	repeated
protein	NN	protein
infusions	NNS	infusion
;	:	;
however	RB	however
,	,	,
efficacy	NN	efficacy
is	VBZ	be
limited	VBN	limit
by	IN	by
immune	JJ	immune
response	NN	response
and	CC	and
inability	NN	inability
to	TO	to
restore	VB	restore
enzymatic	JJ	enzymatic
function	NN	function
in	IN	in
the	DT	the
central	JJ	central
nervous	JJ	nervous
system	NN	system
.	SENT	.
An	DT	an
alternative	JJ	alternative
therapeutic	JJ	therapeutic
option	NN	option
is	VBZ	be
adeno-associated	JJ	<unknown>
virus	NN	virus
(AAV)-mediated	JJ	<unknown>
gene	NN	gene
therapy	NN	therapy
,	,	,
which	WDT	which
results	VBZ	result
in	IN	in
widespread	JJ	widespread
gene	NN	gene
transfer	NN	transfer
and	CC	and
prolonged	JJ	prolonged
transgene	NN	<unknown>
expression	NN	expression
.	SENT	.
Both	DT	both
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
and	CC	and
gene	NN	gene
therapy	NN	therapy
can	MD	can
elicit	VB	elicit
anti-GAA	NP	<unknown>
immune	JJ	immune
reactions	NNS	reaction
that	WDT	that
dampen	VBP	dampen
their	PP$	their
effectiveness	NN	effectiveness
and	CC	and
pose	VB	pose
life-threatening	JJ	life-threatening
risks	NNS	risk
to	TO	to
patient	JJ	patient
safety	NN	safety
.	SENT	.
To	TO	To
modulate	VB	modulate
the	DT	the
immune	JJ	immune
responses	NNS	response
related	VBN	relate
to	TO	to
gene	NN	gene
therapy	NN	therapy
,	,	,
we	PP	we
show	VBP	show
that	IN	that
a	DT	a
human	JJ	human
codon-optimized	JJ	<unknown>
<span class='gene'>
GAA	NP	<unknown>
</span>
(	(	(
coGAA	NN	<unknown>
)	)	)
driven	VBN	drive
by	IN	by
a	DT	a
liver-specific	JJ	<unknown>
promoter	NN	promoter
(	(	(
LSP	NP	<unknown>
)	)	)
using	VBG	use
AAV9	NP	<unknown>
is	VBZ	be
capable	JJ	capable
of	IN	of
promoting	VBG	promote
immune	JJ	immune
tolerance	NN	tolerance
in	IN	in
a	DT	a
Gaa(-/-)	NP	<unknown>
mouse	NN	mouse
model	NN	model
.	SENT	.
Copackaging	NP	<unknown>
AAV9-LSP-coGAA	NP	<unknown>
with	IN	with
the	DT	the
tissue-restricted	JJ	<unknown>
<span class='gene'>
desmin	NN	<unknown>
</span>
promoter	NN	promoter
(	(	(
AAV9-DES-coGAA	NP	<unknown>
)	)	)
demonstrates	VBZ	demonstrate
the	DT	the
necessary	JJ	necessary
cell	NN	cell
autonomous	JJ	autonomous
expression	NN	expression
in	IN	in
cardiac	JJ	cardiac
muscle	NN	muscle
,	,	,
skeletal	JJ	skeletal
muscle	NN	muscle
,	,	,
peripheral	JJ	peripheral
nerve	NN	nerve
,	,	,
and	CC	and
the	DT	the
spinal	JJ	spinal
cord	NN	cord
.	SENT	.
Simultaneous	JJ	simultaneous
high-level	JJ	high-level
expression	NN	expression
in	IN	in
liver	NN	liver
led	VBN	lead
to	TO	to
the	DT	the
expansion	NN	expansion
of	IN	of
GAA-specific	JJ	<unknown>
regulatory	JJ	regulatory
T-cells	NNS	T-cell
(	(	(
Tregs	NP	<unknown>
)	)	)
and	CC	and
induction	NN	induction
of	IN	of
immune	JJ	immune
tolerance	NN	tolerance
.	SENT	.
Transfer	NN	transfer
of	IN	of
Tregs	NNS	<unknown>
into	IN	into
naïve	NN	<unknown>
recipients	NNS	recipient
prevented	VBD	prevent
pathogenic	JJ	pathogenic
allergic	JJ	allergic
reactions	NNS	reaction
after	IN	after
repeated	JJ	repeated
ERT	NN	ERT
challenges	NNS	challenge
.	SENT	.
Copackaged	NP	<unknown>
AAV9	NP	<unknown>
also	RB	also
attenuated	VBN	attenuate
preexisting	VBG	preexist
humoral	JJ	humoral
and	CC	and
cellular	JJ	cellular
immune	JJ	immune
responses	NNS	response
,	,	,
which	WDT	which
enhanced	VBD	enhance
the	DT	the
biochemical	JJ	biochemical
correction	NN	correction
.	SENT	.
Our	PP$	our
data	NNS	datum
present	VB	present
a	DT	a
therapeutic	JJ	therapeutic
design	NN	design
in	IN	in
which	WDT	which
simultaneous	JJ	simultaneous
administration	NN	administration
of	IN	of
two	CD	two
copackaged	JJ	<unknown>
AAV	NP	<unknown>
constructs	NNS	construct
may	MD	may
provide	VB	provide
therapeutic	JJ	therapeutic
benefit	NN	benefit
and	CC	and
resolve	VB	resolve
immune	JJ	immune
reactions	NNS	reaction
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
multisystem	NN	<unknown>
disorders	NNS	disorder
.	SENT	.
<td class='article_title' rowspan='2'>
Can	MD	Can
stapedius	NP	<unknown>
reflex	JJ	reflex
testing	NN	testing
objectively	RB	objectively
measure	NN	measure
muscle	NN	muscle
function	NN	function
in	IN	in
Pompe	NP	<unknown>
patients	NNS	patient
?	SENT	?
</td>
We	PP	we
assessed	VBD	assess
the	DT	the
value	NN	value
of	IN	of
stapedius	JJ	<unknown>
reflex	JJ	reflex
testing	NN	testing
as	IN	as
an	DT	an
objective	JJ	objective
measurement	NN	measurement
of	IN	of
striated	VBN	striate
muscle	NN	muscle
function	NN	function
in	IN	in
four	CD	four
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
Common	JJ	common
tests	NNS	test
of	IN	of
disease	NN	disease
severity	NN	severity
and	CC	and
efficacy	NN	efficacy
of	IN	of
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
yield	VB	yield
highly	RB	highly
variable	JJ	variable
results	NNS	result
that	WDT	that
depend	VBP	depend
on	IN	on
patient	JJ	patient
cooperation	NN	cooperation
and	CC	and
day-to-day	JJ	day-to-day
performance	NN	performance
,	,	,
whereas	IN	whereas
stapedius	JJ	<unknown>
reflex	JJ	reflex
thresholds	NNS	threshold
improved	VBN	improve
in	IN	in
seven	CD	seven
of	IN	of
eight	CD	eight
ears	NNS	ear
after	IN	after
2	CD	2
years	NNS	year
of	IN	of
ERT	NN	ERT
.	SENT	.
<td class='article_title' rowspan='2'>
Multiple	JJ	multiple
,	,	,
Successful	JJ	successful
Pregnancies	NNS	pregnancy
in	IN	in
Pompe	NP	<unknown>
Disease	NP	Disease
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
an	DT	an
autosomal	JJ	autosomal
recessive	JJ	recessive
lysosomal	JJ	lysosomal
storage	NN	storage
disease	NN	disease
characterized	VBN	characterize
in	IN	in
adult	JJ	adult
patients	NNS	patient
by	IN	by
slowly	RB	slowly
progressive	JJ	progressive
<span class='symptom'>
limb-girdle	NN	<unknown>
muscle	NN	muscle
weakness	NN	weakness
</span>
and	CC	and
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
.	SENT	.
Data	NNS	datum
on	IN	on
pregnancy	NN	pregnancy
in	IN	in
women	NNS	woman
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
intrauterine	JJ	intrauterine
development	NN	development
of	IN	of
the	DT	the
fetus	NN	fetus
and	CC	and
parturition	NN	parturition
are	VBP	be
rare	JJ	rare
.	SENT	.
Here	RB	here
we	PP	we
describe	VBP	describe
a	DT	a
twin	JJ	twin
pregnancy	NN	pregnancy
followed	VBN	follow
by	IN	by
a	DT	a
second	JJ	second
pregnancy	NN	pregnancy
in	IN	in
a	DT	a
38-year-old	JJ	38-year-old
female	JJ	female
patient	NN	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
We	PP	we
report	VBP	report
the	DT	the
<span class='gene'>
impact	NN	impact
</span>
of	IN	of
pregnancy	NN	pregnancy
on	IN	on
muscle	NN	muscle
and	CC	and
respiratory	JJ	respiratory
functions	NNS	function
as	RB	as
well	RB	well
as	IN	as
the	DT	the
neurological	JJ	neurological
and	CC	and
endocrine	JJ	endocrine
systems	NNS	system
and	CC	and
discuss	VB	discuss
the	DT	the
medical	JJ	medical
consequences	NNS	consequence
for	IN	for
anaesthetic	JJ	anaesthetic
management	NN	management
at	IN	at
parturition	NN	parturition
.	SENT	.
<td class='article_title' rowspan='2'>
Lower	JJR	low
Urinary	NP	<unknown>
Tract	NP	<unknown>
Symptoms	NP	<unknown>
and	CC	and
Incontinence	NN	incontinence
in	IN	in
Children	NNS	child
with	IN	with
Pompe	NP	<unknown>
Disease	NP	Disease
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
PD	NP	PD
)	)	)
is	VBZ	be
a	DT	a
disorder	NN	disorder
of	IN	of
lysosomal	JJ	lysosomal
glycogen	NN	glycogen
storage	NN	storage
.	SENT	.
The	DT	the
introduction	NN	introduction
of	IN	of
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
has	VBZ	have
shifted	VBN	shift
the	DT	the
focus	NN	focus
of	IN	of
care	NN	care
from	IN	from
survival	NN	survival
to	TO	to
quality	NN	quality
of	IN	of
life	NN	life
.	SENT	.
The	DT	the
presence	NN	presence
of	IN	of
lower	JJR	low
urinary	JJ	urinary
tract	NN	tract
symptoms	NNS	symptom
(	(	(
LUTS	NP	<unknown>
)	)	)
and	CC	and
incontinence	NN	incontinence
has	VBZ	have
not	RB	not
been	VBN	be
previously	RB	previously
described	VBN	describe
in	IN	in
children	NNS	child
with	IN	with
PD.Children	NP	<unknown>
with	IN	with
PD	NP	PD
followed	VBD	follow
in	IN	in
the	DT	the
Duke	NP	Duke
Lysosomal	NP	<unknown>
Storage	NP	Storage
Disease	NP	Disease
Clinic	NP	Clinic
completed	VBD	complete
a	DT	a
validated	VBN	validate
bladder	NN	bladder
control	NN	control
symptom	NN	symptom
score	NN	score
(	(	(
BCSS	NP	<unknown>
)	)	)
and	CC	and
additional	JJ	additional
questions	NNS	question
regarding	VBG	regard
<span class='symptom'>
urinary	JJ	urinary
tract	NN	tract
infections	NNS	infection
</span>
(	(	(
UTIs	NP	<unknown>
)	)	)
,	,	,
giggle	NN	giggle
,	,	,
and	CC	and
stress	NN	stress
incontinence	NN	incontinence
.	SENT	.
Descriptive	JJ	descriptive
statistics	NNS	statistic
were	VBD	be
used	VBN	use
to	TO	to
discriminate	VB	discriminate
urinary	JJ	urinary
symptoms	NNS	symptom
between	IN	between
gender	NN	gender
,	,	,
age	NN	age
,	,	,
and	CC	and
different	JJ	different
types	NNS	type
of	IN	of
PD.Sixteen	NN	<unknown>
of	IN	of
23	CD	@card@
children	NNS	child
(	(	(
aged	VBN	age
4-14	CD	@card@
years	NNS	year
)	)	)
seen	VBN	see
in	IN	in
our	PP$	our
clinic	NN	clinic
participated	VBD	participate
.	SENT	.
Seven	CD	Seven
were	VBD	be
girls	NNS	girl
;	:	;
ten	CD	ten
had	VBD	have
classic	JJ	classic
infantile	JJ	infantile
PD	NN	PD
,	,	,
two	CD	two
atypical	JJ	atypical
infantile	JJ	infantile
PD	NN	PD
,	,	,
and	CC	and
four	CD	four
childhood	NN	childhood
presentation	NN	presentation
late-onset	NN	late-onset
PD	JJ	PD
(LOPD)	NN	<unknown>
.	SENT	.
When	WRB	when
stratified	VBN	stratify
by	IN	by
PD	JJ	PD
subtype	NN	subtype
,	,	,
median	JJ	median
BCSS	NP	<unknown>
was	VBD	be
worst	RB	worst
for	IN	for
the	DT	the
classic	JJ	classic
PD	JJ	PD
subtype	NN	subtype
followed	VBN	follow
by	IN	by
atypical	JJ	atypical
PD	NP	PD
and	CC	and
LOPD	NP	<unknown>
.	SENT	.
Daytime	JJ	daytime
<span class='symptom'>
urinary	JJ	urinary
incontinence	NN	incontinence
</span>
accompanied	VBN	accompany
by	IN	by
<span class='symptom'>
constipation	NN	constipation
</span>
was	VBD	be
noted	VBN	note
in	IN	in
six	CD	six
.	SENT	.
Eight	CD	Eight
reported	JJ	reported
<span class='symptom'>
urinary	JJ	urinary
incontinence	NN	incontinence
</span>
with	IN	with
laughing	JJ	laughing
:	:	:
giggle	NN	giggle
incontinence	NN	incontinence
in	IN	in
six	CD	six
and	CC	and
stress	NN	stress
incontinence	NN	incontinence
in	IN	in
two	CD	two
.	SENT	.
Four	CD	Four
girls	NNS	girl
reported	VBD	report
a	DT	a
history	NN	history
of	IN	of
UTI	NP	<unknown>
.	SENT	.
Longitudinal	JJ	longitudinal
follow-up	NN	follow-up
in	IN	in
11	CD	@card@
patients	NNS	patient
showed	VBD	show
stable	JJ	stable
BCSS	NP	<unknown>
in	IN	in
six	CD	six
,	,	,
improvement	NN	improvement
in	IN	in
three	CD	three
,	,	,
and	CC	and
worsening	VBG	worsen
in	IN	in
two	CD	two
.	SENT	.
Worsening	NN	worsening
corresponded	VBD	correspond
with	IN	with
changes	NNS	change
in	IN	in
bowel	NN	bowel
function	NN	function
and	CC	and
improvement	NN	improvement
with	IN	with
increase	NN	increase
in	IN	in
ERT	NN	ERT
dose	NN	dose
or	CC	or
treatment	NN	treatment
of	IN	of
<span class='symptom'>
constipation	NN	constipation
</span>
.LUTS	NNS	<unknown>
and	CC	and
incontinence	NN	incontinence
are	VBP	be
common	JJ	common
in	IN	in
children	NNS	child
with	IN	with
PD	NN	PD
with	IN	with
greater	JJR	great
symptoms	NNS	symptom
noted	VBD	note
with	IN	with
infantile-type	NN	<unknown>
PD	NN	PD
.	SENT	.
Improved	VBN	improve
bowel	NN	bowel
function	NN	function
and	CC	and
increase	NN	increase
in	IN	in
ERT	NN	ERT
dose	NN	dose
may	MD	may
lead	VB	lead
to	TO	to
improvements	NNS	improvement
in	IN	in
BCSS	NP	<unknown>
.	SENT	.
<td class='article_title' rowspan='2'>
Ten	CD	Ten
Years	NNS	year
of	IN	of
The	DT	the
International	NP	International
Pompe	NP	<unknown>
Survey	NP	Survey
:	:	:
Patient	JJ	patient
Reported	JJ	reported
Outcomes	NNS	outcome
As	IN	as
A	DT	a
Reliable	NP	<unknown>
Tool	NP	Tool
for	IN	for
Studying	NP	<unknown>
Treated	NP	<unknown>
and	CC	and
Untreated	NP	<unknown>
Children	NNS	child
and	CC	and
Adults	NNS	adult
With	IN	with
Non-Classic	JJ	<unknown>
Pompe	NP	<unknown>
Disease	NP	Disease
.	SENT	.
</td>
<td class='article_title' rowspan='2'>
Quality	NN	quality
of	IN	of
life	NN	life
and	CC	and
participation	NN	participation
in	IN	in
daily	JJ	daily
life	NN	life
of	IN	of
adults	NNS	adult
with	IN	with
Pompe	NP	<unknown>
disease	NN	disease
receiving	VBG	receive
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
:	:	:
10	CD	@card@
years	NNS	year
of	IN	of
international	JJ	international
follow-up	NN	follow-up
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
an	DT	an
inheritable	JJ	inheritable
metabolic	JJ	metabolic
disorder	NN	disorder
for	IN	for
which	WDT	which
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
has	VBZ	have
been	VBN	be
available	JJ	available
since	IN	since
2006.	CD	@ord@
Effects	NNS	effect
of	IN	of
ERT	NN	ERT
have	VBP	have
been	VBN	be
shown	VBN	show
on	IN	on
distance	NN	distance
walked	VBD	walk
,	,	,
pulmonary	JJ	pulmonary
function	NN	function
and	CC	and
survival	NN	survival
.	SENT	.
We	PP	we
investigated	VBD	investigate
whether	IN	whether
it	PP	it
also	RB	also
improves	VBZ	improve
quality	NN	quality
of	IN	of
life	NN	life
and	CC	and
participation	NN	participation
in	IN	in
daily	JJ	daily
life	NN	life
in	IN	in
adult	JJ	adult
patients	NNS	patient
with	IN	with
the	DT	the
disease.In	NN	<unknown>
an	DT	an
international	JJ	international
survey	NN	survey
,	,	,
we	PP	we
assessed	VBD	assess
quality	NN	quality
of	IN	of
life	NN	life
(	(	(
Short	NP	Short
Form	NP	Form
36	CD	@card@
,	,	,
SF-36	NP	<unknown>
)	)	)
and	CC	and
participation	NN	participation
(	(	(
Rotterdam	NP	Rotterdam
Handicap	NP	<unknown>
Scale	NP	Scale
,	,	,
RHS	NP	<unknown>
)	)	)
annually	RB	annually
between	IN	between
2002	CD	@card@
and	CC	and
2012.	CD	@ord@
Repeated	JJ	repeated
measurements	NNS	measurement
mixed	JJ	mixed
effects	NNS	effect
models	NNS	model
were	VBD	be
used	VBN	use
to	TO	to
describe	VB	describe
the	DT	the
data	NNS	datum
over	IN	over
time.Responses	NNS	<unknown>
were	VBD	be
available	JJ	available
for	IN	for
174	CD	@card@
adult	NN	adult
patients	NNS	patient
.	SENT	.
In	IN	in
the	DT	the
periods	NNS	period
before	IN	before
and	CC	and
after	IN	after
start	NN	start
of	IN	of
ERT	NN	ERT
,	,	,
the	DT	the
median	JJ	median
follow-up	NN	follow-up
times	NNS	time
were	VBD	be
4	CD	4
years	NNS	year
each	DT	each
(	(	(
range	NN	range
0.5-8)	NN	<unknown>
.	SENT	.
The	DT	the
SF-36	NP	<unknown>
Physical	NP	Physical
Component	NP	<unknown>
Summary	NP	Summary
measure	NN	measure
(	(	(
PCS	NP	PCS
)	)	)
deteriorated	VBD	deteriorate
before	IN	before
ERT	NN	ERT
(	(	(
-0.73	CD	@card@
score	NN	score
points	NNS	point
per	IN	per
year	NN	year
(	(	(
sp/y	NN	<unknown>
)	)	)
;	:	;
CI	NP	<unknown>
95	CD	@card@
%	NN	%
-1.07	CD	@card@
to	TO	to
-0.39	CD	@card@
)	)	)
,	,	,
while	IN	while
it	PP	it
improved	VBD	improve
in	IN	in
the	DT	the
first	JJ	first
2	CD	2
years	NNS	year
of	IN	of
ERT	NN	ERT
(	(	(
1.49	CD	@card@
sp/y	NN	<unknown>
;	:	;
CI	NP	<unknown>
0.76	CD	@card@
to	TO	to
2.21	CD	@card@
)	)	)
,	,	,
and	CC	and
remained	VBD	remain
stable	JJ	stable
thereafter	RB	thereafter
.	SENT	.
The	DT	the
Mental	NP	<unknown>
Component	NP	<unknown>
Summary	NP	Summary
measure	NN	measure
(	(	(
MCS	NP	MCS
)	)	)
remained	VBD	remain
stable	JJ	stable
before	IN	before
and	CC	and
during	IN	during
ERT	NN	ERT
.	SENT	.
After	IN	after
declining	VBG	decline
beforehand	JJ	beforehand
(	(	(
-0.49	CD	@card@
sp/year	NN	<unknown>
;	:	;
CI	NP	<unknown>
-0.64	CD	@card@
to-0.34	NN	<unknown>
)	)	)
,	,	,
the	DT	the
RHS	NP	<unknown>
stabilized	VBD	stabilize
under	IN	under
ERT.In	NP	<unknown>
adult	NN	adult
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
ERT	NN	ERT
positively	RB	positively
affects	VBZ	affect
quality	NN	quality
of	IN	of
life	NN	life
and	CC	and
participation	NN	participation
in	IN	in
daily	JJ	daily
life	NN	life
.	SENT	.
Our	PP$	our
results	NNS	result
reinforce	VBP	reinforce
previous	JJ	previous
findings	NNS	finding
regarding	VBG	regard
the	DT	the
effect	NN	effect
of	IN	of
ERT	NN	ERT
on	IN	on
muscle	NN	muscle
strength	NN	strength
,	,	,
pulmonary	JJ	pulmonary
function	NN	function
and	CC	and
survival	NN	survival
.	SENT	.
<td class='article_title' rowspan='2'>
Lack	NN	lack
of	IN	of
robust	JJ	robust
satellite	NN	satellite
cell	NN	cell
activation	NN	activation
and	CC	and
muscle	NN	muscle
regeneration	NN	regeneration
during	IN	during
the	DT	the
progression	NN	progression
of	IN	of
Pompe	NP	<unknown>
disease	NN	disease
.	SENT	.
</td>
Muscle	NN	muscle
stem	NN	stem
cells	NNS	cell
termed	VBD	term
satellite	NN	satellite
cells	NNS	cell
are	VBP	be
essential	JJ	essential
for	IN	for
muscle	NN	muscle
regeneration	NN	regeneration
.	SENT	.
A	DT	a
central	JJ	central
question	NN	question
in	IN	in
many	JJ	many
neuromuscular	JJ	neuromuscular
disorders	NNS	disorder
is	VBZ	be
why	WRB	why
satellite	JJ	satellite
cells	NNS	cell
are	VBP	be
unable	JJ	unable
to	TO	to
prevent	VB	prevent
progressive	JJ	progressive
<span class='symptom'>
muscle	NN	muscle
wasting	NN	wasting
</span>
.	SENT	.
We	PP	we
have	VBP	have
analyzed	VBN	analyze
muscle	NN	muscle
fiber	NN	fiber
pathology	NN	pathology
and	CC	and
the	DT	the
satellite	JJ	satellite
cell	NN	cell
response	NN	response
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
a	DT	a
metabolic	JJ	metabolic
<span class='symptom'>
myopathy	NN	<unknown>
</span>
caused	VBN	cause
by	IN	by
acid	JJ	acid
alpha-glucosidase	NN	<unknown>
deficiency	NN	deficiency
and	CC	and
lysosomal	JJ	lysosomal
glycogen	NN	glycogen
accumulation	NN	accumulation
.	SENT	.
Pathology	NN	pathology
included	VBD	include
muscle	NN	muscle
fiber	NN	fiber
vacuolization	NN	<unknown>
,	,	,
loss	NN	loss
of	IN	of
cross	NN	cross
striation	NN	striation
,	,	,
and	CC	and
immune	JJ	immune
cell	NN	cell
infiltration.The	NN	<unknown>
total	JJ	total
number	NN	number
of	IN	of
Pax7-positive	JJ	<unknown>
satellite	NN	satellite
cells	NNS	cell
in	IN	in
muscle	NN	muscle
biopsies	NNS	biopsy
from	IN	from
infantile	JJ	infantile
,	,	,
childhood	NN	childhood
onset	NN	onset
and	CC	and
adult	NN	adult
patients	NNS	patient
(	(	(
with	IN	with
different	JJ	different
ages	NNS	age
and	CC	and
disease	NN	disease
severities	NNS	severity
)	)	)
were	VBD	be
indistinguishable	JJ	indistinguishable
from	IN	from
controls	NNS	control
,	,	,
indicating	VBG	indicate
that	IN	that
the	DT	the
satellite	JJ	satellite
cell	NN	cell
pool	NN	pool
is	VBZ	be
not	RB	not
exhausted	VBN	exhaust
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
Pax7/Ki67	JJ	<unknown>
double	JJ	double
stainings	NNS	<unknown>
showed	VBD	show
low	JJ	low
levels	NNS	level
of	IN	of
satellite	JJ	satellite
cell	NN	cell
proliferation	NN	proliferation
similar	JJ	similar
to	TO	to
controls	NNS	control
,	,	,
while	IN	while
MyoD	NP	<unknown>
and	CC	and
Myogenin	NP	<unknown>
stainings	NNS	<unknown>
showed	VBD	show
undetectable	JJ	undetectable
satellite	NN	satellite
cell	NN	cell
differentiation	NN	differentiation
.	SENT	.
Muscle	NN	muscle
regenerative	JJ	regenerative
activity	NN	activity
monitored	VBN	monitor
with	IN	with
expression	NN	expression
of	IN	of
embryonic	JJ	embryonic
Myosin	NP	<unknown>
Heavy	NP	Heavy
Chain	NP	Chain
was	VBD	be
weak	JJ	weak
in	IN	in
the	DT	the
rapidly	RB	rapidly
progressing	VBG	progress
classic	JJ	classic
infantile	JJ	infantile
form	NN	form
and	CC	and
undetectable	JJ	undetectable
in	IN	in
the	DT	the
more	RBR	more
slowly	RB	slowly
progressive	JJ	progressive
childhood	NN	childhood
and	CC	and
adult	NN	adult
onset	NN	onset
disease	NN	disease
including	VBG	include
in	IN	in
severely	RB	severely
affected	VBN	affect
patients.These	JJ	<unknown>
results	NNS	result
imply	VBP	imply
that	IN	that
ongoing	JJ	ongoing
<span class='symptom'>
muscle	NN	muscle
wasting	NN	wasting
</span>
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
may	MD	may
be	VB	be
explained	VBN	explain
by	IN	by
insufficient	JJ	insufficient
satellite	NN	satellite
cell	NN	cell
activation	NN	activation
and	CC	and
muscle	NN	muscle
regeneration	NN	regeneration
.	SENT	.
The	DT	the
preservation	NN	preservation
of	IN	of
the	DT	the
satellite	JJ	satellite
cell	NN	cell
pool	NN	pool
may	MD	may
offer	VB	offer
a	DT	a
venue	NN	venue
for	IN	for
the	DT	the
development	NN	development
of	IN	of
novel	JJ	novel
treatment	NN	treatment
strategies	NNS	strategy
directed	VBN	direct
towards	IN	towards
the	DT	the
activation	NN	activation
of	IN	of
endogenous	JJ	endogenous
satellite	NN	satellite
cells	NNS	cell
.	SENT	.
<td class='article_title' rowspan='2'>
[	SYM	[
Variability	NN	variability
in	IN	in
the	DT	the
clinical	JJ	clinical
presentation	NN	presentation
of	IN	of
Pompe	NP	<unknown>
disease	NN	disease
:	:	:
development	NN	development
following	VBG	follow
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
]	SYM	]
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
generalized	VBN	generalize
progressive	JJ	progressive
disease	NN	disease
caused	VBN	cause
by	IN	by
a	DT	a
deficiency	NN	deficiency
of	IN	of
the	DT	the
lysosome	NN	lysosome
enzyme	NN	enzyme
acid	NN	acid
alpha-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
.	SENT	.
We	PP	we
present	VBP	present
three	CD	three
cases	NNS	case
with	IN	with
different	JJ	different
clinical	JJ	clinical
symptomatology	NN	symptomatology
and	CC	and
treated	VBN	treat
with	IN	with
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
positive	JJ	positive
evolution.Case	NN	<unknown>
1	CD	1
:	:	:
three-month	JJ	three-month
old	JJ	old
male	NN	male
,	,	,
with	IN	with
<span class='symptom'>
weakness	NN	weakness
</span>
and	CC	and
rejecting	VBG	reject
meals	NNS	meal
;	:	;
mild	JJ	mild
<span class='symptom'>
hepatomegaly	NN	<unknown>
</span>
,	,	,
discrete	JJ	discrete
<span class='symptom'>
macroglossia	NN	<unknown>
</span>
and	CC	and
muscular	JJ	muscular
hypotony	NN	<unknown>
;	:	;
and	CC	and
increased	VBD	increase
muscular	JJ	muscular
enzymes	NNS	enzyme
.	SENT	.
Case	NN	case
2	CD	2
:	:	:
five-month	NN	five-month
old	JJ	old
male	NN	male
,	,	,
with	IN	with
<span class='symptom'>
delayed	VBN	delay
motor	NN	motor
development	NN	development
</span>
,	,	,
severe	JJ	severe
neurosensory	JJ	<unknown>
<span class='symptom'>
deafness	NN	deafness
</span>
,	,	,
and	CC	and
respiratory	JJ	respiratory
disorder	NN	disorder
of	IN	of
difficult	JJ	difficult
evolution	NN	evolution
;	:	;
muscular	JJ	muscular
hypotony	NN	<unknown>
;	:	;
and	CC	and
mild	JJ	mild
increase	NN	increase
in	IN	in
creatine	NN	creatine
kinase	NN	kinase
.	SENT	.
Case	NN	case
3	CD	3
:	:	:
22-year	JJ	<unknown>
old	JJ	old
male	NN	male
,	,	,
with	IN	with
progressive	JJ	progressive
<span class='symptom'>
dyspnea	NN	dyspnea
</span>
,	,	,
with	IN	with
history	NN	history
of	IN	of
<span class='symptom'>
increased	VBN	increase
creatine	NN	creatine
kinase	NN	kinase
</span>
and	CC	and
transaminases	NNS	<unknown>
,	,	,
and	CC	and
<span class='symptom'>
hypercholesterolemia	NN	<unknown>
</span>
.	SENT	.
He	PP	he
suffered	VBD	suffer
from	IN	from
severe	JJ	severe
<span class='symptom'>
respiratory	JJ	respiratory
failure	NN	failure
</span>
requiring	VBG	require
endotraqueal	JJ	<unknown>
intubation	NN	intubation
Muscular	JJ	muscular
biopsy	NN	biopsy
showed	VBD	show
glycogen	NN	glycogen
storage	NN	storage
suggestive	JJ	suggestive
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
In	IN	in
the	DT	the
three	CD	three
cases	NNS	case
,	,	,
the	DT	the
EMG	NP	<unknown>
showed	VBD	show
a	DT	a
characteristic	JJ	characteristic
pattern	NN	pattern
with	IN	with
pseudomyotonic	JJ	<unknown>
discharges	NNS	discharge
and	CC	and
the	DT	the
deficiency	NN	deficiency
in	IN	in
<span class='gene'>
GAA	NP	<unknown>
</span>
was	VBD	be
confirmed	VBN	confirm
in	IN	in
lymphocytes	NNS	lymphocyte
.	SENT	.
One	CD	One
single	JJ	single
mutation	NN	mutation
was	VBD	be
observed	VBN	observe
in	IN	in
one	CD	one
case	NN	case
and	CC	and
two	CD	two
in	IN	in
the	DT	the
other	JJ	other
two	CD	two
cases	NNS	case
.	SENT	.
Every	DT	every
patient	NN	patient
received	VBD	receive
ERT	NN	ERT
showing	VBG	show
a	DT	a
favorable	JJ	favorable
evolution	NN	evolution
;	:	;
with	IN	with
disappearance	NN	disappearance
of	IN	of
cardiac	JJ	cardiac
disorders	NNS	disorder
in	IN	in
case	NN	case
1	CD	1
,	,	,
improvement	NN	improvement
in	IN	in
motor	NN	motor
development	NN	development
in	IN	in
both	DT	both
infants	NNS	infant
and	CC	and
no	DT	no
longer	JJR	long
need	NN	need
for	IN	for
mechanical	JJ	mechanical
ventilation	NN	ventilation
in	IN	in
case	NN	case
3.Pompe	JJ	<unknown>
disease	NN	disease
has	VBZ	have
a	DT	a
wide	JJ	wide
variability	NN	variability
in	IN	in
clinical	JJ	clinical
expression	NN	expression
.	SENT	.
ERT	NN	ERT
achieves	VBZ	achieve
a	DT	a
good	JJ	good
response	NN	response
,	,	,
especially	RB	especially
in	IN	in
infant	JJ	infant
forms	NNS	form
of	IN	of
the	DT	the
disease	NN	disease
.	SENT	.
The	DT	the
survival	NN	survival
of	IN	of
treated	VBN	treat
patients	NNS	patient
with	IN	with
these	DT	these
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
forms	NNS	form
will	MD	will
allow	VB	allow
knowing	VBG	know
further	JJR	further
the	DT	the
course	NN	course
of	IN	of
the	DT	the
disease	NN	disease
.	SENT	.
<td class='article_title' rowspan='2'>
[	SYM	[
POMPE	NP	<unknown>
DISEASE	NP	Disease
-	:	-
GUIDELINES	NP	<unknown>
FOR	IN	for
DIAGNOSIS	NN	diagnosis
AND	CC	and
MANAGEMENT	NN	management
OF	IN	of
ADULT	JJ	adult
PATIENTS	NNS	patient
]	SYM	]
.	SENT	.
</td>
These	DT	these
guidelines	NNS	guideline
provide	VBP	provide
a	DT	a
short	JJ	short
summary	NN	summary
of	IN	of
recommendations	NNS	recommendation
on	IN	on
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
,	,	,
how	WRB	how
to	TO	to
diagnose	VB	diagnose
this	DT	this
disease	NN	disease
,	,	,
management	NN	management
of	IN	of
adult	JJ	adult
patients	NNS	patient
with	IN	with
this	DT	this
disease	NN	disease
,	,	,
follow-up	NN	follow-up
of	IN	of
the	DT	the
patients	NNS	patient
and	CC	and
recommendations	NNS	recommendation
on	IN	on
therapy	NN	therapy
and	CC	and
genetic	JJ	genetic
testing	NN	testing
.	SENT	.
Early	JJ	early
diagnosis	NN	diagnosis
and	CC	and
management	NN	management
of	IN	of
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
requires	VBZ	require
a	DT	a
multidisciplinary	JJ	multidisciplinary
approach	NN	approach
of	IN	of
several	JJ	several
different	JJ	different
experts	NNS	expert
.	SENT	.
These	DT	these
guidelines	NNS	guideline
were	VBD	be
produced	VBN	produce
by	IN	by
the	DT	the
Division	NP	Division
of	IN	of
Metabolic	NP	<unknown>
Diseases	NPS	<unknown>
,	,	,
Department	NP	Department
of	IN	of
Internal	NP	Internal
Medicine	NP	Medicine
,	,	,
University	NP	University
Hospital	NP	Hospital
Center	NP	Center
Zagreb	NP	Zagreb
which	WDT	which
is	VBZ	be
a	DT	a
Referral	JJ	<unknown>
expert	NN	expert
center	NN	center
for	IN	for
rare	JJ	rare
and	CC	and
metabolic	JJ	metabolic
diseases	NNS	disease
of	IN	of
the	DT	the
Ministry	NP	Ministry
of	IN	of
Health	NP	Health
of	IN	of
the	DT	the
Republic	NP	Republic
of	IN	of
Croatia	NP	Croatia
.	SENT	.
They	PP	they
were	VBD	be
endorsed	VBN	endorse
by	IN	by
the	DT	the
Croatian	JJ	Croatian
Society	NP	Society
for	IN	for
Rare	NP	<unknown>
Diseases	NP	<unknown>
,	,	,
Croatian	JJ	Croatian
Medical	NP	Medical
Association.These	NP	<unknown>
are	VBP	be
the	DT	the
first	JJ	first
guidelines	NNS	guideline
published	VBN	publish
in	IN	in
Croatia	NN	Croatia
on	IN	on
diagnosis	NN	diagnosis
,	,	,
treatment	NN	treatment
and	CC	and
follow-up	NN	follow-up
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<td class='article_title' rowspan='2'>
[	SYM	[
Thymic	JJ	thymic
neuroendocrine	NN	<unknown>
carcinoma	NN	carcinoma
with	IN	with
Pompe	NP	<unknown>
's	POS	's
disease	NN	disease
of	IN	of
the	DT	the
adult	NN	adult
]	SYM	]
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
glycogenosis	NN	<unknown>
type	NN	type
II	NP	II
)	)	)
is	VBZ	be
an	DT	an
inherited	JJ	inherited
autosomal	JJ	autosomal
recessive	JJ	recessive
lysosomal	JJ	lysosomal
storage	NN	storage
disease	NN	disease
caused	VBN	cause
by	IN	by
a	DT	a
deficiency	NN	deficiency
of	IN	of
acid	JJ	acid
alpha-glucosidase	NN	<unknown>
.	SENT	.
Thymic	JJ	thymic
neuroendocrine	NN	<unknown>
tumors	NNS	tumor
,	,	,
are	VBP	be
primary	JJ	primary
thymic	JJ	thymic
neoplasms	NNS	neoplasm
with	IN	with
neuroendocrine	JJ	<unknown>
differentiation	NN	differentiation
that	IN	that
generally	RB	generally
present	JJ	present
as	IN	as
a	DT	a
mass	NN	mass
within	IN	within
the	DT	the
anterior	JJ	anterior
mediastinum	NN	mediastinum
.	SENT	.
Both	DT	both
diseases	NNS	disease
are	VBP	be
considered	VBN	consider
rare	JJ	rare
.	SENT	.
To	TO	To
our	PP$	our
knowledge	NN	knowledge
the	DT	the
co-existence	NN	co-existence
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
and	CC	and
<span class='disease'>
thymic	JJ	thymic
neuroendocrine	NN	<unknown>
tumor	NN	tumor
</span>
in	IN	in
the	DT	the
same	JJ	same
patient	NN	patient
has	VBZ	have
not	RB	not
been	VBN	be
previously	RB	previously
reported	VBN	report
.	SENT	.
We	PP	we
could	MD	could
not	RB	not
find	VB	find
biological	JJ	biological
plausibility	NN	plausibility
between	IN	between
both	DT	both
diseases	NNS	disease
.	SENT	.
Further	JJR	further
studies	NNS	study
are	VBP	be
needed	VBN	need
to	TO	to
confirm	VB	confirm
the	DT	the
finding	NN	finding
and	CC	and
to	TO	to
further	RBR	further
increase	VB	increase
our	PP$	our
understanding	NN	understanding
of	IN	of
this	DT	this
association	NN	association
.	SENT	.
Clinical	JJ	clinical
data	NNS	datum
from	IN	from
epidemiological	JJ	epidemiological
studies	NNS	study
,	,	,
case	NN	case
reports	NNS	report
,	,	,
case	NN	case
series	NN	series
and	CC	and
small	JJ	small
formal	JJ	formal
open	JJ	open
or	CC	or
controlled	JJ	controlled
clinical	JJ	clinical
trials	NNS	trial
may	MD	may
define	VB	define
both	DT	both
clinical	JJ	clinical
plausibility	NN	plausibility
and	CC	and
causality	NN	causality
between	IN	between
the	DT	the
two	CD	two
conditions	NNS	condition
.	SENT	.
<td class='article_title' rowspan='2'>
Global	NP	Global
N-linked	NP	<unknown>
Glycosylation	NP	<unknown>
is	VBZ	be
Not	RB	not
Significantly	RB	significantly
Impaired	JJ	impaired
in	IN	in
Myoblasts	NNS	<unknown>
in	IN	in
Congenital	NP	<unknown>
Myasthenic	NP	<unknown>
Syndromes	NP	<unknown>
Caused	NP	<unknown>
by	IN	by
Defective	NP	<unknown>
Glutamine-Fructose-6-Phosphate	NN	<unknown>
Transaminase	NP	<unknown>
1	CD	1
(GFPT1)	NN	<unknown>
.	SENT	.
</td>
Glutamine-fructose-6-phosphate	NN	<unknown>
transaminase	NN	<unknown>
1	CD	1
(	(	(
<span class='gene'>
GFPT1	NP	<unknown>
</span>
)	)	)
is	VBZ	be
the	DT	the
first	JJ	first
enzyme	NN	enzyme
of	IN	of
the	DT	the
hexosamine	JJ	<unknown>
biosynthetic	JJ	biosynthetic
pathway	NN	pathway
.	SENT	.
It	PP	it
transfers	VBZ	transfer
an	DT	an
amino	NN	amino
group	NN	group
from	IN	from
glutamine	NN	glutamine
to	TO	to
fructose-6-phosphate	NN	<unknown>
to	TO	to
yield	VB	yield
glucosamine-6-phosphate	NN	<unknown>
,	,	,
thus	RB	thus
providing	VBG	provide
the	DT	the
precursor	NN	precursor
for	IN	for
uridine	NN	uridine
diphosphate	NN	<unknown>
N-acetylglucosamine	NP	<unknown>
(	(	(
UDP-GlcNAc	NP	<unknown>
)	)	)
synthesis	NN	synthesis
.	SENT	.
UDP-GlcNAc	NP	<unknown>
is	VBZ	be
an	DT	an
essential	JJ	essential
substrate	NN	substrate
for	IN	for
all	DT	all
mammalian	JJ	mammalian
glycosylation	NN	<unknown>
biosynthetic	JJ	biosynthetic
pathways	NNS	pathway
and	CC	and
N-glycan	JJ	<unknown>
branching	NN	branching
is	VBZ	be
especially	RB	especially
sensitive	JJ	sensitive
to	TO	to
alterations	NNS	alteration
in	IN	in
the	DT	the
concentration	NN	concentration
of	IN	of
this	DT	this
sugar	NN	sugar
nucleotide	NN	nucleotide
.	SENT	.
It	PP	it
has	VBZ	have
been	VBN	be
reported	VBN	report
that	IN	that
<span class='gene'>
GFPT1	NP	<unknown>
</span>
mutations	NNS	mutation
lead	VBP	lead
to	TO	to
a	DT	a
distinct	JJ	distinct
sub-class	NN	<unknown>
of	IN	of
congenital	JJ	congenital
myasthenic	JJ	myasthenic
syndromes	NNS	syndrome
(	(	(
CMS	NP	CMS
)	)	)
termed	VBD	term
"	``	"
limb-girdle	NP	<unknown>
CMS	NP	CMS
with	IN	with
tubular	JJ	tubular
aggregates	NNS	aggregate
"	''	"
.	SENT	.
CMS	NP	CMS
are	VBP	be
hereditary	JJ	hereditary
neuromuscular	JJ	neuromuscular
transmission	NN	transmission
disorders	NNS	disorder
in	IN	in
which	WDT	which
neuromuscular	JJ	neuromuscular
junctions	NNS	junction
are	VBP	be
impaired	VBN	impair
.	SENT	.
To	TO	To
investigate	VB	investigate
whether	IN	whether
alterations	NNS	alteration
in	IN	in
protein	NN	protein
glycosylation	NN	<unknown>
at	IN	at
the	DT	the
neuromuscular	JJ	neuromuscular
junction	NN	junction
might	MD	might
be	VB	be
involved	VBN	involve
in	IN	in
this	DT	this
impairment	NN	impairment
,	,	,
we	PP	we
have	VBP	have
employed	VBN	employ
mass	JJ	mass
spectrometric	JJ	spectrometric
strategies	NNS	strategy
to	TO	to
study	VB	study
the	DT	the
N-glycomes	NP	<unknown>
of	IN	of
myoblasts	NNS	<unknown>
and	CC	and
myotubes	NNS	<unknown>
derived	VBN	derive
from	IN	from
two	CD	two
healthy	JJ	healthy
controls	NNS	control
,	,	,
three	CD	three
<span class='gene'>
GFPT1	NP	<unknown>
</span>
patients	NNS	patient
,	,	,
and	CC	and
four	CD	four
patients	NNS	patient
with	IN	with
other	JJ	other
muscular	JJ	muscular
diseases	NNS	disease
,	,	,
namely	RB	namely
CMS	NP	CMS
caused	VBD	cause
by	IN	by
mutations	NNS	mutation
in	IN	in
<span class='gene'>
DOK7	JJ	<unknown>
</span>
,	,	,
<span class='symptom'>
myopathy	NN	<unknown>
</span>
caused	VBN	cause
by	IN	by
mutations	NNS	mutation
in	IN	in
MTND5	NP	<unknown>
,	,	,
limb	NN	limb
girdle	NN	girdle
<span class='symptom'>
muscular	JJ	muscular
dystrophy	NN	dystrophy
</span>
type	NN	type
2A	NP	<unknown>
(	(	(
<span class='disease'>
LGMD2A	NP	<unknown>
</span>
)	)	)
,	,	,
and	CC	and
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
A	DT	a
comparison	NN	comparison
of	IN	of
the	DT	the
relative	JJ	relative
abundances	NNS	abundance
of	IN	of
bi-	JJ	<unknown>
,	,	,
tri-	NN	<unknown>
,	,	,
and	CC	and
tetra-antennary	JJ	<unknown>
N-glycans	NNS	<unknown>
in	IN	in
each	DT	each
of	IN	of
the	DT	the
cell	NN	cell
preparations	NNS	preparation
revealed	VBD	reveal
that	IN	that
all	DT	all
samples	NNS	sample
exhibited	VBD	exhibit
broadly	RB	broadly
similar	JJ	similar
levels	NNS	level
of	IN	of
branching	VBG	branch
.	SENT	.
Moreover	RB	moreover
,	,	,
although	IN	although
some	DT	some
differences	NNS	difference
were	VBD	be
observed	VBN	observe
in	IN	in
the	DT	the
relative	JJ	relative
abundances	NNS	abundance
of	IN	of
some	DT	some
of	IN	of
the	DT	the
N-glycan	NP	<unknown>
constituents	NNS	constituent
,	,	,
these	DT	these
variations	NNS	variation
were	VBD	be
modest	JJ	modest
and	CC	and
were	VBD	be
not	RB	not
confined	VBN	confine
to	TO	to
the	DT	the
<span class='gene'>
GFPT1	JJ	<unknown>
</span>
samples	NNS	sample
.	SENT	.
Therefore	RB	therefore
,	,	,
<span class='gene'>
GFPT1	JJ	<unknown>
</span>
mutations	NNS	mutation
in	IN	in
CMS	NP	CMS
patients	NNS	patient
do	VBP	do
not	RB	not
appear	VB	appear
to	TO	to
compromise	VB	compromise
global	JJ	global
N-glycosylation	NN	<unknown>
in	IN	in
muscle	NN	muscle
cells	NNS	cell
.	SENT	.
<td class='article_title' rowspan='2'>
Response	NN	response
of	IN	of
33	CD	@card@
UK	NP	UK
patients	NNS	patient
with	IN	with
infantile-onset	NN	<unknown>
Pompe	NP	<unknown>
disease	NN	disease
to	TO	to
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
.	SENT	.
</td>
Enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
for	IN	for
infantile-onset	NN	<unknown>
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
has	VBZ	have
been	VBN	be
commercially	RB	commercially
available	JJ	available
for	IN	for
almost	RB	almost
10	CD	@card@
years	NNS	year
.	SENT	.
We	PP	we
report	VBP	report
the	DT	the
experience	NN	experience
of	IN	of
its	PP$	its
use	NN	use
in	IN	in
a	DT	a
cohort	NN	cohort
treated	VBN	treat
at	IN	at
three	CD	three
specialist	NN	specialist
lysosomal	JJ	lysosomal
treatment	NN	treatment
centres	NNS	centre
in	IN	in
the	DT	the
UK.A	NP	<unknown>
retrospective	JJ	retrospective
case-note	NN	<unknown>
review	NN	review
was	VBD	be
performed	VBN	perform
,	,	,
with	IN	with
additional	JJ	additional
data	NNS	datum
being	VBG	be
gathered	VBN	gather
from	IN	from
two	CD	two
national	JJ	national
audits	NNS	audit
on	IN	on
all	DT	all
such	JJ	such
patients	NNS	patient
treated	VBN	treat
with	IN	with
ERT	NN	ERT
.	SENT	.
The	DT	the
<span class='gene'>
impact	NN	impact
</span>
on	IN	on
the	DT	the
outcome	NN	outcome
of	IN	of
various	JJ	various
characteristics	NNS	characteristic
,	,	,
measured	VBN	measure
just	RB	just
prior	RB	prior
to	TO	to
the	DT	the
initiation	NN	initiation
of	IN	of
ERT	NN	ERT
(	(	(
baseline	NN	baseline
)	)	)
,	,	,
was	VBD	be
evaluated	VBN	evaluate
using	VBG	use
logistic	JJ	logistic
regression.Thirty-three	NN	<unknown>
patients	NNS	patient
were	VBD	be
identified	VBN	identify
;	:	;
13/29	CD	@card@
(	(	(
45	CD	@card@
%	NN	%
)	)	)
were	VBD	be
cross-reactive	JJ	<unknown>
immunological	JJ	immunological
material	NN	material
(	(	(
CRIM	NP	Crim
)	)	)
negative	JJ	negative
,	,	,
and	CC	and
nine	CD	nine
were	VBD	be
immunomodulated	JJ	<unknown>
.	SENT	.
At	IN	at
baseline	JJ	baseline
assessment	NN	assessment
,	,	,
79	CD	@card@
%	NN	%
were	VBD	be
in	IN	in
<span class='symptom'>
heart	NN	heart
failure	NN	failure
</span>
,	,	,
66	CD	@card@
%	NN	%
had	VBD	have
<span class='symptom'>
failure	NN	failure
to	TO	to
thrive	VB	thrive
</span>
and	CC	and
70	CD	@card@
%	NN	%
had	VBD	have
radiological	JJ	radiological
signs	NNS	sign
of	IN	of
focal	JJ	focal
pulmonary	JJ	pulmonary
collapse	NN	collapse
.	SENT	.
The	DT	the
overall	JJ	overall
survival	NN	survival
rate	NN	rate
was	VBD	be
60	CD	@card@
%	NN	%
,	,	,
ventilation-free	JJ	<unknown>
survival	NN	survival
was	VBD	be
40	CD	@card@
%	NN	%
and	CC	and
30	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
were	VBD	be
ambulatory	JJ	ambulatory
.	SENT	.
Median	JJ	Median
follow-up	NN	follow-up
of	IN	of
survivors	NNS	survivor
was	VBD	be
4	CD	4
years	NNS	year
,	,	,
1.5	CD	@card@
months	NNS	month
(	(	(
range	NN	range
6	CD	6
months	NNS	month
to	TO	to
13.5	CD	@card@
years)	NN	<unknown>
.	SENT	.
As	RB	as
with	IN	with
previous	JJ	previous
studies	NNS	study
,	,	,
the	DT	the
CRIM	NP	Crim
status	NN	status
impacted	VBN	impact
on	IN	on
all	DT	all
outcome	NN	outcome
measures	NNS	measure
.	SENT	.
However	RB	however
,	,	,
in	IN	in
this	DT	this
cohort	NN	cohort
,	,	,
baseline	JJ	baseline
<span class='symptom'>
failure	NN	failure
to	TO	to
thrive	VB	thrive
</span>
was	VBD	be
related	VBN	relate
to	TO	to
death	NN	death
and	CC	and
lack	NN	lack
of	IN	of
ambulation	NN	ambulation
,	,	,
and	CC	and
left	VBD	leave
<span class='symptom'>
ventricular	JJ	ventricular
dilatation	NN	<unknown>
</span>
was	VBD	be
a	DT	a
risk	NN	risk
factor	NN	factor
for	IN	for
non-ventilator-free	JJ	<unknown>
survival.The	NN	<unknown>
outcome	NN	outcome
of	IN	of
treated	VBN	treat
patients	NNS	patient
remains	VBZ	remain
heterogeneous	JJ	heterogeneous
despite	IN	despite
attempts	NNS	attempt
at	IN	at
immunomodulation	NN	<unknown>
.	SENT	.
<span class='symptom'>
Failure	NN	failure
to	TO	to
thrive	VB	thrive
</span>
at	IN	at
baseline	NN	baseline
and	CC	and
left	VBD	leave
ventricular	JJ	ventricular
dilation	NN	dilation
appear	VBP	appear
to	TO	to
be	VB	be
associated	VBN	associate
with	IN	with
poorer	JJR	poor
outcomes	NNS	outcome
.	SENT	.
<td class='article_title' rowspan='2'>
Asymptomatic	JJ	asymptomatic
Pompe	NP	<unknown>
disease	NN	disease
:	:	:
Can	MD	Can
muscle	VB	muscle
magnetic	JJ	magnetic
resonance	NN	resonance
imaging	NN	imaging
facilitate	VBP	facilitate
diagnosis	NN	diagnosis
?	SENT	?
</td>
<td class='article_title' rowspan='2'>
Diagnosis	NN	diagnosis
and	CC	and
treatment	NN	treatment
of	IN	of
late-onset	NN	late-onset
Pompe	NN	<unknown>
disease	NN	disease
in	IN	in
the	DT	the
Middle	NP	Middle
East	NP	East
and	CC	and
North	NP	North
Africa	NP	Africa
region	NN	region
:	:	:
consensus	NN	consensus
recommendations	NNS	recommendation
from	IN	from
an	DT	an
expert	NN	expert
group	NN	group
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
is	VBZ	be
a	DT	a
rare	JJ	rare
autosomal	JJ	autosomal
recessive	JJ	recessive
disorder	NN	disorder
caused	VBN	cause
by	IN	by
a	DT	a
deficiency	NN	deficiency
of	IN	of
the	DT	the
lysosomal	JJ	lysosomal
enzyme	NN	enzyme
alpha-glucosidase	NN	<unknown>
responsible	JJ	responsible
for	IN	for
degrading	JJ	degrading
glycogen	NN	glycogen
.	SENT	.
Late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
has	VBZ	have
a	DT	a
complex	JJ	complex
multisystem	NN	<unknown>
phenotype	NN	phenotype
characterized	VBN	characterize
by	IN	by
a	DT	a
range	NN	range
of	IN	of
symptoms.An	JJ	<unknown>
expert	NN	expert
panel	NN	panel
from	IN	from
the	DT	the
Middle	NP	Middle
East	NP	East
and	CC	and
North	NP	North
Africa	NP	Africa
(	(	(
MENA	NP	Mena
)	)	)
region	NN	region
met	VBD	meet
to	TO	to
create	VB	create
consensus-based	JJ	<unknown>
guidelines	NNS	guideline
for	IN	for
the	DT	the
diagnosis	NN	diagnosis
and	CC	and
treatment	NN	treatment
of	IN	of
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
for	IN	for
the	DT	the
MENA	NP	Mena
region	NN	region
,	,	,
where	WRB	where
the	DT	the
relative	JJ	relative
prevalence	NN	prevalence
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
is	VBZ	be
thought	VBN	think
to	TO	to
be	VB	be
high	JJ	high
but	CC	but
there	EX	there
is	VBZ	be
a	DT	a
lack	NN	lack
of	IN	of
awareness	NN	awareness
and	CC	and
diagnostic	JJ	diagnostic
facilities.These	JJ	<unknown>
guidelines	NNS	guideline
set	VBN	set
out	IN	out
practical	JJ	practical
recommendations	NNS	recommendation
and	CC	and
include	VBP	include
algorithms	NNS	algorithm
for	IN	for
the	DT	the
diagnosis	NN	diagnosis
and	CC	and
treatment	NN	treatment
of	IN	of
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
.	SENT	.
They	PP	they
detail	VBP	detail
the	DT	the
ideal	JJ	ideal
diagnostic	JJ	diagnostic
workup	NN	workup
,	,	,
indicate	VBP	indicate
the	DT	the
patients	NNS	patient
in	IN	in
whom	WP	whom
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
should	MD	should
be	VB	be
initiated	VBN	initiate
,	,	,
and	CC	and
provide	VB	provide
guidance	NN	guidance
on	IN	on
appropriate	JJ	appropriate
patient	JJ	patient
monitoring.These	JJ	<unknown>
guidelines	NNS	guideline
will	MD	will
serve	VB	serve
to	TO	to
increase	VB	increase
awareness	NN	awareness
of	IN	of
the	DT	the
condition	NN	condition
,	,	,
optimize	VB	optimize
patient	JJ	patient
diagnosis	NN	diagnosis
and	CC	and
treatment	NN	treatment
,	,	,
reduce	VB	reduce
disease	NN	disease
burden	NN	burden
,	,	,
and	CC	and
improve	VB	improve
patient	JJ	patient
outcomes	NNS	outcome
.	SENT	.
<td class='article_title' rowspan='2'>
A	DT	a
beta-blocker	NN	beta-blocker
,	,	,
propranolol	NN	propranolol
,	,	,
decreases	VBZ	decrease
the	DT	the
efficacy	NN	efficacy
from	IN	from
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
in	IN	in
Pompe	NP	<unknown>
disease	NN	disease
.	SENT	.
</td>
Enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
recombinant	JJ	recombinant
human	JJ	human
acid	NN	acid
α-glucosidase	NN	<unknown>
(	(	(
rhGAA	NN	<unknown>
)	)	)
fails	VBZ	fail
to	TO	to
completely	RB	completely
reverse	VB	reverse
<span class='symptom'>
muscle	NN	muscle
weakness	NN	weakness
</span>
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
β2-agonists	NNS	<unknown>
enhanced	VBD	enhance
ERT	NN	ERT
by	IN	by
increasing	VBG	increase
receptor-mediated	JJ	<unknown>
uptake	NN	uptake
of	IN	of
rhGAA	NN	<unknown>
in	IN	in
skeletal	JJ	skeletal
muscles.To	NN	<unknown>
test	NN	test
the	DT	the
hypothesis	NN	hypothesis
that	IN	that
a	DT	a
β-blocker	NN	<unknown>
might	MD	might
reduce	VB	reduce
the	DT	the
efficacy	NN	efficacy
of	IN	of
ERT	NN	ERT
,	,	,
because	IN	because
the	DT	the
action	NN	action
of	IN	of
β-blockers	NNS	<unknown>
opposes	VBZ	oppose
those	DT	those
of	IN	of
β2-agonists.Mice	NNS	<unknown>
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
were	VBD	be
treated	VBN	treat
with	IN	with
propranolol	NN	propranolol
(	(	(
a	DT	a
β-blocker	NN	<unknown>
)	)	)
or	CC	or
clenbuterol	NN	<unknown>
in	IN	in
combination	NN	combination
with	IN	with
ERT	NN	ERT
,	,	,
or	CC	or
with	IN	with
ERT	NN	ERT
alone.Propranolol-treated	JJ	<unknown>
mice	NNS	mouse
had	VBD	have
<span class='symptom'>
decreased	VBN	decrease
<span class='symptom'>
weight	NN	weight
</span>
gain	NN	gain
</span>
(	(	(
p<0.01	JJ	<unknown>
)	)	)
,	,	,
in	IN	in
comparison	NN	comparison
with	IN	with
clenbuterol-treated	JJ	<unknown>
mice	NNS	mouse
.	SENT	.
Left	VBN	leave
ventricular	JJ	ventricular
mass	NN	mass
was	VBD	be
decreased	VBN	decrease
(	(	(
and	CC	and
comparable	JJ	comparable
to	TO	to
wild-type	NN	<unknown>
)	)	)
in	IN	in
ERT	NN	ERT
only	JJ	only
and	CC	and
clenbuterol-treated	JJ	<unknown>
groups	NNS	group
of	IN	of
mice	NNS	mouse
,	,	,
and	CC	and
unchanged	JJ	unchanged
in	IN	in
propranolol-treated	JJ	<unknown>
mice	NNS	mouse
.	SENT	.
<span class='gene'>
GAA	NP	<unknown>
</span>
activity	NN	activity
increased	VBD	increase
following	VBG	follow
either	DT	either
clenbuterol	NN	<unknown>
or	CC	or
propranolol	NN	propranolol
in	IN	in
skeletal	JJ	skeletal
muscles	NNS	muscle
.	SENT	.
However	RB	however
,	,	,
muscle	NN	muscle
glycogen	NN	glycogen
was	VBD	be
reduced	VBN	reduce
only	RB	only
in	IN	in
clenbuterol-treated	JJ	<unknown>
mice	NNS	mouse
,	,	,
not	RB	not
in	IN	in
propranolol-treated	JJ	<unknown>
mice	NNS	mouse
.	SENT	.
Cell-based	JJ	<unknown>
experiments	NNS	experiment
confirmed	VBD	confirm
that	IN	that
propranolol	NN	propranolol
reduces	VBZ	reduce
uptake	NN	uptake
of	IN	of
rhGAA	NN	<unknown>
into	IN	into
Pompe	NP	<unknown>
fibroblasts	NNS	fibroblast
and	CC	and
also	RB	also
demonstrated	VBD	demonstrate
that	IN	that
the	DT	the
drug	NN	drug
induces	VBZ	induce
intracellular	JJ	intracellular
accumulation	NN	accumulation
of	IN	of
glycoproteins	NNS	<unknown>
at	IN	at
higher	JJR	high
doses.Propranolol	NN	<unknown>
,	,	,
a	DT	a
commonly	RB	commonly
prescribed	VBN	prescribe
β-blocker	NN	<unknown>
,	,	,
reduced	VBN	reduce
weight	NN	weight
,	,	,
increased	VBD	increase
left	JJ	left
ventricular	JJ	ventricular
mass	NN	mass
and	CC	and
decreased	VBD	decrease
glycogen	NN	glycogen
clearance	NN	clearance
in	IN	in
skeletal	JJ	skeletal
muscle	NN	muscle
following	VBG	follow
ERT	NN	ERT
.	SENT	.
β-Blockers	NNS	<unknown>
might	MD	might
therefore	RB	therefore
decrease	VB	decrease
the	DT	the
efficacy	NN	efficacy
from	IN	from
ERT	NN	ERT
in	IN	in
patients	NNS	patient
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<td class='article_title' rowspan='2'>
Synergistic	JJ	synergistic
Efficacy	NN	efficacy
from	IN	from
Gene	NP	Gene
Therapy	NN	therapy
with	IN	with
Coreceptor	NP	<unknown>
Blockade	NP	<unknown>
and	CC	and
a	DT	a
β2-Agonist	NN	<unknown>
in	IN	in
Murine	NP	<unknown>
Pompe	NP	<unknown>
Disease	NP	Disease
.	SENT	.
</td>
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
glycogen	NN	glycogen
storage	NN	storage
disease	NN	disease
type	NN	type
II	NP	II
;	:	;
acid	JJ	acid
maltase	NN	maltase
deficiency	NN	deficiency
)	)	)
is	VBZ	be
a	DT	a
devastating	JJ	devastating
<span class='symptom'>
myopathy	NN	<unknown>
</span>
resulting	VBG	result
from	IN	from
acid	JJ	acid
α-glucosidase	NN	<unknown>
(	(	(
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
deficiency	NN	deficiency
in	IN	in
striated	VBN	striate
and	CC	and
smooth	JJ	smooth
muscle	NN	muscle
.	SENT	.
Despite	IN	despite
the	DT	the
availability	NN	availability
of	IN	of
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
with	IN	with
recombinant	JJ	recombinant
human	JJ	human
<span class='gene'>
GAA	NP	<unknown>
</span>
(	(	(
rhGAA	NN	<unknown>
)	)	)
,	,	,
the	DT	the
limitations	NNS	limitation
of	IN	of
ERT	NN	ERT
have	VBP	have
prompted	VBN	prompt
the	DT	the
preclinical	JJ	preclinical
development	NN	development
of	IN	of
gene	NN	gene
therapy	NN	therapy
.	SENT	.
Gene	NN	gene
therapy	NN	therapy
has	VBZ	have
the	DT	the
advantage	NN	advantage
of	IN	of
continuously	RB	continuously
producing	VBG	produce
<span class='gene'>
GAA	NP	<unknown>
</span>
,	,	,
in	IN	in
contrast	NN	contrast
to	TO	to
ERT	NN	ERT
,	,	,
which	WDT	which
requires	VBZ	require
frequent	JJ	frequent
injections	NNS	injection
of	IN	of
rhGAA	NN	<unknown>
.	SENT	.
An	DT	an
adeno-associated	JJ	<unknown>
viral	JJ	viral
(	(	(
AAV	NP	<unknown>
)	)	)
vector	NN	vector
containing	VBG	contain
a	DT	a
muscle-specific	JJ	<unknown>
promoter	NN	promoter
,	,	,
AAV-MHCK7hGAApA	NP	<unknown>
,	,	,
achieved	VBD	achieve
high	JJ	high
<span class='gene'>
GAA	NP	<unknown>
</span>
expression	NN	expression
in	IN	in
heart	NN	heart
and	CC	and
skeletal	JJ	skeletal
muscle	NN	muscle
in	IN	in
mice	NNS	mouse
with	IN	with
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
However	RB	however
,	,	,
elevated	JJ	elevated
<span class='gene'>
GAA	NP	<unknown>
</span>
activity	NN	activity
was	VBD	be
not	RB	not
sufficient	JJ	sufficient
to	TO	to
completely	RB	completely
clear	VB	clear
accumulated	VBN	accumulate
glycogen	NN	glycogen
in	IN	in
skeletal	JJ	skeletal
muscle	NN	muscle
.	SENT	.
The	DT	the
process	NN	process
of	IN	of
glycogen	NN	glycogen
clearance	NN	clearance
from	IN	from
lysosomes	NNS	lysosome
might	MD	might
require	VB	require
improved	VBN	improve
trafficking	NN	trafficking
of	IN	of
<span class='gene'>
GAA	NP	<unknown>
</span>
to	TO	to
the	DT	the
lysosomes	NNS	lysosome
in	IN	in
skeletal	JJ	skeletal
muscle	NN	muscle
,	,	,
previously	RB	previously
achieved	VBN	achieve
with	IN	with
the	DT	the
β(2)-agonist	NN	<unknown>
clenbuterol	NN	<unknown>
that	IN	that
enhanced	JJ	enhanced
glycogen	NN	glycogen
clearance	NN	clearance
in	IN	in
skeletal	JJ	skeletal
muscle	NN	muscle
without	IN	without
increasing	VBG	increase
<span class='gene'>
GAA	NP	<unknown>
</span>
activity	NN	activity
.	SENT	.
Glycogen	NN	glycogen
clearance	NN	clearance
was	VBD	be
clearly	RB	clearly
enhanced	VBN	enhance
by	IN	by
treatment	NN	treatment
with	IN	with
a	DT	a
nondepleting	JJ	<unknown>
anti-CD4	NN	<unknown>
monoclonal	NN	monoclonal
antibody	NN	antibody
(	(	(
anti-CD4	JJ	<unknown>
mAb	NN	<unknown>
)	)	)
along	IN	along
with	IN	with
muscle-specific	JJ	<unknown>
<span class='gene'>
GAA	NP	<unknown>
</span>
expression	NN	expression
in	IN	in
cardiac	JJ	cardiac
muscle	NN	muscle
,	,	,
but	CC	but
that	IN	that
treatment	NN	treatment
was	VBD	be
not	RB	not
effective	JJ	effective
in	IN	in
skeletal	JJ	skeletal
muscle	NN	muscle
.	SENT	.
Furthermore	RB	furthermore
,	,	,
anti-CD4	JJ	<unknown>
mAb	NN	<unknown>
treatment	NN	treatment
along	IN	along
with	IN	with
clenbuterol	NN	<unknown>
achieved	VBN	achieve
synergistic	JJ	synergistic
therapeutic	JJ	therapeutic
efficacy	NN	efficacy
in	IN	in
both	DT	both
cardiac	JJ	cardiac
and	CC	and
skeletal	JJ	skeletal
muscle	NN	muscle
.	SENT	.
This	DT	this
triple	JJ	triple
therapy	NN	therapy
increased	VBD	increase
both	DT	both
muscle	NN	muscle
strength	NN	strength
and	CC	and
<span class='symptom'>
weight	NN	weight
gain	NN	gain
</span>
.	SENT	.
Overall	RB	overall
,	,	,
triple	JJ	triple
therapy	NN	therapy
to	TO	to
enhance	VB	enhance
<span class='gene'>
GAA	NP	<unknown>
</span>
trafficking	NN	trafficking
and	CC	and
to	TO	to
suppress	VB	suppress
immune	JJ	immune
responses	NNS	response
significantly	RB	significantly
improved	VBD	improve
the	DT	the
efficacy	NN	efficacy
of	IN	of
muscle-targeted	JJ	<unknown>
gene	NN	gene
therapy	NN	therapy
in	IN	in
murine	JJ	murine
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
<td class='article_title' rowspan='2'>
Spinal	JJ	spinal
fusion	NN	fusion
as	IN	as
a	DT	a
viable	JJ	viable
treatment	NN	treatment
option	NN	option
for	IN	for
scoliosis	NN	scoliosis
management	NN	management
in	IN	in
Pompe	NP	<unknown>
disease	NN	disease
:	:	:
a	DT	a
postoperative	JJ	postoperative
3-year	JJ	<unknown>
follow-up	NN	follow-up
.	SENT	.
</td>
This	DT	this
study	NN	study
presents	VBZ	present
3-year	JJ	<unknown>
postoperative	JJ	postoperative
outcomes	NNS	outcome
of	IN	of
posterior	JJ	posterior
spinal	JJ	spinal
correction	NN	correction
and	CC	and
fusion	NN	fusion
of	IN	of
a	DT	a
patient	NN	patient
diagnosed	VBN	diagnose
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
(	(	(
PD	JJ	PD
)	)	)
for	IN	for
his	PP$	his
progressive	JJ	progressive
<span class='symptom'>
scoliosis	NN	scoliosis
</span>
.The	NN	<unknown>
patient	NN	patient
was	VBD	be
diagnosed	VBN	diagnose
for	IN	for
PD	NP	PD
during	IN	during
his	PP$	his
infancy	NN	infancy
.	SENT	.
Enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
(	(	(
ERT	NN	ERT
)	)	)
was	VBD	be
initiated	VBN	initiate
at	IN	at
the	DT	the
age	NN	age
of	IN	of
13.	CD	@ord@
First	NP	First
office	NN	office
visit	NN	visit
for	IN	for
his	PP$	his
spinal	JJ	spinal
deformity	NN	deformity
was	VBD	be
at	IN	at
the	DT	the
age	NN	age
of	IN	of
15	CD	@card@
,	,	,
and	CC	and
40°	JJ	<unknown>
,	,	,
34°	JJ	<unknown>
,	,	,
6°	JJ	<unknown>
spinal	JJ	spinal
curvatures	NNS	curvature
were	VBD	be
seen	VBN	see
in	IN	in
T6-L3	NP	<unknown>
,	,	,
T1-6	NP	<unknown>
,	,	,
and	CC	and
L3-S	NP	<unknown>
,	,	,
respectively	RB	respectively
.	SENT	.
Reduced	VBN	reduce
pulmonary	JJ	pulmonary
function	NN	function
,	,	,
limited	JJ	limited
gait	NN	gait
function	NN	function
and	CC	and
atrophied	VBN	atrophy
limb	NN	limb
were	VBD	be
documented	VBN	document
.	SENT	.
Initial	JJ	initial
brace	NN	brace
treatment	NN	treatment
could	MD	could
not	RB	not
control	VB	control
curve	NN	curve
progression	NN	progression
;	:	;
therefore	RB	therefore
,	,	,
posterior	JJ	posterior
spinal	JJ	spinal
correction	NN	correction
and	CC	and
fusion	NN	fusion
were	VBD	be
performed	VBN	perform
at	IN	at
the	DT	the
age	NN	age
of	IN	of
17.Immediate	JJ	<unknown>
preoperative	JJ	<unknown>
curves	NNS	curve
of	IN	of
55°	JJ	<unknown>
,	,	,
42°	JJ	<unknown>
and	CC	and
23°	JJ	<unknown>
were	VBD	be
corrected	VBN	correct
to	TO	to
18°	JJ	<unknown>
,	,	,
26°	JJ	<unknown>
and	CC	and
7°	JJ	<unknown>
in	IN	in
T6-L2	NP	<unknown>
,	,	,
T1-T6	NP	<unknown>
and	CC	and
L2-S	NP	<unknown>
,	,	,
respectively	RB	respectively
.	SENT	.
<span class='symptom'>
Spinal	JJ	spinal
fusion	NN	fusion
</span>
was	VBD	be
performed	VBN	perform
from	IN	from
T3	NP	<unknown>
to	TO	to
L4	NP	<unknown>
.	SENT	.
The	DT	the
patient	NN	patient
exhibited	VBD	exhibit
an	DT	an
excessively	RB	excessively
low	JJ	low
pulmonary	JJ	pulmonary
function	NN	function
preoperatively	RB	<unknown>
with	IN	with
a	DT	a
VC	NP	VC
,	,	,
FVC	NP	<unknown>
,	,	,
and	CC	and
%VC	NN	<unknown>
of	IN	of
1.45	CD	@card@
L	NP	L
,	,	,
1.36	CD	@card@
L	NN	L
,	,	,
and	CC	and
35	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
.	SENT	.
This	DT	this
has	VBZ	have
been	VBN	be
managed	VBN	manage
with	IN	with
only	JJ	only
moderate	JJ	moderate
reductions	NNS	reduction
despite	IN	despite
reduced	VBN	reduce
pulmonary	JJ	pulmonary
function	NN	function
from	IN	from
PD	NP	PD
throughout	IN	throughout
the	DT	the
operative	JJ	operative
period	NN	period
and	CC	and
at	IN	at
3	CD	3
years	NNS	year
.	SENT	.
At	IN	at
the	DT	the
final	JJ	final
follow-up	NN	follow-up
,	,	,
VC	NP	VC
,	,	,
FVC	NP	<unknown>
and	CC	and
%VC	NP	<unknown>
were	VBD	be
1.33	CD	@card@
L	NN	L
,	,	,
1.12	CD	@card@
L	NP	L
and	CC	and
28.5	CD	@card@
%	NN	%
,	,	,
respectively.Posterior	JJ	<unknown>
spinal	JJ	spinal
correction	NN	correction
and	CC	and
fusion	NN	fusion
adequately	RB	adequately
controlled	VBN	control
spinal	JJ	spinal
curvatures	NNS	curvature
for	IN	for
3	CD	3
years	NNS	year
after	IN	after
surgery	NN	surgery
.	SENT	.
Additionally	RB	additionally
,	,	,
pulmonary	JJ	pulmonary
function	NN	function
was	VBD	be
managed	VBN	manage
throughout	IN	throughout
the	DT	the
follow-up	NN	follow-up
period	NN	period
.	SENT	.
Despite	IN	despite
ERT	NN	ERT
,	,	,
skeletal	JJ	skeletal
muscle	NN	muscle
and	CC	and
pulmonary	JJ	pulmonary
function	NN	function
can	MD	can
still	RB	still
be	VB	be
severely	RB	severely
affected	VBN	affect
by	IN	by
PD	NP	PD
.	SENT	.
Spinal	JJ	spinal
correction	NN	correction
and	CC	and
fusion	NN	fusion
is	VBZ	be
a	DT	a
useful	JJ	useful
method	NN	method
for	IN	for
the	DT	the
management	NN	management
of	IN	of
spinal	JJ	spinal
curvature	NN	curvature
and	CC	and
pulmonary	JJ	pulmonary
function	NN	function
in	IN	in
patients	NNS	patient
with	IN	with
PD	NP	PD
.	SENT	.
<td class='article_title' rowspan='2'>
Clinical	JJ	clinical
and	CC	and
pathophysiological	JJ	<unknown>
clues	NNS	clue
of	IN	of
respiratory	JJ	respiratory
dysfunction	NN	dysfunction
in	IN	in
late-onset	NN	late-onset
Pompe	NN	<unknown>
disease	NN	disease
:	:	:
New	JJ	new
insights	NNS	insight
from	IN	from
a	DT	a
comparative	JJ	comparative
study	NN	study
by	IN	by
MRI	NP	MRI
and	CC	and
respiratory	JJ	respiratory
function	NN	function
assessment	NN	assessment
.	SENT	.
</td>
<span class='symptom'>
Respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
commonly	RB	commonly
develops	VBZ	develop
in	IN	in
patients	NNS	patient
with	IN	with
Late	JJ	late
Onset	NN	onset
<span class='disease'>
Pompe	NP	<unknown>
Disease	NP	Disease
</span>
(LOPD)	NN	<unknown>
.	SENT	.
It	PP	it
is	VBZ	be
conceivable	JJ	conceivable
that	IN	that
a	DT	a
timely	JJ	timely
starting	NN	starting
of	IN	of
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
could	MD	could
avoid	VB	avoid
this	DT	this
life-threatening	JJ	life-threatening
complication	NN	complication
.	SENT	.
Respiratory	JJ	respiratory
function	NN	function
in	IN	in
LOPD	NP	<unknown>
is	VBZ	be
commonly	RB	commonly
evaluated	VBN	evaluate
with	IN	with
standard	JJ	standard
pulmonary	JJ	pulmonary
tests	NNS	test
which	WDT	which
do	VBP	do
not	RB	not
extensively	RB	extensively
provide	VB	provide
an	DT	an
accurate	JJ	accurate
definition	NN	definition
of	IN	of
the	DT	the
muscular	JJ	muscular
pathophysiology	NN	<unknown>
.	SENT	.
In	IN	in
eleven	NN	eleven
patients	NNS	patient
with	IN	with
LOPD	NP	<unknown>
and	CC	and
five	CD	five
healthy	JJ	healthy
subjects	NNS	subject
,	,	,
we	PP	we
compared	VBD	compare
pulmonary	JJ	pulmonary
function	NN	function
results	NNS	result
with	IN	with
MRI	NP	MRI
data	NNS	datum
,	,	,
based	VBN	base
on	IN	on
scans	NNS	scan
of	IN	of
the	DT	the
right	JJ	right
lung	NN	lung
acquired	VBN	acquire
on	IN	on
maximum	JJ	maximum
expiration	NN	expiration
and	CC	and
inspiration	NN	inspiration
.	SENT	.
We	PP	we
observed	VBD	observe
that	IN	that
variations	NNS	variation
in	IN	in
the	DT	the
cranio-caudal	JJ	<unknown>
lung	NN	lung
height	NN	height
and	CC	and
of	IN	of
lung	NN	lung
areas	NNS	area
in	IN	in
inspiration	NN	inspiration
and	CC	and
expiration	NN	expiration
(	(	(
lung	NN	lung
delta	NN	delta
)	)	)
as	RB	as
well	RB	well
as	IN	as
the	DT	the
area	NN	area
of	IN	of
diaphragmatic	JJ	diaphragmatic
movement	NN	movement
strongly	RB	strongly
correlated	VBN	correlate
with	IN	with
pulmonary	JJ	pulmonary
function	NN	function
results	NNS	result
.	SENT	.
Moreover	RB	moreover
,	,	,
MRI	NP	MRI
data	NNS	datum
confirmed	VBD	confirm
that	DT	that
development	NN	development
of	IN	of
<span class='symptom'>
respiratory	JJ	respiratory
insufficiency	NN	insufficiency
</span>
in	IN	in
LOPD	NP	<unknown>
is	VBZ	be
mainly	RB	mainly
due	JJ	due
to	TO	to
the	DT	the
<span class='symptom'>
diaphragmatic	JJ	diaphragmatic
weakness	NN	weakness
</span>
with	IN	with
sparing	VBG	spare
of	IN	of
the	DT	the
antero-posterior	NN	<unknown>
chest	NN	chest
expansion	NN	expansion
related	VBN	relate
to	TO	to
the	DT	the
activity	NN	activity
of	IN	of
the	DT	the
intercostal	JJ	intercostal
muscles	NNS	muscle
.	SENT	.
These	DT	these
results	NNS	result
suggest	VBP	suggest
that	IN	that
respiratory	JJ	respiratory
muscle	NN	muscle
MRI	NP	MRI
is	VBZ	be
a	DT	a
quick	JJ	quick
,	,	,
useful	JJ	useful
and	CC	and
reproducible	JJ	reproducible
tool	NN	tool
for	IN	for
patient	JJ	patient
management	NN	management
as	RB	as
well	RB	well
as	IN	as
a	DT	a
reliable	JJ	reliable
outcome	NN	outcome
measure	NN	measure
for	IN	for
future	JJ	future
LOPD	JJ	<unknown>
therapeutic	JJ	therapeutic
trials	NNS	trial
.	SENT	.
<td class='article_title' rowspan='2'>
Evaluation	NN	evaluation
of	IN	of
Readministration	NN	<unknown>
of	IN	of
a	DT	a
Recombinant	NP	<unknown>
Adeno-Associated	NP	<unknown>
Virus	NP	<unknown>
Vector	NP	Vector
Expressing	NP	<unknown>
Acid	NP	<unknown>
Alpha-Glucosidase	NN	<unknown>
in	IN	in
Pompe	NP	<unknown>
Disease	NP	Disease
:	:	:
Preclinical	JJ	preclinical
to	TO	to
Clinical	NP	<unknown>
Planning	NP	Planning
.	SENT	.
</td>
A	DT	a
recombinant	JJ	recombinant
serotype	NN	<unknown>
9	CD	9
adeno-associated	JJ	<unknown>
virus	NN	virus
(	(	(
rAAV9	NN	<unknown>
)	)	)
vector	NN	vector
carrying	VBG	carry
a	DT	a
transgene	NN	<unknown>
that	WDT	that
expresses	VBZ	express
codon-optimized	JJ	<unknown>
human	JJ	human
acid	NN	acid
alpha-glucosidase	NN	<unknown>
(	(	(
hGAA	NP	<unknown>
,	,	,
or	CC	or
<span class='gene'>
GAA	NP	<unknown>
</span>
)	)	)
driven	VBN	drive
by	IN	by
a	DT	a
human	JJ	human
<span class='gene'>
desmin	NN	<unknown>
</span>
(	(	(
<span class='gene'>
DES	NP	DES
</span>
)	)	)
promoter	NN	promoter
(	(	(
i.e.	FW	i.e.
,	,	,
rAAV9-DES-hGAA	NP	<unknown>
)	)	)
has	VBZ	have
been	VBN	be
generated	VBN	generate
as	IN	as
a	DT	a
clinical	JJ	clinical
candidate	NN	candidate
vector	NN	vector
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
The	DT	the
rAAV9-DES-hGAA	NN	<unknown>
vector	NN	vector
is	VBZ	be
being	VBG	be
developed	VBN	develop
as	IN	as
a	DT	a
treatment	NN	treatment
for	IN	for
both	DT	both
early-	NN	early-
and	CC	and
late-onset	NN	late-onset
<span class='disease'>
Pompe	NN	<unknown>
disease	NN	disease
</span>
,	,	,
in	IN	in
which	WDT	which
patients	NNS	patient
lack	VBP	lack
sufficient	JJ	sufficient
lysosomal	JJ	lysosomal
alpha-glucosidase	NN	<unknown>
leading	VBG	lead
to	TO	to
glycogen	NN	glycogen
accumulation	NN	accumulation
.	SENT	.
In	IN	in
young	JJ	young
patients	NNS	patient
,	,	,
the	DT	the
therapy	NN	therapy
may	MD	may
need	VB	need
to	TO	to
be	VB	be
readministered	VBN	<unknown>
after	IN	after
a	DT	a
period	NN	period
of	IN	of
time	NN	time
to	TO	to
maintain	VB	maintain
therapeutic	JJ	therapeutic
levels	NNS	level
of	IN	of
<span class='gene'>
GAA	NP	<unknown>
</span>
.	SENT	.
Administration	NN	administration
of	IN	of
AAV-based	JJ	<unknown>
gene	NN	gene
therapies	NNS	therapy
is	VBZ	be
commonly	RB	commonly
associated	VBN	associate
with	IN	with
the	DT	the
production	NN	production
of	IN	of
neutralizing	VBG	neutralize
antibodies	NNS	antibody
that	WDT	that
may	MD	may
reduce	VB	reduce
the	DT	the
effectiveness	NN	effectiveness
of	IN	of
the	DT	the
vector	NN	vector
,	,	,
especially	RB	especially
if	IN	if
readministration	NN	<unknown>
is	VBZ	be
required	VBN	require
.	SENT	.
Previous	JJ	previous
studies	NNS	study
have	VBP	have
demonstrated	VBN	demonstrate
the	DT	the
ability	NN	ability
of	IN	of
rAAV9-DES-hGAA	NN	<unknown>
to	TO	to
correct	VB	correct
cardiac	JJ	cardiac
and	CC	and
skeletal	JJ	skeletal
muscle	NN	muscle
pathology	NN	pathology
in	IN	in
Gaa(-/-)	NP	<unknown>
mice	NNS	mouse
,	,	,
an	DT	an
animal	JJ	animal
model	NN	model
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
This	DT	this
article	NN	article
describes	VBZ	describe
the	DT	the
IND-enabling	JJ	<unknown>
preclinical	JJ	preclinical
studies	NNS	study
supporting	VBG	support
the	DT	the
program	NN	program
for	IN	for
a	DT	a
phase	NN	phase
I/II	NP	<unknown>
clinical	JJ	clinical
trial	NN	trial
in	IN	in
adult	JJ	adult
patients	NNS	patient
with	IN	with
Pompe	NP	<unknown>
.	SENT	.
These	DT	these
studies	NNS	study
were	VBD	be
designed	VBN	design
to	TO	to
evaluate	VB	evaluate
the	DT	the
toxicology	NN	toxicology
,	,	,
biodistribution	NN	<unknown>
,	,	,
and	CC	and
potential	JJ	potential
for	IN	for
readministration	NN	<unknown>
of	IN	of
rAAV9-DES-hGAA	NN	<unknown>
injected	VBN	inject
intramuscularly	RB	intramuscularly
into	IN	into
the	DT	the
tibialis	NN	<unknown>
anterior	JJ	anterior
muscle	NN	muscle
using	VBG	use
an	DT	an
immune	JJ	immune
modulation	NN	modulation
strategy	NN	strategy
developed	VBN	develop
for	IN	for
this	DT	this
study	NN	study
.	SENT	.
In	IN	in
the	DT	the
proposed	VBN	propose
clinical	JJ	clinical
study	NN	study
,	,	,
six	CD	six
adult	JJ	adult
participants	NNS	participant
with	IN	with
late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
will	MD	will
be	VB	be
enrolled	VBN	enroll
.	SENT	.
The	DT	the
goal	NN	goal
of	IN	of
the	DT	the
immune	JJ	immune
modulation	NN	modulation
strategy	NN	strategy
is	VBZ	be
to	TO	to
ablate	VB	ablate
B-cells	NP	<unknown>
before	IN	before
the	DT	the
initial	JJ	initial
exposure	NN	exposure
of	IN	of
the	DT	the
study	NN	study
agent	NN	agent
in	IN	in
one	CD	one
leg	NN	leg
and	CC	and
the	DT	the
subsequent	JJ	subsequent
exposure	NN	exposure
of	IN	of
the	DT	the
same	JJ	same
vector	NN	vector
to	TO	to
the	DT	the
contralateral	JJ	<unknown>
leg	NN	leg
four	CD	four
months	NNS	month
after	IN	after
initial	JJ	initial
dosing	VBG	dose
.	SENT	.
The	DT	the
dosing	VBG	dose
of	IN	of
the	DT	the
active	JJ	active
agent	NN	agent
is	VBZ	be
accompanied	VBN	accompany
by	IN	by
a	DT	a
control	NN	control
injection	NN	injection
of	IN	of
excipient	NN	excipient
dosing	VBG	dose
in	IN	in
the	DT	the
contralateral	JJ	<unknown>
leg	NN	leg
to	TO	to
allow	VB	allow
for	IN	for
blinding	NN	blinding
and	CC	and
randomization	NN	randomization
of	IN	of
dosing	VBG	dose
,	,	,
which	WDT	which
may	MD	may
also	RB	also
strengthen	VB	strengthen
the	DT	the
evidence	NN	evidence
generated	VBN	generate
from	IN	from
gene	NN	gene
therapy	NN	therapy
studies	NNS	study
in	IN	in
the	DT	the
future	NN	future
.	SENT	.
Patients	NNS	patient
will	MD	will
act	VB	act
as	IN	as
their	PP$	their
own	JJ	own
controls	NNS	control
.	SENT	.
Repeated	JJ	repeated
measures	NNS	measure
,	,	,
at	IN	at
baseline	NN	baseline
and	CC	and
during	IN	during
the	DT	the
three	CD	three
months	NNS	month
following	VBG	follow
each	DT	each
dosing	VBG	dose
will	MD	will
assess	VB	assess
the	DT	the
safety	NN	safety
,	,	,
biochemical	JJ	biochemical
,	,	,
and	CC	and
functional	JJ	functional
<span class='gene'>
impact	NN	impact
</span>
of	IN	of
the	DT	the
vector	NN	vector
.	SENT	.
<td class='article_title' rowspan='2'>
Respiratory	JJ	respiratory
muscle	NN	muscle
training	NN	training
(	(	(
RMT	NP	<unknown>
)	)	)
in	IN	in
late-onset	NN	late-onset
Pompe	NN	<unknown>
disease	NN	disease
(	(	(
LOPD	NP	<unknown>
)	)	)
:	:	:
Effects	NNS	effect
of	IN	of
training	VBG	train
and	CC	and
detraining	VBG	detrain
.	SENT	.
</td>
Determine	VB	determine
the	DT	the
effects	NNS	effect
of	IN	of
a	DT	a
12-week	JJ	<unknown>
respiratory	JJ	respiratory
muscle	NN	muscle
training	NN	training
(	(	(
RMT	NP	<unknown>
)	)	)
program	NN	program
in	IN	in
late-onset	NN	late-onset
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
(LOPD).We	NP	<unknown>
investigated	VBD	investigate
the	DT	the
effects	NNS	effect
of	IN	of
12-weeks	NP	<unknown>
of	IN	of
RMT	NP	<unknown>
followed	VBD	follow
by	IN	by
3-months	NNS	<unknown>
detraining	VBG	detrain
using	VBG	use
a	DT	a
single-subject	JJ	<unknown>
A-B-A	NP	<unknown>
experimental	JJ	experimental
design	NN	design
replicated	VBN	replicate
across	IN	across
8	CD	8
adults	NNS	adult
with	IN	with
LOPD	NP	<unknown>
.	SENT	.
To	TO	To
assess	VB	assess
maximal	JJ	maximal
volitional	JJ	volitional
respiratory	JJ	respiratory
strength	NN	strength
,	,	,
our	PP$	our
primary	JJ	primary
outcomes	NNS	outcome
were	VBD	be
maximum	JJ	maximum
inspiratory	JJ	inspiratory
pressure	NN	pressure
(	(	(
<span class='gene'>
MIP	NP	<unknown>
</span>
)	)	)
and	CC	and
maximum	JJ	maximum
expiratory	JJ	expiratory
pressure	NN	pressure
(MEP)	NN	<unknown>
.	SENT	.
Effect	NN	effect
sizes	NNS	size
for	IN	for
changes	NNS	change
in	IN	in
<span class='gene'>
MIP	NP	<unknown>
</span>
and	CC	and
MEP	NP	<unknown>
were	VBD	be
determined	VBN	determine
using	VBG	use
Cohen	NP	Cohen
's	POS	's
d	NN	d
statistic	NN	statistic
.	SENT	.
Exploratory	JJ	exploratory
outcomes	NNS	outcome
targeted	VBN	target
motor	NN	motor
function	NN	function
,	,	,
and	CC	and
peak	NN	peak
cough	NN	cough
flow	NN	flow
(	(	(
PCF	NN	PCF
)	)	)
was	VBD	be
measured	VBN	measure
in	IN	in
the	DT	the
last	JJ	last
5	CD	5
subjects.From	NN	<unknown>
pretest	NNS	<unknown>
to	TO	to
posttest	NNS	<unknown>
,	,	,
all	RB	all
8	CD	8
subjects	NNS	subject
exhibited	VBD	exhibit
increases	NNS	increase
in	IN	in
<span class='gene'>
MIP	NP	<unknown>
</span>
,	,	,
and	CC	and
7	CD	7
of	IN	of
8	CD	8
showed	VBD	show
increases	NNS	increase
in	IN	in
MEP	NN	<unknown>
.	SENT	.
Effect	NN	effect
size	NN	size
data	NNS	datum
reveal	VBP	reveal
the	DT	the
magnitude	NN	magnitude
of	IN	of
increases	NNS	increase
in	IN	in
<span class='gene'>
MIP	NN	<unknown>
</span>
to	TO	to
be	VB	be
large	JJ	large
in	IN	in
4	CD	4
(	(	(
d≥1.0	NN	<unknown>
)	)	)
and	CC	and
very	RB	very
large	JJ	large
in	IN	in
4	CD	4
(	(	(
d≥2.0	NN	<unknown>
)	)	)
,	,	,
and	CC	and
effect	NN	effect
sizes	NNS	size
for	IN	for
increases	NNS	increase
in	IN	in
MEP	NN	<unknown>
were	VBD	be
large	JJ	large
in	IN	in
1	CD	1
(	(	(
d≥1.0	NN	<unknown>
)	)	)
and	CC	and
very	RB	very
large	JJ	large
in	IN	in
6	CD	6
(d≥2.0)	NN	<unknown>
.	SENT	.
Across	IN	across
participants	NNS	participant
,	,	,
pretest	VBG	<unknown>
to	TO	to
posttest	VB	<unknown>
<span class='gene'>
MIP	NP	<unknown>
</span>
and	CC	and
MEP	NP	<unknown>
increased	VBD	increase
by	IN	by
a	DT	a
mean	NN	mean
of	IN	of
19.6	CD	@card@
%	NN	%
(	(	(
sd=9.9	NN	<unknown>
)	)	)
and	CC	and
16.1	CD	@card@
%	NN	%
(	(	(
sd=17.3	NN	<unknown>
)	)	)
,	,	,
respectively	RB	respectively
.	SENT	.
Respiratory	JJ	respiratory
strength	NN	strength
increases	NNS	increase
,	,	,
particularly	RB	particularly
for	IN	for
the	DT	the
inspiratory	JJ	inspiratory
muscles	NNS	muscle
,	,	,
were	VBD	be
generally	RB	generally
durable	JJ	durable
to	TO	to
3-months	JJ	<unknown>
detraining.These	JJ	<unknown>
data	NNS	datum
suggest	VBP	suggest
our	PP$	our
12-week	JJ	<unknown>
RMT	NP	<unknown>
program	NN	program
results	NNS	result
in	IN	in
large	JJ	large
to	TO	to
very	RB	very
large	JJ	large
increases	NNS	increase
in	IN	in
inspiratory	JJ	inspiratory
and	CC	and
expiratory	JJ	expiratory
muscle	NN	muscle
strength	NN	strength
in	IN	in
adults	NNS	adult
with	IN	with
LOPD	NP	<unknown>
.	SENT	.
Additionally	RB	additionally
,	,	,
increases	NNS	increase
in	IN	in
respiratory	JJ	respiratory
strength	NN	strength
appeared	VBD	appear
to	TO	to
be	VB	be
relatively	RB	relatively
durable	JJ	durable
following	VBG	follow
3-months	NNS	<unknown>
detraining	VBG	detrain
.	SENT	.
Although	IN	although
additional	JJ	additional
research	NN	research
is	VBZ	be
needed	VBN	need
,	,	,
RMT	NP	<unknown>
appears	VBZ	appear
to	TO	to
offer	VB	offer
promise	NN	promise
as	IN	as
an	DT	an
adjunctive	JJ	adjunctive
treatment	NN	treatment
for	IN	for
respiratory	JJ	respiratory
<span class='symptom'>
weakness	NN	weakness
</span>
in	IN	in
LOPD	NP	<unknown>
.	SENT	.
<td class='article_title' rowspan='2'>
A	DT	a
conceptual	JJ	conceptual
disease	NN	disease
model	NN	model
for	IN	for
adult	JJ	adult
Pompe	NP	<unknown>
disease	NN	disease
.	SENT	.
</td>
Studies	NNS	study
in	IN	in
orphan	NN	orphan
diseases	NNS	disease
are	VBP	be
,	,	,
by	IN	by
nature	NN	nature
,	,	,
confronted	VBN	confront
with	IN	with
small	JJ	small
patient	JJ	patient
populations	NNS	population
,	,	,
meaning	VBG	mean
that	IN	that
randomized	VBN	randomize
controlled	JJ	controlled
trials	NNS	trial
will	MD	will
have	VB	have
limited	VBN	limit
statistical	JJ	statistical
power	NN	power
.	SENT	.
In	IN	in
order	NN	order
to	TO	to
estimate	VB	estimate
the	DT	the
effectiveness	NN	effectiveness
of	IN	of
treatments	NNS	treatment
in	IN	in
orphan	NN	orphan
diseases	NNS	disease
and	CC	and
extrapolate	VB	extrapolate
effects	NNS	effect
into	IN	into
the	DT	the
future	JJ	future
,	,	,
alternative	JJ	alternative
models	NNS	model
might	MD	might
be	VB	be
needed	VBN	need
.	SENT	.
The	DT	the
purpose	NN	purpose
of	IN	of
this	DT	this
study	NN	study
is	VBZ	be
to	TO	to
develop	VB	develop
a	DT	a
conceptual	JJ	conceptual
disease	NN	disease
model	NN	model
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
in	IN	in
adults	NNS	adult
(	(	(
an	DT	an
orphan	NN	orphan
disease)	NN	<unknown>
.	SENT	.
This	DT	this
conceptual	JJ	conceptual
model	NN	model
describes	VBZ	describe
the	DT	the
associations	NNS	association
between	IN	between
the	DT	the
most	RBS	most
important	JJ	important
levels	NNS	level
of	IN	of
health	NN	health
concepts	NNS	concept
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
in	IN	in
adults	NNS	adult
,	,	,
from	IN	from
biological	JJ	biological
parameters	NNS	parameter
via	IN	via
physiological	JJ	physiological
parameters	NNS	parameter
,	,	,
symptoms	NNS	symptom
and	CC	and
functional	JJ	functional
indicators	NNS	indicator
to	TO	to
health	NN	health
perceptions	NNS	perception
and	CC	and
final	JJ	final
health	NN	health
outcomes	NNS	outcome
as	RB	as
measured	VBN	measure
in	IN	in
terms	NNS	term
of	IN	of
health-related	JJ	health-related
quality	NN	quality
of	IN	of
life.The	JJ	<unknown>
structure	NN	structure
of	IN	of
the	DT	the
Wilson-Cleary	NP	<unknown>
health	NN	health
outcomes	NNS	outcome
model	NN	model
was	VBD	be
used	VBN	use
as	IN	as
a	DT	a
blueprint	NN	blueprint
,	,	,
and	CC	and
filled	VBN	fill
with	IN	with
clinically	RB	clinically
relevant	JJ	relevant
aspects	NNS	aspect
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
based	VBN	base
on	IN	on
literature	NN	literature
and	CC	and
expert	NN	expert
opinion	NN	opinion
.	SENT	.
Multiple	JJ	multiple
observations	NNS	observation
per	IN	per
patient	NN	patient
from	IN	from
a	DT	a
Dutch	JJ	Dutch
cohort	NN	cohort
study	NN	study
in	IN	in
untreated	JJ	untreated
patients	NNS	patient
were	VBD	be
used	VBN	use
to	TO	to
quantify	VB	quantify
the	DT	the
relationships	NNS	relationship
between	IN	between
the	DT	the
different	JJ	different
levels	NNS	level
of	IN	of
health	NN	health
concepts	NNS	concept
in	IN	in
the	DT	the
model	NN	model
by	IN	by
means	NNS	mean
of	IN	of
regression	NN	regression
analyses.Enzyme	NN	<unknown>
activity	NN	activity
,	,	,
muscle	NN	muscle
strength	NN	strength
,	,	,
respiratory	JJ	respiratory
function	NN	function
,	,	,
<span class='symptom'>
fatigue	NN	fatigue
</span>
,	,	,
level	NN	level
of	IN	of
handicap	NN	handicap
,	,	,
general	JJ	general
health	NN	health
perceptions	NNS	perception
,	,	,
mental	JJ	mental
and	CC	and
physical	JJ	physical
component	NN	component
scales	NNS	scale
and	CC	and
utility	NN	utility
described	VBD	describe
the	DT	the
different	JJ	different
levels	NNS	level
of	IN	of
health	NN	health
concepts	NNS	concept
in	IN	in
the	DT	the
Wilson-Cleary	NP	<unknown>
model	NN	model
for	IN	for
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
Regression	NN	regression
analyses	NNS	analysis
showed	VBD	show
that	IN	that
functional	JJ	functional
status	NN	status
was	VBD	be
affected	VBN	affect
by	IN	by
<span class='symptom'>
fatigue	NN	fatigue
</span>
,	,	,
muscle	NN	muscle
strength	NN	strength
and	CC	and
respiratory	JJ	respiratory
function	NN	function
.	SENT	.
Health	NN	health
perceptions	NNS	perception
were	VBD	be
affected	VBN	affect
by	IN	by
handicap	NN	handicap
.	SENT	.
In	IN	in
turn	NN	turn
,	,	,
self-reported	JJ	<unknown>
quality	NN	quality
of	IN	of
life	NN	life
was	VBD	be
affected	VBN	affect
by	IN	by
health	NN	health
perceptions.We	NNS	<unknown>
conceptualized	VBD	conceptualize
a	DT	a
disease	NN	disease
model	NN	model
that	WDT	that
incorporated	VBD	incorporate
the	DT	the
mechanisms	NNS	mechanism
believed	VBN	believe
to	TO	to
be	VB	be
responsible	JJ	responsible
for	IN	for
impaired	JJ	impaired
quality	NN	quality
of	IN	of
life	NN	life
in	IN	in
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
.	SENT	.
The	DT	the
model	NN	model
provides	VBZ	provide
a	DT	a
comprehensive	JJ	comprehensive
overview	NN	overview
of	IN	of
various	JJ	various
aspects	NNS	aspect
of	IN	of
<span class='disease'>
Pompe	NP	<unknown>
disease	NN	disease
</span>
in	IN	in
adults	NNS	adult
,	,	,
which	WDT	which
can	MD	can
be	VB	be
useful	JJ	useful
for	IN	for
both	DT	both
clinicians	NNS	clinician
and	CC	and
policymakers	NNS	policymaker
to	TO	to
support	VB	support
their	PP$	their
multi-faceted	JJ	multi-faceted
decision	NN	decision
making	NN	making
.	SENT	.
